Mitch Report

date generated: 2022-10-12

Background

Mitch performs unidimensional and multidimensional gene set enrichment analysis. The concept behind this dates to work by Cox and Mann (https://doi.org/10.1186/1471-2105-13-S16-S12). This implementation is suited to R based workflows of multi-omics datasets. This software was developed by Antony Kaspi and Mark Ziemann. Learn more about Mitch at the website: https://github.com/markziemann/Mitch

Input profiles

Here is the first few lines of the input profile.

##                  bl         gu
## A1BG     -0.4938909 -0.2212730
## A1BG-AS1  0.2105059 -0.4788491
## A1CF     -0.9150025 -2.4988040
## A2BP1    -2.9002957 -1.4137889
## A2LD1    -0.4071121 -0.3741118
## A2M      -3.9190498 -1.4501573

Here are some metrics about the input data profile:

Profile metrics

	Profile metrics
num_genes_in_profile	25716
duplicated_genes_present	0
num_profile_genes_in_sets	10215
num_profile_genes_not_in_sets	15501
profile_pearson_correl	0.33757
profile_spearman_correl	0.26225

Here is a plot of the input profiles. Note the dynamic ranges.

Here is the contour plot of the profile including all detected genes.

Input genesets

Here are some metrics about the gene sets used: GMT file of genesets: ReactomePathways.gmt

Gene sets metrics

	Gene sets metrics
num_genesets	2584
num_genesets_excluded	1038
num_genesets_included	1546

Gene sets by quadrant

Number of significant gene sets (FDR<0.05)= 598

Interactive enrichment scatterplot

All sets with FDR<0.05. Try hovering over the points.

Top N sets irrespective of FDR. Try hovering over the points.

A heatmap of S values for top results

A plot of effect size versus significance

Significance is the -log2(p.adjustMANOVA) and effect size is the s.dist which is the hypotenuse of the s scores.

Results table

Top N= 50 gene sets

set	setSize	pMANOVA	p.adjustMANOVA	s.dist	s.bl	s.gu	p.bl	p.gu
Activation of RAC1	11	1.62e-05	1.20e-04	0.870	-0.811	-0.3150	3.20e-06	7.05e-02
Regulation of commissural axon pathfinding by SLIT and ROBO	10	4.01e-04	1.87e-03	0.810	-0.535	-0.6080	3.36e-03	8.68e-04
cGMP effects	15	5.18e-06	4.47e-05	0.796	-0.343	-0.7180	2.13e-02	1.48e-06
MET activates PTK2 signaling	18	9.31e-06	7.46e-05	0.729	-0.594	-0.4220	1.26e-05	1.95e-03
Laminin interactions	23	5.23e-07	6.58e-06	0.722	-0.578	-0.4340	1.60e-06	3.17e-04
Presynaptic depolarization and calcium channel opening	12	6.68e-04	2.99e-03	0.715	-0.530	-0.4810	1.48e-03	3.93e-03
DCC mediated attractive signaling	14	2.06e-04	1.07e-03	0.714	-0.514	-0.4960	8.63e-04	1.32e-03
Collagen chain trimerization	42	2.85e-11	1.00e-09	0.694	-0.429	-0.5460	1.51e-06	9.00e-10
Regulation of TP53 Activity through Association with Co-factors	14	1.06e-04	6.06e-04	0.690	-0.660	-0.2030	1.92e-05	1.88e-01
Carnitine metabolism	11	3.98e-05	2.67e-04	0.685	-0.604	0.3230	5.22e-04	6.32e-02
Apoptotic cleavage of cell adhesion proteins	11	2.29e-03	8.71e-03	0.676	-0.549	-0.3940	1.61e-03	2.36e-02
Nitric oxide stimulates guanylate cyclase	22	7.02e-06	5.77e-05	0.654	-0.307	-0.5780	1.27e-02	2.69e-06
Bicarbonate transporters	10	6.16e-03	2.01e-02	0.652	-0.409	-0.5080	2.53e-02	5.41e-03
Eicosanoids	12	9.68e-05	5.65e-04	0.649	0.626	-0.1730	1.75e-04	2.98e-01
Induction of Cell-Cell Fusion	12	2.74e-03	1.01e-02	0.643	-0.463	-0.4460	5.43e-03	7.44e-03
VEGFR2 mediated vascular permeability	26	3.62e-07	4.70e-06	0.635	-0.617	-0.1530	5.15e-08	1.77e-01
Adherens junctions interactions	26	5.31e-06	4.56e-05	0.625	-0.391	-0.4870	5.49e-04	1.73e-05
SARS-CoV-1 modulates host translation machinery	34	7.87e-08	1.20e-06	0.621	0.541	0.3040	4.72e-08	2.14e-03
Collagen biosynthesis and modifying enzymes	65	5.48e-13	2.57e-11	0.605	-0.420	-0.4360	4.75e-09	1.22e-09
Nephrin family interactions	21	1.12e-04	6.29e-04	0.603	-0.398	-0.4530	1.58e-03	3.26e-04
MET promotes cell motility	29	2.93e-06	2.96e-05	0.595	-0.513	-0.3000	1.69e-06	5.12e-03
Termination of O-glycan biosynthesis	25	2.23e-05	1.59e-04	0.588	-0.505	-0.3010	1.21e-05	9.26e-03
Neurexins and neuroligins	52	8.85e-10	2.10e-08	0.579	-0.445	-0.3710	2.73e-08	3.71e-06
RHO GTPases activate IQGAPs	11	8.81e-03	2.69e-02	0.576	-0.526	-0.2350	2.51e-03	1.77e-01
Defective C1GALT1C1 causes TNPS	18	1.03e-03	4.38e-03	0.567	-0.415	-0.3860	2.28e-03	4.58e-03
Interaction between L1 and Ankyrins	28	6.49e-06	5.39e-05	0.562	-0.182	-0.5320	9.56e-02	1.11e-06
ALK mutants bind TKIs	12	5.05e-03	1.70e-02	0.560	-0.542	-0.1410	1.14e-03	3.99e-01
Non-integrin membrane-ECM interactions	40	2.75e-07	3.72e-06	0.560	-0.451	-0.3310	7.96e-07	2.86e-04
Class C/3 (Metabotropic glutamate/pheromone receptors)	39	3.68e-07	4.75e-06	0.558	-0.307	-0.4660	9.17e-04	4.77e-07
MET activates RAS signaling	11	1.01e-03	4.33e-03	0.557	-0.432	0.3510	1.30e-02	4.41e-02
Reactions specific to the complex N-glycan synthesis pathway	10	2.36e-02	5.87e-02	0.556	-0.455	-0.3200	1.28e-02	7.97e-02
Effects of PIP2 hydrolysis	26	6.18e-05	3.95e-04	0.553	-0.459	-0.3080	5.03e-05	6.55e-03
RHOU GTPase cycle	37	2.97e-07	3.96e-06	0.553	-0.517	-0.1960	5.26e-08	3.88e-02
Free fatty acids regulate insulin secretion	10	1.32e-02	3.69e-02	0.551	-0.537	-0.1250	3.28e-03	4.94e-01
Repression of WNT target genes	13	9.46e-03	2.84e-02	0.548	-0.419	-0.3530	8.91e-03	2.74e-02
PLC beta mediated events	47	3.12e-08	5.36e-07	0.544	-0.470	-0.2740	2.44e-08	1.13e-03
RHOJ GTPase cycle	51	1.59e-09	3.61e-08	0.543	-0.513	-0.1780	2.28e-10	2.75e-02
Defective GALNT12 causes CRCS1	18	1.80e-03	7.00e-03	0.543	-0.409	-0.3570	2.67e-03	8.73e-03
RHOV GTPase cycle	36	1.71e-06	1.89e-05	0.540	-0.479	-0.2500	6.47e-07	9.47e-03
Formation of Senescence-Associated Heterochromatin Foci (SAHF)	11	2.21e-03	8.47e-03	0.540	-0.500	0.2030	4.05e-03	2.43e-01
Defective GALNT3 causes HFTC	18	1.99e-03	7.67e-03	0.538	-0.407	-0.3520	2.79e-03	9.63e-03
Netrin-1 signaling	49	4.11e-08	6.84e-07	0.535	-0.437	-0.3090	1.17e-07	1.83e-04
Notch-HLH transcription pathway	24	3.38e-05	2.31e-04	0.533	-0.529	-0.0639	7.14e-06	5.88e-01
Defective EXT1 causes exostoses 1, TRPS2 and CHDS	12	1.76e-02	4.64e-02	0.531	-0.402	-0.3470	1.58e-02	3.74e-02
Defective EXT2 causes exostoses 2	12	1.76e-02	4.64e-02	0.531	-0.402	-0.3470	1.58e-02	3.74e-02
DAG and IP3 signaling	39	1.58e-06	1.77e-05	0.531	-0.437	-0.3020	2.32e-06	1.10e-03
POU5F1 (OCT4), SOX2, NANOG repress genes related to differentiation	10	3.25e-03	1.19e-02	0.531	-0.387	0.3640	3.42e-02	4.64e-02
Defective B3GALTL causes PpS	36	5.41e-06	4.62e-05	0.530	-0.328	-0.4170	6.64e-04	1.51e-05
O-glycosylation of TSR domain-containing proteins	37	3.79e-06	3.55e-05	0.529	-0.317	-0.4240	8.31e-04	8.17e-06
CLEC7A (Dectin-1) induces NFAT activation	11	2.69e-02	6.52e-02	0.525	-0.350	-0.3920	4.45e-02	2.44e-02

---

Results (complete table)

Click HERE to show results for all gene sets

Complete results

set	setSize	pMANOVA	p.adjustMANOVA	s.dist	s.bl	s.gu	p.bl	p.gu
Activation of RAC1	11	1.62e-05	1.20e-04	0.87000	-8.11e-01	-3.15e-01	3.20e-06	7.05e-02
Regulation of commissural axon pathfinding by SLIT and ROBO	10	4.01e-04	1.87e-03	0.81000	-5.35e-01	-6.08e-01	3.36e-03	8.68e-04
cGMP effects	15	5.18e-06	4.47e-05	0.79600	-3.43e-01	-7.18e-01	2.13e-02	1.48e-06
MET activates PTK2 signaling	18	9.31e-06	7.46e-05	0.72900	-5.94e-01	-4.22e-01	1.26e-05	1.95e-03
Laminin interactions	23	5.23e-07	6.58e-06	0.72200	-5.78e-01	-4.34e-01	1.60e-06	3.17e-04
Presynaptic depolarization and calcium channel opening	12	6.68e-04	2.99e-03	0.71500	-5.30e-01	-4.81e-01	1.48e-03	3.93e-03
DCC mediated attractive signaling	14	2.06e-04	1.07e-03	0.71400	-5.14e-01	-4.96e-01	8.63e-04	1.32e-03
Collagen chain trimerization	42	2.85e-11	1.00e-09	0.69400	-4.29e-01	-5.46e-01	1.51e-06	9.00e-10
Regulation of TP53 Activity through Association with Co-factors	14	1.06e-04	6.06e-04	0.69000	-6.60e-01	-2.03e-01	1.92e-05	1.88e-01
Carnitine metabolism	11	3.98e-05	2.67e-04	0.68500	-6.04e-01	3.23e-01	5.22e-04	6.32e-02
Apoptotic cleavage of cell adhesion proteins	11	2.29e-03	8.71e-03	0.67600	-5.49e-01	-3.94e-01	1.61e-03	2.36e-02
Nitric oxide stimulates guanylate cyclase	22	7.02e-06	5.77e-05	0.65400	-3.07e-01	-5.78e-01	1.27e-02	2.69e-06
Bicarbonate transporters	10	6.16e-03	2.01e-02	0.65200	-4.09e-01	-5.08e-01	2.53e-02	5.41e-03
Eicosanoids	12	9.68e-05	5.65e-04	0.64900	6.26e-01	-1.73e-01	1.75e-04	2.98e-01
Induction of Cell-Cell Fusion	12	2.74e-03	1.01e-02	0.64300	-4.63e-01	-4.46e-01	5.43e-03	7.44e-03
VEGFR2 mediated vascular permeability	26	3.62e-07	4.70e-06	0.63500	-6.17e-01	-1.53e-01	5.15e-08	1.77e-01
Adherens junctions interactions	26	5.31e-06	4.56e-05	0.62500	-3.91e-01	-4.87e-01	5.49e-04	1.73e-05
SARS-CoV-1 modulates host translation machinery	34	7.87e-08	1.20e-06	0.62100	5.41e-01	3.04e-01	4.72e-08	2.14e-03
Collagen biosynthesis and modifying enzymes	65	5.48e-13	2.57e-11	0.60500	-4.20e-01	-4.36e-01	4.75e-09	1.22e-09
Nephrin family interactions	21	1.12e-04	6.29e-04	0.60300	-3.98e-01	-4.53e-01	1.58e-03	3.26e-04
MET promotes cell motility	29	2.93e-06	2.96e-05	0.59500	-5.13e-01	-3.00e-01	1.69e-06	5.12e-03
Termination of O-glycan biosynthesis	25	2.23e-05	1.59e-04	0.58800	-5.05e-01	-3.01e-01	1.21e-05	9.26e-03
Neurexins and neuroligins	52	8.85e-10	2.10e-08	0.57900	-4.45e-01	-3.71e-01	2.73e-08	3.71e-06
RHO GTPases activate IQGAPs	11	8.81e-03	2.69e-02	0.57600	-5.26e-01	-2.35e-01	2.51e-03	1.77e-01
Defective C1GALT1C1 causes TNPS	18	1.03e-03	4.38e-03	0.56700	-4.15e-01	-3.86e-01	2.28e-03	4.58e-03
Interaction between L1 and Ankyrins	28	6.49e-06	5.39e-05	0.56200	-1.82e-01	-5.32e-01	9.56e-02	1.11e-06
ALK mutants bind TKIs	12	5.05e-03	1.70e-02	0.56000	-5.42e-01	-1.41e-01	1.14e-03	3.99e-01
Non-integrin membrane-ECM interactions	40	2.75e-07	3.72e-06	0.56000	-4.51e-01	-3.31e-01	7.96e-07	2.86e-04
Class C/3 (Metabotropic glutamate/pheromone receptors)	39	3.68e-07	4.75e-06	0.55800	-3.07e-01	-4.66e-01	9.17e-04	4.77e-07
MET activates RAS signaling	11	1.01e-03	4.33e-03	0.55700	-4.32e-01	3.51e-01	1.30e-02	4.41e-02
Reactions specific to the complex N-glycan synthesis pathway	10	2.36e-02	5.87e-02	0.55600	-4.55e-01	-3.20e-01	1.28e-02	7.97e-02
Effects of PIP2 hydrolysis	26	6.18e-05	3.95e-04	0.55300	-4.59e-01	-3.08e-01	5.03e-05	6.55e-03
RHOU GTPase cycle	37	2.97e-07	3.96e-06	0.55300	-5.17e-01	-1.96e-01	5.26e-08	3.88e-02
Free fatty acids regulate insulin secretion	10	1.32e-02	3.69e-02	0.55100	-5.37e-01	-1.25e-01	3.28e-03	4.94e-01
Repression of WNT target genes	13	9.46e-03	2.84e-02	0.54800	-4.19e-01	-3.53e-01	8.91e-03	2.74e-02
PLC beta mediated events	47	3.12e-08	5.36e-07	0.54400	-4.70e-01	-2.74e-01	2.44e-08	1.13e-03
RHOJ GTPase cycle	51	1.59e-09	3.61e-08	0.54300	-5.13e-01	-1.78e-01	2.28e-10	2.75e-02
Defective GALNT12 causes CRCS1	18	1.80e-03	7.00e-03	0.54300	-4.09e-01	-3.57e-01	2.67e-03	8.73e-03
RHOV GTPase cycle	36	1.71e-06	1.89e-05	0.54000	-4.79e-01	-2.50e-01	6.47e-07	9.47e-03
Formation of Senescence-Associated Heterochromatin Foci (SAHF)	11	2.21e-03	8.47e-03	0.54000	-5.00e-01	2.03e-01	4.05e-03	2.43e-01
Defective GALNT3 causes HFTC	18	1.99e-03	7.67e-03	0.53800	-4.07e-01	-3.52e-01	2.79e-03	9.63e-03
Netrin-1 signaling	49	4.11e-08	6.84e-07	0.53500	-4.37e-01	-3.09e-01	1.17e-07	1.83e-04
Notch-HLH transcription pathway	24	3.38e-05	2.31e-04	0.53300	-5.29e-01	-6.39e-02	7.14e-06	5.88e-01
Defective EXT1 causes exostoses 1, TRPS2 and CHDS	12	1.76e-02	4.64e-02	0.53100	-4.02e-01	-3.47e-01	1.58e-02	3.74e-02
Defective EXT2 causes exostoses 2	12	1.76e-02	4.64e-02	0.53100	-4.02e-01	-3.47e-01	1.58e-02	3.74e-02
DAG and IP3 signaling	39	1.58e-06	1.77e-05	0.53100	-4.37e-01	-3.02e-01	2.32e-06	1.10e-03
POU5F1 (OCT4), SOX2, NANOG repress genes related to differentiation	10	3.25e-03	1.19e-02	0.53100	-3.87e-01	3.64e-01	3.42e-02	4.64e-02
Defective B3GALTL causes PpS	36	5.41e-06	4.62e-05	0.53000	-3.28e-01	-4.17e-01	6.64e-04	1.51e-05
O-glycosylation of TSR domain-containing proteins	37	3.79e-06	3.55e-05	0.52900	-3.17e-01	-4.24e-01	8.31e-04	8.17e-06
CLEC7A (Dectin-1) induces NFAT activation	11	2.69e-02	6.52e-02	0.52500	-3.50e-01	-3.92e-01	4.45e-02	2.44e-02
DSCAM interactions	11	2.46e-02	6.08e-02	0.52500	-4.39e-01	-2.87e-01	1.16e-02	9.95e-02
Collagen formation	88	3.92e-13	1.96e-11	0.52300	-3.75e-01	-3.65e-01	1.19e-09	3.13e-09
Thyroxine biosynthesis	10	3.77e-02	8.37e-02	0.52300	-4.11e-01	-3.23e-01	2.43e-02	7.72e-02
TICAM1,TRAF6-dependent induction of TAK1 complex	10	3.94e-02	8.67e-02	0.52200	3.78e-01	3.60e-01	3.85e-02	4.89e-02
Uptake and function of anthrax toxins	11	1.50e-02	4.10e-02	0.52100	-5.05e-01	-1.28e-01	3.75e-03	4.63e-01
Recycling pathway of L1	23	9.72e-05	5.65e-04	0.52000	-5.14e-01	-7.65e-02	1.96e-05	5.25e-01
Sensory processing of sound by outer hair cells of the cochlea	49	1.29e-07	1.86e-06	0.52000	-4.09e-01	-3.21e-01	7.37e-07	1.01e-04
TICAM1-dependent activation of IRF3/IRF7	12	2.22e-02	5.63e-02	0.51700	3.76e-01	3.54e-01	2.41e-02	3.36e-02
G-protein mediated events	52	2.31e-08	4.05e-07	0.51600	-4.61e-01	-2.33e-01	8.97e-09	3.61e-03
Adenylate cyclase activating pathway	10	3.33e-02	7.67e-02	0.51600	-4.64e-01	-2.25e-01	1.10e-02	2.17e-01
RHOQ GTPase cycle	57	2.74e-09	5.88e-08	0.51600	-4.73e-01	-2.04e-01	6.20e-10	7.65e-03
NRAGE signals death through JNK	53	4.43e-08	7.29e-07	0.51200	-4.27e-01	-2.82e-01	7.48e-08	3.83e-04
Sensory processing of sound by inner hair cells of the cochlea	62	4.98e-09	1.03e-07	0.51000	-3.57e-01	-3.64e-01	1.16e-06	7.01e-07
Ca-dependent events	35	1.79e-05	1.31e-04	0.50900	-4.07e-01	-3.06e-01	3.08e-05	1.70e-03
VEGFR2 mediated cell proliferation	19	8.88e-04	3.84e-03	0.50900	-4.96e-01	-1.13e-01	1.79e-04	3.92e-01
PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases	14	3.85e-03	1.36e-02	0.50900	-5.07e-01	-4.57e-02	1.03e-03	7.67e-01
Elevation of cytosolic Ca2+ levels	16	1.24e-03	5.11e-03	0.50700	-5.07e-01	9.09e-03	4.42e-04	9.50e-01
Peptide chain elongation	84	5.05e-12	2.06e-10	0.50400	4.21e-01	2.77e-01	2.52e-11	1.13e-05
Acetylcholine regulates insulin secretion	10	1.89e-02	4.92e-02	0.50400	-5.03e-01	-2.75e-02	5.89e-03	8.80e-01
Sensory processing of sound	69	1.04e-09	2.41e-08	0.50300	-3.68e-01	-3.42e-01	1.24e-07	8.69e-07
RORA activates gene expression	17	1.09e-03	4.59e-03	0.50100	-5.01e-01	-5.81e-03	3.50e-04	9.67e-01
Synthesis of IP3 and IP4 in the cytosol	25	5.23e-04	2.38e-03	0.50100	-4.03e-01	-2.97e-01	4.87e-04	1.01e-02
Ephrin signaling	17	3.66e-03	1.31e-02	0.50100	-4.64e-01	-1.87e-01	9.19e-04	1.81e-01
Negative regulation of NMDA receptor-mediated neuronal transmission	20	2.75e-03	1.02e-02	0.49800	-3.40e-01	-3.64e-01	8.51e-03	4.82e-03
Long-term potentiation	22	1.55e-03	6.19e-03	0.49700	-3.35e-01	-3.68e-01	6.55e-03	2.83e-03
Sensory perception of sweet, bitter, and umami (glutamate) taste	41	5.96e-06	5.00e-05	0.49700	-3.42e-01	-3.61e-01	1.52e-04	6.31e-05
Diseases associated with O-glycosylation of proteins	66	3.70e-09	7.74e-08	0.49600	-3.86e-01	-3.12e-01	5.90e-08	1.17e-05
Metabolism of amine-derived hormones	17	6.53e-03	2.10e-02	0.49600	-3.97e-01	-2.96e-01	4.56e-03	3.45e-02
Digestion	18	2.88e-03	1.06e-02	0.49300	-1.70e-01	-4.63e-01	2.13e-01	6.72e-04
Pexophagy	11	4.05e-02	8.83e-02	0.49200	3.95e-01	2.92e-01	2.32e-02	9.33e-02
RHO GTPases activate PAKs	19	3.86e-03	1.36e-02	0.49000	-4.06e-01	-2.74e-01	2.16e-03	3.89e-02
Pre-NOTCH Processing in Golgi	18	2.80e-04	1.38e-03	0.49000	-4.57e-01	1.77e-01	7.94e-04	1.93e-01
Protein-protein interactions at synapses	78	2.18e-10	6.47e-09	0.49000	-3.69e-01	-3.22e-01	1.75e-08	8.60e-07
RHOB GTPase cycle	66	2.45e-09	5.34e-08	0.49000	-4.30e-01	-2.35e-01	1.53e-09	9.76e-04
Role of LAT2/NTAL/LAB on calcium mobilization	13	1.42e-02	3.93e-02	0.48900	-4.67e-01	-1.45e-01	3.57e-03	3.66e-01
Phase 2 - plateau phase	14	1.81e-02	4.74e-02	0.48900	-3.01e-01	-3.85e-01	5.13e-02	1.26e-02
Phase 0 - rapid depolarisation	31	6.51e-05	4.08e-04	0.48800	-1.92e-01	-4.49e-01	6.37e-02	1.51e-05
Eukaryotic Translation Termination	87	9.97e-12	3.88e-10	0.48600	4.14e-01	2.55e-01	2.35e-11	3.87e-05
PRC2 methylates histones and DNA	13	3.45e-03	1.25e-02	0.48500	-4.62e-01	1.47e-01	3.89e-03	3.60e-01
Regulation of RUNX1 Expression and Activity	25	4.65e-05	3.07e-04	0.48500	-4.82e-01	5.20e-02	3.04e-05	6.53e-01
CRMPs in Sema3A signaling	15	1.45e-02	3.99e-02	0.48300	-2.81e-01	-3.93e-01	5.92e-02	8.45e-03
Aspartate and asparagine metabolism	11	4.47e-02	9.56e-02	0.48300	-3.93e-01	-2.81e-01	2.40e-02	1.06e-01
Eukaryotic Translation Elongation	88	1.51e-11	5.55e-10	0.48100	4.05e-01	2.60e-01	5.08e-11	2.48e-05
Mucopolysaccharidoses	10	3.66e-02	8.20e-02	0.48100	-4.69e-01	-1.04e-01	1.02e-02	5.69e-01
CaM pathway	33	9.40e-05	5.50e-04	0.48100	-3.97e-01	-2.71e-01	7.84e-05	7.09e-03
Calmodulin induced events	33	9.40e-05	5.50e-04	0.48100	-3.97e-01	-2.71e-01	7.84e-05	7.09e-03
Viral mRNA Translation	84	5.73e-11	1.89e-09	0.48000	4.00e-01	2.66e-01	2.37e-10	2.46e-05
TICAM1, RIP1-mediated IKK complex recruitment	18	7.19e-03	2.27e-02	0.47800	2.91e-01	3.79e-01	3.27e-02	5.39e-03
RHO GTPases activate KTN1	11	6.22e-03	2.02e-02	0.47700	-3.52e-01	3.22e-01	4.34e-02	6.44e-02
PKA activation in glucagon signalling	17	6.72e-03	2.16e-02	0.47700	-4.35e-01	-1.94e-01	1.89e-03	1.65e-01
A tetrasaccharide linker sequence is required for GAG synthesis	23	1.63e-03	6.46e-03	0.47500	-4.06e-01	-2.47e-01	7.41e-04	4.05e-02
Receptor Mediated Mitophagy	10	1.02e-02	3.02e-02	0.47500	-3.55e-01	3.16e-01	5.18e-02	8.39e-02
Unblocking of NMDA receptors, glutamate binding and activation	19	5.83e-03	1.92e-02	0.47500	-2.92e-01	-3.74e-01	2.73e-02	4.72e-03
Sema3A PAK dependent Axon repulsion	14	1.90e-02	4.92e-02	0.47300	-4.20e-01	-2.16e-01	6.44e-03	1.62e-01
Synthesis of PIPs at the plasma membrane	48	1.89e-07	2.68e-06	0.47200	-4.63e-01	-9.23e-02	2.81e-08	2.68e-01
Hh mutants are degraded by ERAD	54	6.91e-07	8.35e-06	0.47000	3.47e-01	3.17e-01	1.01e-05	5.53e-05
Activation of the phototransduction cascade	11	5.21e-02	1.06e-01	0.46800	-3.92e-01	-2.56e-01	2.42e-02	1.42e-01
Negative regulation of TCF-dependent signaling by WNT ligand antagonists	15	1.62e-03	6.43e-03	0.46800	-4.16e-01	2.15e-01	5.25e-03	1.50e-01
Defective B4GALT7 causes EDS, progeroid type	17	1.01e-02	3.00e-02	0.46700	-4.02e-01	-2.37e-01	4.10e-03	9.01e-02
Fatty acids	15	3.84e-03	1.36e-02	0.46600	4.63e-01	-5.24e-02	1.88e-03	7.25e-01
Selenocysteine synthesis	87	8.25e-11	2.66e-09	0.46600	3.96e-01	2.46e-01	1.73e-10	7.07e-05
Receptor-type tyrosine-protein phosphatases	16	1.29e-02	3.63e-02	0.46600	-2.25e-01	-4.08e-01	1.20e-01	4.71e-03
PKA-mediated phosphorylation of CREB	19	4.67e-03	1.58e-02	0.46500	-4.28e-01	-1.84e-01	1.25e-03	1.66e-01
Assembly of collagen fibrils and other multimeric structures	56	5.43e-07	6.77e-06	0.46500	-3.03e-01	-3.53e-01	8.73e-05	4.91e-06
Regulation of localization of FOXO transcription factors	11	5.16e-02	1.05e-01	0.46400	-4.06e-01	-2.23e-01	1.96e-02	1.99e-01
GSK3B and BTRC:CUL1-mediated-degradation of NFE2L2	50	3.04e-06	3.04e-05	0.46300	3.35e-01	3.19e-01	4.09e-05	9.57e-05
CaMK IV-mediated phosphorylation of CREB	10	7.76e-02	1.43e-01	0.46200	-2.91e-01	-3.59e-01	1.11e-01	4.94e-02
SCF(Skp2)-mediated degradation of p27/p21	58	4.76e-07	6.03e-06	0.46000	3.16e-01	3.34e-01	3.14e-05	1.07e-05
Sensory perception of taste	47	6.60e-06	5.46e-05	0.46000	-2.79e-01	-3.65e-01	9.45e-04	1.45e-05
Platelet Adhesion to exposed collagen	13	2.85e-02	6.84e-02	0.45800	-4.21e-01	-1.82e-01	8.60e-03	2.57e-01
Defective B3GALT6 causes EDSP2 and SEMDJL1	17	1.30e-02	3.66e-02	0.45800	-3.78e-01	-2.59e-01	6.98e-03	6.43e-02
Nucleotide-like (purinergic) receptors	13	2.67e-02	6.50e-02	0.45800	-4.28e-01	-1.64e-01	7.55e-03	3.07e-01
Antigen activates B Cell Receptor (BCR) leading to generation of second messengers	28	6.74e-04	3.00e-03	0.45700	-3.98e-01	-2.26e-01	2.71e-04	3.82e-02
ECM proteoglycans	55	1.25e-06	1.43e-05	0.45600	-3.30e-01	-3.16e-01	2.34e-05	5.10e-05
SARS-CoV-2 modulates host translation machinery	46	7.08e-06	5.79e-05	0.45500	3.94e-01	2.28e-01	3.68e-06	7.48e-03
AUF1 (hnRNP D0) binds and destabilizes mRNA	53	1.94e-06	2.09e-05	0.45500	3.59e-01	2.80e-01	6.19e-06	4.24e-04
Ubiquitin Mediated Degradation of Phosphorylated Cdc25A	50	4.29e-06	3.85e-05	0.45500	3.54e-01	2.86e-01	1.52e-05	4.69e-04
p53-Independent DNA Damage Response	50	4.29e-06	3.85e-05	0.45500	3.54e-01	2.86e-01	1.52e-05	4.69e-04
p53-Independent G1/S DNA damage checkpoint	50	4.29e-06	3.85e-05	0.45500	3.54e-01	2.86e-01	1.52e-05	4.69e-04
Signaling by WNT in cancer	32	1.06e-05	8.28e-05	0.45400	-4.49e-01	6.72e-02	1.07e-05	5.11e-01
Interaction With Cumulus Cells And The Zona Pellucida	11	1.48e-02	4.06e-02	0.45400	1.42e-01	-4.31e-01	4.14e-01	1.34e-02
Collagen degradation	39	6.03e-05	3.87e-04	0.45300	-3.72e-01	-2.59e-01	5.85e-05	5.09e-03
Myogenesis	29	2.42e-04	1.23e-03	0.45300	-4.38e-01	-1.16e-01	4.49e-05	2.78e-01
Dectin-2 family	28	9.66e-04	4.15e-03	0.45300	-3.67e-01	-2.65e-01	7.66e-04	1.52e-02
SUMOylation of intracellular receptors	29	5.33e-05	3.46e-04	0.45300	-4.52e-01	2.45e-02	2.50e-05	8.19e-01
MECP2 regulates neuronal receptors and channels	17	1.09e-02	3.20e-02	0.45300	-4.14e-01	-1.84e-01	3.15e-03	1.89e-01
Other semaphorin interactions	18	7.29e-03	2.29e-02	0.45200	-4.25e-01	-1.55e-01	1.81e-03	2.55e-01
Trafficking of GluR2-containing AMPA receptors	15	2.62e-02	6.40e-02	0.45200	-3.30e-01	-3.08e-01	2.67e-02	3.86e-02
PKA activation	18	9.34e-03	2.81e-02	0.45100	-4.04e-01	-2.01e-01	2.97e-03	1.40e-01
Vpu mediated degradation of CD4	50	5.71e-06	4.82e-05	0.45000	3.44e-01	2.90e-01	2.59e-05	3.81e-04
Constitutive Signaling by Overexpressed ERBB2	10	2.49e-02	6.16e-02	0.45000	-1.18e-01	4.34e-01	5.17e-01	1.75e-02
Transcriptional regulation of granulopoiesis	31	3.10e-06	3.07e-05	0.44900	-3.20e-01	3.14e-01	2.02e-03	2.45e-03
Cell-cell junction organization	56	1.49e-06	1.69e-05	0.44800	-2.83e-01	-3.47e-01	2.51e-04	6.96e-06
ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression	16	1.48e-03	5.98e-03	0.44800	-3.15e-01	3.18e-01	2.94e-02	2.74e-02
NCAM1 interactions	36	2.05e-04	1.07e-03	0.44600	-3.06e-01	-3.24e-01	1.50e-03	7.54e-04
RHOF GTPase cycle	40	7.62e-05	4.68e-04	0.44500	-3.47e-01	-2.78e-01	1.43e-04	2.33e-03
Response of EIF2AK4 (GCN2) to amino acid deficiency	95	1.01e-10	3.12e-09	0.44500	3.75e-01	2.40e-01	2.68e-10	5.23e-05
Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC)	89	4.75e-10	1.22e-08	0.44500	3.71e-01	2.45e-01	1.36e-09	6.51e-05
Prednisone ADME	10	7.44e-02	1.39e-01	0.44500	-1.69e-01	-4.11e-01	3.54e-01	2.43e-02
Aberrant regulation of mitotic G1/S transition in cancer due to RB1 defects	17	1.18e-03	4.89e-03	0.44300	-2.79e-01	3.44e-01	4.65e-02	1.41e-02
Defective binding of RB1 mutants to E2F1,(E2F2, E2F3)	17	1.18e-03	4.89e-03	0.44300	-2.79e-01	3.44e-01	4.65e-02	1.41e-02
Formation of a pool of free 40S subunits	94	1.40e-10	4.25e-09	0.44200	3.81e-01	2.24e-01	1.73e-10	1.77e-04
Adenylate cyclase inhibitory pathway	14	2.64e-02	6.45e-02	0.44100	-4.13e-01	-1.54e-01	7.40e-03	3.17e-01
Vif-mediated degradation of APOBEC3G	50	8.77e-06	7.14e-05	0.44000	3.49e-01	2.69e-01	1.98e-05	9.92e-04
SCF-beta-TrCP mediated degradation of Emi1	53	5.02e-06	4.39e-05	0.44000	3.21e-01	3.01e-01	5.12e-05	1.50e-04
MET activates RAP1 and RAC1	11	2.94e-02	7.02e-02	0.43700	-4.36e-01	3.46e-02	1.23e-02	8.42e-01
Ubiquitin-dependent degradation of Cyclin D	50	1.03e-05	8.08e-05	0.43700	3.48e-01	2.65e-01	2.11e-05	1.17e-03
Cell junction organization	79	1.63e-08	3.00e-07	0.43700	-2.93e-01	-3.25e-01	6.77e-06	6.00e-07
Formation of the ternary complex, and subsequently, the 43S complex	46	1.24e-05	9.41e-05	0.43700	3.96e-01	1.85e-01	3.31e-06	3.02e-02
Autodegradation of Cdh1 by Cdh1:APC/C	62	7.81e-07	9.29e-06	0.43700	2.91e-01	3.26e-01	7.51e-05	8.90e-06
TFAP2 (AP-2) family regulates transcription of growth factors and their receptors	12	1.15e-02	3.31e-02	0.43600	-3.88e-01	2.00e-01	2.00e-02	2.30e-01
Defective B3GAT3 causes JDSSDHD	17	2.04e-02	5.23e-02	0.43600	-3.48e-01	-2.63e-01	1.30e-02	6.00e-02
APC/C:Cdc20 mediated degradation of Cyclin B	24	3.70e-03	1.31e-02	0.43600	2.34e-01	3.68e-01	4.72e-02	1.80e-03
Regulation of activated PAK-2p34 by proteasome mediated degradation	48	1.78e-05	1.30e-04	0.43600	3.44e-01	2.68e-01	3.70e-05	1.33e-03
Autodegradation of the E3 ubiquitin ligase COP1	50	1.00e-05	7.89e-05	0.43500	3.60e-01	2.44e-01	1.04e-05	2.85e-03
SRP-dependent cotranslational protein targeting to membrane	105	3.10e-11	1.07e-09	0.43300	3.67e-01	2.30e-01	7.49e-11	4.70e-05
VEGFA-VEGFR2 Pathway	93	1.13e-11	4.26e-10	0.43200	-4.24e-01	-8.06e-02	1.44e-12	1.79e-01
Cell-Cell communication	112	1.80e-11	6.45e-10	0.43200	-3.16e-01	-2.94e-01	7.30e-09	7.49e-08
Signaling by VEGF	101	3.59e-12	1.59e-10	0.43100	-4.18e-01	-1.05e-01	3.89e-13	6.82e-02
The role of GTSE1 in G2/M progression after G2 checkpoint	58	2.82e-06	2.89e-05	0.43100	3.18e-01	2.90e-01	2.78e-05	1.30e-04
SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion	13	3.72e-02	8.31e-02	0.43000	-4.10e-01	-1.29e-01	1.04e-02	4.21e-01
Hh mutants abrogate ligand secretion	57	4.17e-06	3.82e-05	0.42800	3.04e-01	3.02e-01	7.25e-05	8.15e-05
Extracellular matrix organization	287	1.23e-27	9.54e-25	0.42700	-3.28e-01	-2.73e-01	9.24e-22	1.61e-15
EPHA-mediated growth cone collapse	15	3.72e-02	8.31e-02	0.42600	-3.44e-01	-2.51e-01	2.09e-02	9.25e-02
Pyrimidine salvage	10	3.54e-02	8.01e-02	0.42400	-4.04e-01	1.29e-01	2.69e-02	4.79e-01
Digestion and absorption	23	5.43e-03	1.80e-02	0.42400	-1.96e-01	-3.76e-01	1.03e-01	1.82e-03
Post NMDA receptor activation events	58	2.71e-06	2.79e-05	0.42300	-3.63e-01	-2.18e-01	1.77e-06	4.10e-03
Transcriptional Regulation by MECP2	60	2.61e-07	3.57e-06	0.42100	-4.11e-01	-9.38e-02	3.74e-08	2.09e-01
RAC1 GTPase cycle	170	2.57e-17	2.49e-15	0.42000	-3.78e-01	-1.84e-01	1.74e-17	3.28e-05
BMAL1:CLOCK,NPAS2 activates circadian gene expression	27	2.88e-03	1.06e-02	0.42000	-3.54e-01	-2.26e-01	1.44e-03	4.16e-02
RHOC GTPase cycle	69	8.82e-08	1.32e-06	0.42000	-3.94e-01	-1.46e-01	1.48e-08	3.57e-02
FBXL7 down-regulates AURKA during mitotic entry and in early mitosis	53	1.42e-05	1.07e-04	0.42000	3.25e-01	2.65e-01	4.16e-05	8.32e-04
CREB1 phosphorylation through NMDA receptor-mediated activation of RAS signaling	25	4.50e-03	1.53e-02	0.42000	-3.54e-01	-2.25e-01	2.16e-03	5.16e-02
Stabilization of p53	55	9.52e-06	7.59e-05	0.41900	3.28e-01	2.60e-01	2.52e-05	8.35e-04
Respiratory electron transport	90	3.11e-09	6.59e-08	0.41900	2.10e-01	3.62e-01	5.55e-04	2.80e-09
PINK1-PRKN Mediated Mitophagy	21	9.31e-03	2.81e-02	0.41900	1.88e-01	3.74e-01	1.35e-01	3.01e-03
APC/C:Cdc20 mediated degradation of Securin	66	1.16e-06	1.34e-05	0.41800	3.05e-01	2.85e-01	1.82e-05	6.00e-05
Mitochondrial iron-sulfur cluster biogenesis	12	6.48e-02	1.24e-01	0.41600	1.56e-01	3.86e-01	3.50e-01	2.06e-02
RND2 GTPase cycle	42	1.71e-04	9.26e-04	0.41500	-3.28e-01	-2.54e-01	2.38e-04	4.31e-03
GTP hydrolysis and joining of the 60S ribosomal subunit	104	2.56e-10	7.47e-09	0.41500	3.56e-01	2.12e-01	3.38e-10	1.81e-04
Early Phase of HIV Life Cycle	14	2.56e-02	6.30e-02	0.41400	4.16e-02	4.12e-01	7.87e-01	7.57e-03
Regulation of NPAS4 gene expression	13	5.57e-02	1.11e-01	0.41400	-3.78e-01	-1.68e-01	1.82e-02	2.94e-01
Cross-presentation of soluble exogenous antigens (endosomes)	46	7.91e-05	4.83e-04	0.41300	3.32e-01	2.45e-01	9.53e-05	4.11e-03
SUMOylation of DNA methylation proteins	16	1.01e-02	3.00e-02	0.41200	-4.10e-01	3.97e-02	4.50e-03	7.83e-01
L1CAM interactions	92	6.21e-09	1.23e-07	0.41200	-3.37e-01	-2.36e-01	2.19e-08	8.81e-05
Reduction of cytosolic Ca++ levels	11	9.77e-02	1.69e-01	0.41200	-2.03e-01	-3.58e-01	2.43e-01	3.97e-02
Ras activation upon Ca2+ influx through NMDA receptor	19	2.22e-02	5.62e-02	0.41000	-3.08e-01	-2.71e-01	1.99e-02	4.11e-02
Regulation of KIT signaling	16	3.31e-02	7.64e-02	0.40900	-3.67e-01	-1.81e-01	1.11e-02	2.11e-01
Platelet calcium homeostasis	27	2.42e-03	9.08e-03	0.40800	-3.84e-01	-1.41e-01	5.60e-04	2.06e-01
Ca2+ pathway	62	4.03e-06	3.73e-05	0.40800	-3.27e-01	-2.44e-01	8.26e-06	9.05e-04
L13a-mediated translational silencing of Ceruloplasmin expression	103	7.65e-10	1.88e-08	0.40600	3.50e-01	2.04e-01	7.89e-10	3.34e-04
Inositol phosphate metabolism	45	8.15e-05	4.87e-04	0.40400	-3.65e-01	-1.72e-01	2.21e-05	4.64e-02
Regulation of RUNX3 expression and activity	53	3.62e-05	2.47e-04	0.40300	2.89e-01	2.81e-01	2.69e-04	3.99e-04
Spry regulation of FGF signaling	16	2.17e-02	5.53e-02	0.40300	6.57e-02	3.98e-01	6.49e-01	5.89e-03
Gap junction degradation	10	1.34e-01	2.13e-01	0.40200	-3.47e-01	-2.03e-01	5.75e-02	2.66e-01
Heme signaling	45	8.16e-05	4.87e-04	0.40200	-3.67e-01	-1.63e-01	2.00e-05	5.87e-02
APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1	72	1.06e-06	1.24e-05	0.40100	2.79e-01	2.89e-01	4.20e-05	2.28e-05
O-linked glycosylation	107	8.40e-10	2.03e-08	0.40100	-3.31e-01	-2.26e-01	3.10e-09	5.21e-05
Defective CFTR causes cystic fibrosis	59	1.17e-05	8.97e-05	0.40100	3.16e-01	2.46e-01	2.66e-05	1.06e-03
G alpha (12/13) signalling events	74	2.12e-07	2.95e-06	0.40100	-3.66e-01	-1.63e-01	5.12e-08	1.53e-02
Cap-dependent Translation Initiation	111	2.70e-10	7.58e-09	0.40000	3.46e-01	2.02e-01	3.06e-10	2.33e-04
Eukaryotic Translation Initiation	111	2.70e-10	7.58e-09	0.40000	3.46e-01	2.02e-01	3.06e-10	2.33e-04
Disorders of Developmental Biology	11	3.04e-02	7.15e-02	0.40000	-3.43e-01	2.05e-01	4.86e-02	2.38e-01
Disorders of Nervous System Development	11	3.04e-02	7.15e-02	0.40000	-3.43e-01	2.05e-01	4.86e-02	2.38e-01
Loss of function of MECP2 in Rett syndrome	11	3.04e-02	7.15e-02	0.40000	-3.43e-01	2.05e-01	4.86e-02	2.38e-01
Pervasive developmental disorders	11	3.04e-02	7.15e-02	0.40000	-3.43e-01	2.05e-01	4.86e-02	2.38e-01
Selenoamino acid metabolism	103	2.36e-09	5.20e-08	0.40000	3.26e-01	2.31e-01	1.05e-08	5.10e-05
Organic cation transport	10	7.13e-02	1.35e-01	0.39900	-3.99e-01	2.17e-02	2.90e-02	9.05e-01
CDC42 GTPase cycle	143	1.87e-13	9.97e-12	0.39800	-3.64e-01	-1.62e-01	5.43e-14	8.04e-04
Integrin signaling	27	1.74e-03	6.77e-03	0.39800	-3.94e-01	-5.91e-02	3.98e-04	5.95e-01
TRP channels	24	1.09e-02	3.20e-02	0.39800	-2.80e-01	-2.83e-01	1.77e-02	1.63e-02
Heparan sulfate/heparin (HS-GAG) metabolism	49	6.69e-05	4.17e-04	0.39700	-3.44e-01	-1.98e-01	3.06e-05	1.62e-02
Androgen biosynthesis	11	5.88e-02	1.15e-01	0.39700	1.05e-02	-3.97e-01	9.52e-01	2.26e-02
Scavenging of heme from plasma	12	1.05e-01	1.76e-01	0.39700	-3.03e-01	-2.56e-01	6.90e-02	1.25e-01
Regulation of innate immune responses to cytosolic DNA	14	6.36e-02	1.22e-01	0.39600	3.48e-01	1.88e-01	2.41e-02	2.24e-01
FCERI mediated Ca+2 mobilization	27	5.35e-03	1.78e-02	0.39500	-3.40e-01	-2.01e-01	2.20e-03	7.08e-02
Elastic fibre formation	40	2.37e-04	1.21e-03	0.39500	-3.71e-01	-1.33e-01	4.79e-05	1.44e-01
STAT5 activation downstream of FLT3 ITD mutants	10	9.04e-02	1.60e-01	0.39400	2.77e-02	3.93e-01	8.79e-01	3.15e-02
Synthesis of bile acids and bile salts via 27-hydroxycholesterol	15	6.10e-02	1.18e-01	0.39400	-2.37e-01	-3.14e-01	1.12e-01	3.51e-02
Syndecan interactions	19	1.98e-02	5.09e-02	0.39300	-3.69e-01	-1.36e-01	5.36e-03	3.06e-01
N-glycan antennae elongation in the medial/trans-Golgi	26	3.73e-03	1.32e-02	0.39300	-3.79e-01	-1.05e-01	8.26e-04	3.56e-01
MET receptor recycling	10	5.03e-02	1.03e-01	0.39300	-3.54e-01	1.70e-01	5.28e-02	3.51e-01
Suppression of phagosomal maturation	13	8.95e-02	1.59e-01	0.39100	2.24e-01	3.20e-01	1.62e-01	4.54e-02
RIPK1-mediated regulated necrosis	27	7.05e-03	2.24e-02	0.39100	2.41e-01	3.08e-01	3.04e-02	5.55e-03
Regulation of necroptotic cell death	27	7.05e-03	2.24e-02	0.39100	2.41e-01	3.08e-01	3.04e-02	5.55e-03
Negative regulation of NOTCH4 signaling	52	8.31e-05	4.94e-04	0.39000	2.85e-01	2.66e-01	3.69e-04	9.06e-04
Respiratory electron transport, ATP synthesis by chemiosmotic coupling, and heat production by uncoupling proteins.	95	1.47e-08	2.74e-07	0.38900	1.84e-01	3.43e-01	1.92e-03	7.66e-09
HS-GAG biosynthesis	28	6.06e-03	1.99e-02	0.38900	-3.13e-01	-2.31e-01	4.13e-03	3.46e-02
Synthesis of IP2, IP, and Ins in the cytosol	13	6.93e-02	1.31e-01	0.38900	-3.69e-01	-1.22e-01	2.12e-02	4.46e-01
Attachment and Entry 9694614	16	4.29e-02	9.26e-02	0.38900	-3.57e-01	-1.54e-01	1.34e-02	2.86e-01
Activation of NMDA receptors and postsynaptic events	69	2.53e-06	2.65e-05	0.38800	-3.35e-01	-1.97e-01	1.51e-06	4.67e-03
Role of phospholipids in phagocytosis	23	1.27e-02	3.60e-02	0.38800	-3.42e-01	-1.83e-01	4.46e-03	1.29e-01
CDK-mediated phosphorylation and removal of Cdc6	71	3.16e-06	3.09e-05	0.38700	2.49e-01	2.96e-01	2.82e-04	1.60e-05
O-linked glycosylation of mucins	62	6.41e-06	5.36e-05	0.38700	-3.52e-01	-1.60e-01	1.63e-06	2.90e-02
Insulin processing	26	9.29e-03	2.80e-02	0.38700	-3.09e-01	-2.32e-01	6.29e-03	4.09e-02
MyD88 deficiency (TLR2/4)	16	1.18e-02	3.37e-02	0.38600	-1.21e-01	3.67e-01	4.00e-01	1.11e-02
CREB1 phosphorylation through the activation of Adenylate Cyclase	11	9.67e-02	1.68e-01	0.38600	-3.76e-01	-8.72e-02	3.07e-02	6.17e-01
TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest	14	1.46e-02	4.03e-02	0.38600	-2.86e-01	2.58e-01	6.37e-02	9.42e-02
Opioid Signalling	88	5.87e-08	9.17e-07	0.38500	-3.46e-01	-1.69e-01	1.93e-08	6.06e-03
RAC2 GTPase cycle	80	5.53e-08	8.82e-07	0.38500	-3.74e-01	-9.42e-02	7.44e-09	1.45e-01
p38MAPK events	13	2.10e-02	5.36e-02	0.38500	-3.12e-01	2.25e-01	5.14e-02	1.60e-01
Regulation of MECP2 expression and activity	30	1.06e-03	4.48e-03	0.38400	-3.83e-01	-2.95e-02	2.78e-04	7.79e-01
Energy dependent regulation of mTOR by LKB1-AMPK	28	2.25e-04	1.16e-03	0.38400	-2.74e-01	2.69e-01	1.21e-02	1.36e-02
PI Metabolism	79	4.50e-08	7.32e-07	0.38400	-3.77e-01	-7.24e-02	6.58e-09	2.66e-01
Metabolism of nitric oxide: NOS3 activation and regulation	15	4.41e-02	9.47e-02	0.38400	-3.73e-01	-9.30e-02	1.25e-02	5.33e-01
Cdc20:Phospho-APC/C mediated degradation of Cyclin A	71	4.14e-06	3.81e-05	0.38400	2.74e-01	2.69e-01	6.54e-05	8.95e-05
Assembly and cell surface presentation of NMDA receptors	23	1.75e-02	4.64e-02	0.38400	-2.95e-01	-2.45e-01	1.43e-02	4.17e-02
eNOS activation	11	1.10e-01	1.83e-01	0.38400	-3.65e-01	-1.19e-01	3.62e-02	4.94e-01
Chemokine receptors bind chemokines	56	4.08e-07	5.21e-06	0.38300	3.74e-01	-8.45e-02	1.30e-06	2.74e-01
ABC transporters in lipid homeostasis	17	5.15e-02	1.05e-01	0.38300	-2.59e-01	-2.82e-01	6.42e-02	4.41e-02
RND3 GTPase cycle	41	7.61e-04	3.34e-03	0.38300	-2.96e-01	-2.43e-01	1.04e-03	7.10e-03
CASP8 activity is inhibited	11	1.17e-01	1.91e-01	0.38300	3.58e-01	1.34e-01	3.96e-02	4.40e-01
Dimerization of procaspase-8	11	1.17e-01	1.91e-01	0.38300	3.58e-01	1.34e-01	3.96e-02	4.40e-01
Regulation by c-FLIP	11	1.17e-01	1.91e-01	0.38300	3.58e-01	1.34e-01	3.96e-02	4.40e-01
RHOG GTPase cycle	69	2.13e-06	2.27e-05	0.38300	-3.49e-01	-1.56e-01	5.20e-07	2.48e-02
FCGR3A-mediated IL10 synthesis	37	1.20e-03	4.94e-03	0.38100	-3.33e-01	-1.86e-01	4.52e-04	5.05e-02
HuR (ELAVL1) binds and stabilizes mRNA	10	8.06e-02	1.47e-01	0.38100	-3.76e-01	5.81e-02	3.94e-02	7.51e-01
Chondroitin sulfate biosynthesis	18	1.12e-02	3.23e-02	0.38000	-3.77e-01	5.28e-02	5.64e-03	6.98e-01
Signaling by Hippo	19	3.52e-02	7.99e-02	0.38000	-3.15e-01	-2.14e-01	1.76e-02	1.07e-01
CS/DS degradation	12	5.19e-02	1.06e-01	0.38000	-3.78e-01	4.31e-02	2.35e-02	7.96e-01
Integrin cell surface interactions	66	8.99e-06	7.24e-05	0.37900	-3.19e-01	-2.05e-01	7.40e-06	3.88e-03
Defensins	36	2.90e-04	1.43e-03	0.37900	3.79e-01	1.64e-02	8.29e-05	8.65e-01
APC/C:Cdc20 mediated degradation of mitotic proteins	74	3.54e-06	3.34e-05	0.37800	2.59e-01	2.75e-01	1.15e-04	4.17e-05
APC:Cdc20 mediated degradation of cell cycle proteins prior to satisfation of the cell cycle checkpoint	72	5.06e-06	4.40e-05	0.37800	2.67e-01	2.68e-01	8.98e-05	8.52e-05
Beta defensins	28	1.15e-03	4.81e-03	0.37800	3.76e-01	-3.78e-02	5.74e-04	7.29e-01
Activation of APC/C and APC/C:Cdc20 mediated degradation of mitotic proteins	75	3.12e-06	3.07e-05	0.37800	2.58e-01	2.75e-01	1.09e-04	3.72e-05
Serotonin Neurotransmitter Release Cycle	16	6.58e-02	1.26e-01	0.37700	-2.93e-01	-2.37e-01	4.23e-02	1.01e-01
p53-Dependent G1 DNA Damage Response	64	2.09e-05	1.50e-04	0.37700	2.56e-01	2.76e-01	3.96e-04	1.31e-04
p53-Dependent G1/S DNA damage checkpoint	64	2.09e-05	1.50e-04	0.37700	2.56e-01	2.76e-01	3.96e-04	1.31e-04
Mitophagy	27	4.25e-03	1.46e-02	0.37600	7.99e-02	3.67e-01	4.72e-01	9.63e-04
Regulation of ornithine decarboxylase (ODC)	49	2.73e-04	1.36e-03	0.37500	2.81e-01	2.48e-01	6.55e-04	2.63e-03
Cleavage of the damaged pyrimidine	16	2.97e-02	7.04e-02	0.37500	2.11e-02	3.75e-01	8.84e-01	9.48e-03
Depyrimidination	16	2.97e-02	7.04e-02	0.37500	2.11e-02	3.75e-01	8.84e-01	9.48e-03
Recognition and association of DNA glycosylase with site containing an affected pyrimidine	16	2.97e-02	7.04e-02	0.37500	2.11e-02	3.75e-01	8.84e-01	9.48e-03
HS-GAG degradation	18	4.58e-02	9.63e-02	0.37500	-3.11e-01	-2.09e-01	2.22e-02	1.25e-01
Major pathway of rRNA processing in the nucleolus and cytosol	171	2.92e-13	1.50e-11	0.37500	3.03e-01	2.20e-01	7.44e-12	6.80e-07
RUNX1 interacts with co-factors whose precise effect on RUNX1 targets is not known	37	5.65e-04	2.55e-03	0.37400	-3.67e-01	-7.55e-02	1.13e-04	4.27e-01
VxPx cargo-targeting to cilium	20	3.58e-02	8.06e-02	0.37400	-2.74e-01	-2.55e-01	3.39e-02	4.84e-02
Glucuronidation	25	1.05e-02	3.08e-02	0.37400	-1.48e-01	-3.44e-01	2.01e-01	2.94e-03
Transcriptional regulation of pluripotent stem cells	30	3.49e-04	1.69e-03	0.37400	-3.47e-01	1.38e-01	9.93e-04	1.90e-01
Signaling by BMP	27	7.61e-03	2.37e-02	0.37300	-1.51e-01	-3.41e-01	1.75e-01	2.13e-03
Degradation of DVL	55	1.10e-04	6.23e-04	0.37300	2.88e-01	2.36e-01	2.15e-04	2.48e-03
Transport of inorganic cations/anions and amino acids/oligopeptides	101	5.78e-08	9.12e-07	0.37200	-2.39e-01	-2.86e-01	3.33e-05	7.01e-07
Cleavage of the damaged purine	11	4.54e-02	9.63e-02	0.37200	-2.77e-01	2.49e-01	1.12e-01	1.53e-01
Depurination	11	4.54e-02	9.63e-02	0.37200	-2.77e-01	2.49e-01	1.12e-01	1.53e-01
Recognition and association of DNA glycosylase with site containing an affected purine	11	4.54e-02	9.63e-02	0.37200	-2.77e-01	2.49e-01	1.12e-01	1.53e-01
Erythrocytes take up carbon dioxide and release oxygen	12	1.35e-01	2.13e-01	0.37200	-2.21e-01	-2.99e-01	1.84e-01	7.29e-02
O2/CO2 exchange in erythrocytes	12	1.35e-01	2.13e-01	0.37200	-2.21e-01	-2.99e-01	1.84e-01	7.29e-02
Purine ribonucleoside monophosphate biosynthesis	11	5.87e-02	1.15e-01	0.37200	-1.18e-01	3.53e-01	4.99e-01	4.28e-02
RND1 GTPase cycle	41	9.11e-04	3.92e-03	0.37200	-3.18e-01	-1.92e-01	4.18e-04	3.33e-02
Cardiac conduction	123	1.84e-09	4.13e-08	0.37200	-2.55e-01	-2.71e-01	1.06e-06	2.13e-07
Assembly of active LPL and LIPC lipase complexes	17	1.73e-02	4.62e-02	0.37100	5.33e-02	-3.68e-01	7.04e-01	8.70e-03
Ketone body metabolism	10	1.92e-01	2.81e-01	0.37100	-2.89e-01	-2.32e-01	1.13e-01	2.04e-01
rRNA processing in the nucleus and cytosol	180	1.51e-13	8.35e-12	0.37100	2.92e-01	2.29e-01	1.39e-11	1.18e-07
G1/S DNA Damage Checkpoints	66	2.19e-05	1.57e-04	0.37000	2.51e-01	2.72e-01	4.17e-04	1.33e-04
GLI3 is processed to GLI3R by the proteasome	58	8.04e-05	4.86e-04	0.36900	2.83e-01	2.37e-01	1.95e-04	1.76e-03
Regulation of APC/C activators between G1/S and early anaphase	79	2.56e-06	2.65e-05	0.36900	2.29e-01	2.89e-01	4.29e-04	8.62e-06
Kinesins	42	3.72e-04	1.77e-03	0.36900	-3.54e-01	-1.03e-01	7.11e-05	2.48e-01
Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC)	108	1.93e-08	3.47e-07	0.36900	3.02e-01	2.12e-01	5.77e-08	1.43e-04
Nonsense-Mediated Decay (NMD)	108	1.93e-08	3.47e-07	0.36900	3.02e-01	2.12e-01	5.77e-08	1.43e-04
Degradation of GLI2 by the proteasome	58	8.14e-05	4.87e-04	0.36900	2.85e-01	2.33e-01	1.70e-04	2.10e-03
Signal attenuation	10	1.19e-01	1.94e-01	0.36800	-3.67e-01	-1.57e-02	4.42e-02	9.31e-01
Regulation of signaling by CBL	18	5.46e-02	1.09e-01	0.36800	-2.83e-01	-2.34e-01	3.75e-02	8.51e-02
Stimuli-sensing channels	96	2.14e-07	2.95e-06	0.36700	-2.66e-01	-2.53e-01	6.43e-06	1.80e-05
Ribosomal scanning and start codon recognition	53	1.10e-04	6.23e-04	0.36700	3.30e-01	1.60e-01	3.19e-05	4.35e-02
Tie2 Signaling	18	1.26e-02	3.57e-02	0.36700	-3.56e-01	8.91e-02	9.01e-03	5.13e-01
Interleukin-6 signaling	11	1.42e-01	2.22e-01	0.36600	-1.32e-01	-3.41e-01	4.48e-01	4.99e-02
NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux	43	1.49e-04	8.10e-04	0.36600	-3.64e-01	-3.42e-02	3.54e-05	6.98e-01
Tryptophan catabolism	12	1.46e-01	2.27e-01	0.36600	-2.88e-01	-2.25e-01	8.38e-02	1.77e-01
Activation of the mRNA upon binding of the cap-binding complex and eIFs, and subsequent binding to 43S	54	9.30e-05	5.49e-04	0.36500	3.33e-01	1.49e-01	2.33e-05	5.74e-02
APC-Cdc20 mediated degradation of Nek2A	26	1.25e-02	3.56e-02	0.36400	1.64e-01	3.25e-01	1.47e-01	4.11e-03
Defects of contact activation system (CAS) and kallikrein/kinin system (KKS)	14	1.10e-01	1.83e-01	0.36400	-2.65e-01	-2.49e-01	8.57e-02	1.06e-01
Diseases of hemostasis	14	1.10e-01	1.83e-01	0.36400	-2.65e-01	-2.49e-01	8.57e-02	1.06e-01
PKMTs methylate histone lysines	37	1.53e-03	6.12e-03	0.36400	-3.39e-01	-1.32e-01	3.57e-04	1.65e-01
TBC/RABGAPs	42	1.46e-05	1.09e-04	0.36400	-2.06e-01	3.00e-01	2.10e-02	7.64e-04
NR1H2 and NR1H3-mediated signaling	53	4.89e-05	3.20e-04	0.36300	-3.54e-01	-8.38e-02	8.43e-06	2.91e-01
Mitochondrial translation termination	87	1.12e-06	1.30e-05	0.36300	2.28e-01	2.83e-01	2.35e-04	5.17e-06
NIK–>noncanonical NF-kB signaling	57	1.40e-04	7.62e-04	0.36200	2.50e-01	2.62e-01	1.10e-03	6.08e-04
Germ layer formation at gastrulation	16	5.62e-02	1.11e-01	0.36200	-3.46e-01	-1.07e-01	1.66e-02	4.59e-01
POU5F1 (OCT4), SOX2, NANOG activate genes related to proliferation	12	7.27e-02	1.37e-01	0.36200	-3.61e-01	2.56e-02	3.05e-02	8.78e-01
Synthesis of PIPs at the early endosome membrane	15	8.03e-02	1.47e-01	0.36100	-3.28e-01	-1.51e-01	2.78e-02	3.11e-01
Glucagon signaling in metabolic regulation	33	1.41e-03	5.71e-03	0.36100	-3.59e-01	-3.62e-02	3.53e-04	7.19e-01
Synthesis of bile acids and bile salts	34	4.89e-03	1.65e-02	0.36100	-2.86e-01	-2.20e-01	3.84e-03	2.66e-02
IRAK4 deficiency (TLR2/4)	17	1.51e-02	4.11e-02	0.36100	-1.31e-01	3.36e-01	3.49e-01	1.64e-02
Regulation of Apoptosis	51	3.50e-04	1.69e-03	0.36100	2.85e-01	2.21e-01	4.23e-04	6.41e-03
EPH-ephrin mediated repulsion of cells	48	1.38e-04	7.57e-04	0.36000	-3.51e-01	-8.04e-02	2.51e-05	3.35e-01
Translation initiation complex formation	53	1.31e-04	7.23e-04	0.36000	3.30e-01	1.44e-01	3.17e-05	6.93e-02
Gastrulation	21	2.34e-02	5.85e-02	0.36000	-3.45e-01	-1.03e-01	6.18e-03	4.12e-01
CD28 co-stimulation	32	3.33e-03	1.21e-02	0.35900	-3.45e-01	-1.01e-01	7.34e-04	3.24e-01
rRNA processing	186	4.19e-13	2.02e-11	0.35900	2.77e-01	2.29e-01	7.26e-11	7.15e-08
Competing endogenous RNAs (ceRNAs) regulate PTEN translation	16	1.77e-02	4.66e-02	0.35900	-3.17e-01	1.68e-01	2.82e-02	2.44e-01
Signal regulatory protein family interactions	13	4.12e-02	8.96e-02	0.35900	-3.31e-01	1.37e-01	3.85e-02	3.93e-01
IKK complex recruitment mediated by RIP1	22	2.17e-02	5.53e-02	0.35800	1.13e-01	3.40e-01	3.57e-01	5.78e-03
Mitochondrial translation	93	6.83e-07	8.32e-06	0.35800	2.28e-01	2.76e-01	1.42e-04	4.29e-06
RET signaling	41	7.23e-04	3.20e-03	0.35700	-3.43e-01	-9.79e-02	1.44e-04	2.78e-01
Dectin-1 mediated noncanonical NF-kB signaling	60	1.18e-04	6.56e-04	0.35700	2.46e-01	2.58e-01	9.92e-04	5.36e-04
Mitochondrial translation elongation	87	1.92e-06	2.09e-05	0.35600	2.24e-01	2.77e-01	3.04e-04	8.08e-06
Aberrant regulation of mitotic cell cycle due to RB1 defects	36	2.72e-04	1.36e-03	0.35500	-8.54e-02	3.45e-01	3.75e-01	3.40e-04
RHO GTPases Activate ROCKs	19	4.72e-02	9.82e-02	0.35500	-3.19e-01	-1.56e-01	1.62e-02	2.38e-01
Assembly of the pre-replicative complex	82	2.86e-06	2.91e-05	0.35500	1.82e-01	3.05e-01	4.45e-03	1.79e-06
Regulation of TP53 Activity through Acetylation	29	1.52e-03	6.08e-03	0.35500	-3.47e-01	7.34e-02	1.22e-03	4.94e-01
FCERI mediated MAPK activation	29	1.72e-03	6.73e-03	0.35400	-3.50e-01	5.87e-02	1.12e-03	5.84e-01
EGR2 and SOX10-mediated initiation of Schwann cell myelination	27	1.78e-02	4.68e-02	0.35400	-2.34e-01	-2.65e-01	3.50e-02	1.70e-02
Degradation of the extracellular matrix	108	1.12e-07	1.64e-06	0.35400	-2.53e-01	-2.48e-01	5.70e-06	8.61e-06
Mitochondrial translation initiation	87	2.37e-06	2.49e-05	0.35400	2.29e-01	2.70e-01	2.22e-04	1.37e-05
Na+/Cl- dependent neurotransmitter transporters	18	3.26e-02	7.58e-02	0.35300	-3.45e-02	-3.51e-01	8.00e-01	9.88e-03
Activation of IRF3/IRF7 mediated by TBK1/IKK epsilon	17	5.72e-02	1.13e-01	0.35300	1.14e-01	3.34e-01	4.16e-01	1.71e-02
Molecules associated with elastic fibres	29	1.12e-02	3.23e-02	0.35300	-3.06e-01	-1.75e-01	4.30e-03	1.03e-01
Degradation of GLI1 by the proteasome	58	1.93e-04	1.02e-03	0.35200	2.58e-01	2.40e-01	6.78e-04	1.55e-03
Base-Excision Repair, AP Site Formation	18	1.92e-02	4.96e-02	0.35200	-7.04e-02	3.45e-01	6.05e-01	1.13e-02
Sema4D induced cell migration and growth-cone collapse	20	2.09e-02	5.35e-02	0.35100	-3.51e-01	-1.68e-02	6.62e-03	8.97e-01
Ion transport by P-type ATPases	51	5.84e-04	2.63e-03	0.35100	-2.40e-01	-2.56e-01	3.07e-03	1.56e-03
Intrinsic Pathway of Fibrin Clot Formation	21	4.50e-02	9.62e-02	0.35000	-2.12e-01	-2.79e-01	9.23e-02	2.70e-02
Platelet homeostasis	85	3.30e-06	3.17e-05	0.35000	-2.87e-01	-2.00e-01	4.66e-06	1.40e-03
Apoptotic cleavage of cellular proteins	35	2.30e-03	8.75e-03	0.34900	-3.40e-01	-7.99e-02	4.95e-04	4.13e-01
Signaling by PDGF	52	3.54e-04	1.70e-03	0.34900	-3.06e-01	-1.68e-01	1.33e-04	3.58e-02
Golgi Cisternae Pericentriolar Stack Reorganization	14	6.04e-02	1.17e-01	0.34900	-1.37e-02	3.49e-01	9.29e-01	2.37e-02
APC/C-mediated degradation of cell cycle proteins	86	3.49e-06	3.31e-05	0.34900	2.13e-01	2.76e-01	6.21e-04	9.32e-06
Regulation of mitotic cell cycle	86	3.49e-06	3.31e-05	0.34900	2.13e-01	2.76e-01	6.21e-04	9.32e-06
Semaphorin interactions	61	5.61e-05	3.61e-04	0.34800	-3.25e-01	-1.26e-01	1.15e-05	8.77e-02
NCAM signaling for neurite out-growth	57	2.70e-04	1.35e-03	0.34800	-2.66e-01	-2.24e-01	5.11e-04	3.42e-03
Activation of BH3-only proteins	30	4.48e-03	1.53e-02	0.34800	-3.44e-01	-4.87e-02	1.10e-03	6.45e-01
Maturation of spike protein 9694548	35	5.40e-04	2.46e-03	0.34700	-3.40e-01	7.29e-02	5.06e-04	4.55e-01
Neuronal System	371	3.00e-24	7.73e-22	0.34700	-2.92e-01	-1.88e-01	3.69e-22	4.87e-10
Metabolism of polyamines	55	3.68e-04	1.76e-03	0.34700	2.69e-01	2.19e-01	5.48e-04	5.04e-03
RHOA GTPase cycle	140	3.66e-10	9.94e-09	0.34700	-3.17e-01	-1.41e-01	9.39e-11	3.94e-03
Constitutive Signaling by AKT1 E17K in Cancer	25	1.32e-02	3.69e-02	0.34600	-3.39e-01	-6.96e-02	3.31e-03	5.47e-01
Synthesis of very long-chain fatty acyl-CoAs	23	3.78e-02	8.38e-02	0.34600	-2.44e-01	-2.45e-01	4.24e-02	4.16e-02
Signaling by PDGFR in disease	20	2.25e-02	5.66e-02	0.34600	-3.46e-01	-9.91e-03	7.41e-03	9.39e-01
SARS-CoV-2 targets host intracellular signalling and regulatory pathways	12	1.43e-01	2.22e-01	0.34600	-3.28e-01	-1.09e-01	4.90e-02	5.13e-01
Anti-inflammatory response favouring Leishmania parasite infection	75	1.08e-05	8.38e-05	0.34600	-3.11e-01	-1.51e-01	3.20e-06	2.34e-02
Leishmania parasite growth and survival	75	1.08e-05	8.38e-05	0.34600	-3.11e-01	-1.51e-01	3.20e-06	2.34e-02
Recycling of bile acids and salts	18	7.52e-02	1.40e-01	0.34600	-2.08e-01	-2.76e-01	1.26e-01	4.27e-02
Condensation of Prometaphase Chromosomes	11	1.20e-01	1.95e-01	0.34500	-3.35e-03	3.45e-01	9.85e-01	4.75e-02
Chondroitin sulfate/dermatan sulfate metabolism	45	3.91e-04	1.85e-03	0.34400	-3.40e-01	-5.71e-02	8.05e-05	5.07e-01
Paracetamol ADME	27	2.25e-02	5.66e-02	0.34400	-2.45e-01	-2.41e-01	2.74e-02	2.99e-02
Dermatan sulfate biosynthesis	10	2.06e-01	2.96e-01	0.34400	-3.23e-01	-1.19e-01	7.74e-02	5.13e-01
Defective pyroptosis	11	7.48e-02	1.39e-01	0.34400	-1.87e-01	2.88e-01	2.82e-01	9.78e-02
Influenza Viral RNA Transcription and Replication	129	1.33e-08	2.52e-07	0.34400	2.65e-01	2.18e-01	1.94e-07	1.82e-05
Sodium/Calcium exchangers	11	1.59e-01	2.43e-01	0.34300	-8.05e-02	-3.34e-01	6.44e-01	5.54e-02
Degradation of AXIN	53	5.46e-04	2.47e-03	0.34300	2.76e-01	2.03e-01	5.03e-04	1.04e-02
Lysosome Vesicle Biogenesis	33	3.94e-04	1.85e-03	0.34300	-2.19e-01	2.64e-01	2.97e-02	8.70e-03
Signalling to RAS	20	1.11e-02	3.22e-02	0.34200	-3.13e-01	1.39e-01	1.54e-02	2.83e-01
Signaling by cytosolic FGFR1 fusion mutants	17	3.67e-02	8.23e-02	0.34200	-3.41e-01	2.24e-02	1.49e-02	8.73e-01
Diseases associated with glycosaminoglycan metabolism	38	3.66e-03	1.31e-02	0.34100	-3.04e-01	-1.54e-01	1.17e-03	1.00e-01
Signaling by FLT3 fusion proteins	19	1.41e-02	3.91e-02	0.34100	-3.10e-01	1.42e-01	1.93e-02	2.84e-01
Phosphorylation of the APC/C	20	4.59e-02	9.63e-02	0.34000	1.18e-01	3.19e-01	3.63e-01	1.36e-02
CTNNB1 S33 mutants aren’t phosphorylated	14	1.05e-01	1.76e-01	0.34000	-3.28e-01	-8.93e-02	3.38e-02	5.63e-01
CTNNB1 S37 mutants aren’t phosphorylated	14	1.05e-01	1.76e-01	0.34000	-3.28e-01	-8.93e-02	3.38e-02	5.63e-01
CTNNB1 S45 mutants aren’t phosphorylated	14	1.05e-01	1.76e-01	0.34000	-3.28e-01	-8.93e-02	3.38e-02	5.63e-01
CTNNB1 T41 mutants aren’t phosphorylated	14	1.05e-01	1.76e-01	0.34000	-3.28e-01	-8.93e-02	3.38e-02	5.63e-01
Signaling by CTNNB1 phospho-site mutants	14	1.05e-01	1.76e-01	0.34000	-3.28e-01	-8.93e-02	3.38e-02	5.63e-01
Signaling by GSK3beta mutants	14	1.05e-01	1.76e-01	0.34000	-3.28e-01	-8.93e-02	3.38e-02	5.63e-01
Josephin domain DUBs	11	2.08e-01	2.98e-01	0.33900	1.72e-01	2.92e-01	3.24e-01	9.32e-02
Crosslinking of collagen fibrils	10	2.41e-01	3.30e-01	0.33900	-2.92e-01	-1.72e-01	1.10e-01	3.47e-01
Regulation of expression of SLITs and ROBOs	159	3.32e-10	9.17e-09	0.33800	2.72e-01	2.00e-01	3.01e-09	1.28e-05
Muscle contraction	193	4.90e-12	2.05e-10	0.33800	-2.25e-01	-2.52e-01	6.51e-08	1.63e-09
Biotin transport and metabolism	10	2.18e-01	3.07e-01	0.33700	-3.17e-01	-1.12e-01	8.23e-02	5.39e-01
RHOH GTPase cycle	36	7.29e-04	3.21e-03	0.33600	-3.30e-01	6.69e-02	6.17e-04	4.87e-01
Bile acid and bile salt metabolism	45	2.35e-03	8.88e-03	0.33600	-2.22e-01	-2.52e-01	9.91e-03	3.38e-03
Signaling by BRAF and RAF1 fusions	60	8.01e-05	4.85e-04	0.33600	-3.24e-01	-8.97e-02	1.41e-05	2.29e-01
Assembly of the ORC complex at the origin of replication	10	1.01e-01	1.73e-01	0.33600	-2.43e-01	2.32e-01	1.83e-01	2.03e-01
RHOD GTPase cycle	48	1.33e-03	5.40e-03	0.33600	-2.82e-01	-1.82e-01	7.09e-04	2.95e-02
Processing of Intronless Pre-mRNAs	19	1.73e-02	4.62e-02	0.33400	-1.28e-01	3.09e-01	3.35e-01	1.96e-02
Ion homeostasis	50	1.17e-03	4.88e-03	0.33400	-2.71e-01	-1.95e-01	9.05e-04	1.68e-02
ADORA2B mediated anti-inflammatory cytokines production	42	1.70e-03	6.66e-03	0.33400	-3.18e-01	-1.04e-01	3.65e-04	2.45e-01
Switching of origins to a post-replicative state	90	4.40e-06	3.90e-05	0.33400	1.77e-01	2.83e-01	3.67e-03	3.34e-06
MTOR signalling	40	1.18e-04	6.56e-04	0.33400	-2.51e-01	2.20e-01	5.97e-03	1.59e-02
Translation of Replicase and Assembly of the Replication Transcription Complex 9694676	14	7.68e-02	1.42e-01	0.33300	-1.63e-02	3.33e-01	9.16e-01	3.11e-02
Signal amplification	33	9.11e-04	3.92e-03	0.33300	-3.07e-01	1.29e-01	2.27e-03	1.98e-01
Vasopressin regulates renal water homeostasis via Aquaporins	42	2.43e-03	9.08e-03	0.33300	-3.04e-01	-1.36e-01	6.57e-04	1.26e-01
Synthesis of PIPs at the late endosome membrane	10	1.28e-01	2.05e-01	0.33300	-3.17e-01	1.01e-01	8.25e-02	5.79e-01
Complex I biogenesis	49	1.33e-03	5.41e-03	0.33200	1.81e-01	2.79e-01	2.86e-02	7.27e-04
Dopamine Neurotransmitter Release Cycle	20	7.21e-02	1.36e-01	0.33200	-2.48e-01	-2.21e-01	5.44e-02	8.74e-02
Erythropoietin activates Phosphoinositide-3-kinase (PI3K)	12	2.03e-01	2.94e-01	0.33200	-2.67e-01	-1.97e-01	1.09e-01	2.38e-01
RUNX1 regulates genes involved in megakaryocyte differentiation and platelet function	38	1.62e-03	6.43e-03	0.33100	-3.30e-01	-2.44e-02	4.33e-04	7.95e-01
Regulation of TLR by endogenous ligand	17	2.31e-02	5.79e-02	0.33100	-2.18e-01	2.49e-01	1.20e-01	7.59e-02
Miscellaneous transport and binding events	21	6.28e-02	1.21e-01	0.33100	-1.96e-01	-2.66e-01	1.20e-01	3.47e-02
Nuclear Receptor transcription pathway	51	4.36e-04	2.02e-03	0.33000	-3.18e-01	-8.89e-02	8.39e-05	2.72e-01
RAC3 GTPase cycle	84	4.42e-06	3.90e-05	0.33000	-3.12e-01	-1.06e-01	7.40e-07	9.38e-02
HDL remodeling	10	2.75e-01	3.67e-01	0.32900	-2.41e-01	-2.25e-01	1.87e-01	2.19e-01
DNA Replication Pre-Initiation	97	2.23e-06	2.36e-05	0.32900	1.66e-01	2.84e-01	4.71e-03	1.30e-06
GABA receptor activation	57	2.80e-04	1.38e-03	0.32900	-3.07e-01	-1.18e-01	5.98e-05	1.24e-01
RHO GTPases Activate NADPH Oxidases	22	1.28e-02	3.62e-02	0.32900	-3.16e-01	9.01e-02	1.02e-02	4.64e-01
G-protein beta:gamma signalling	30	7.54e-03	2.35e-02	0.32800	-3.26e-01	-3.85e-02	1.99e-03	7.15e-01
SUMOylation of transcription factors	20	2.58e-02	6.33e-02	0.32800	-3.36e-02	3.27e-01	7.95e-01	1.14e-02
Plasma lipoprotein remodeling	32	8.94e-03	2.73e-02	0.32800	-9.72e-02	-3.13e-01	3.41e-01	2.16e-03
PI3K events in ERBB2 signaling	16	1.29e-01	2.05e-01	0.32800	-2.16e-01	-2.46e-01	1.34e-01	8.80e-02
Glycosaminoglycan metabolism	116	3.57e-08	6.07e-07	0.32800	-3.14e-01	-9.29e-02	4.84e-09	8.39e-02
Translation	262	4.64e-15	2.87e-13	0.32700	2.36e-01	2.26e-01	4.26e-11	2.88e-10
Regulation of BACH1 activity	15	1.42e-01	2.22e-01	0.32700	1.82e-01	2.71e-01	2.23e-01	6.89e-02
Diseases of mitotic cell cycle	37	7.20e-04	3.19e-03	0.32600	-9.16e-02	3.13e-01	3.35e-01	9.73e-04
Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha	62	3.94e-04	1.85e-03	0.32600	2.22e-01	2.39e-01	2.50e-03	1.12e-03
Hormone ligand-binding receptors	13	1.03e-01	1.75e-01	0.32600	1.40e-02	-3.26e-01	9.30e-01	4.19e-02
Ion channel transport	168	6.59e-10	1.64e-08	0.32500	-2.49e-01	-2.09e-01	2.40e-08	2.84e-06
RHO GTPase cycle	420	4.06e-26	2.09e-23	0.32500	-3.05e-01	-1.14e-01	6.57e-27	5.76e-05
SARS-CoV-2 modulates autophagy	11	9.53e-02	1.66e-01	0.32500	-1.98e-01	2.59e-01	2.57e-01	1.37e-01
Sema4D in semaphorin signaling	24	1.94e-02	5.01e-02	0.32500	-3.24e-01	-2.16e-02	5.93e-03	8.55e-01
GPER1 signaling	44	1.05e-03	4.44e-03	0.32500	-3.21e-01	-5.15e-02	2.30e-04	5.55e-01
Senescence-Associated Secretory Phenotype (SASP)	53	3.87e-04	1.84e-03	0.32400	7.81e-02	3.15e-01	3.25e-01	7.39e-05
Activation of GABAB receptors	43	3.96e-03	1.37e-02	0.32400	-2.73e-01	-1.74e-01	1.93e-03	4.83e-02
GABA B receptor activation	43	3.96e-03	1.37e-02	0.32400	-2.73e-01	-1.74e-01	1.93e-03	4.83e-02
Aberrant regulation of mitotic exit in cancer due to RB1 defects	20	4.29e-02	9.26e-02	0.32400	4.20e-02	3.21e-01	7.45e-01	1.29e-02
Circadian Clock	69	2.59e-05	1.82e-04	0.32400	-3.19e-01	-5.70e-02	4.67e-06	4.13e-01
Influenza Infection	148	1.13e-08	2.17e-07	0.32300	2.37e-01	2.19e-01	6.02e-07	4.06e-06
ERBB2 Activates PTK6 Signaling	13	1.95e-01	2.85e-01	0.32300	-1.93e-01	-2.59e-01	2.29e-01	1.06e-01
Norepinephrine Neurotransmitter Release Cycle	16	1.37e-01	2.15e-01	0.32300	-2.47e-01	-2.07e-01	8.72e-02	1.51e-01
Hedgehog ligand biogenesis	63	4.33e-04	2.01e-03	0.32200	2.21e-01	2.34e-01	2.44e-03	1.29e-03
E2F mediated regulation of DNA replication	20	1.64e-02	4.42e-02	0.32200	-2.73e-01	1.69e-01	3.44e-02	1.90e-01
Activation of kainate receptors upon glutamate binding	29	2.53e-02	6.23e-02	0.32100	-2.73e-01	-1.68e-01	1.08e-02	1.17e-01
Orc1 removal from chromatin	69	2.16e-04	1.11e-03	0.32000	2.06e-01	2.45e-01	3.07e-03	4.22e-04
PI3K events in ERBB4 signaling	10	2.89e-01	3.79e-01	0.32000	-1.82e-01	-2.63e-01	3.19e-01	1.50e-01
Rap1 signalling	16	1.20e-01	1.95e-01	0.31900	-2.93e-01	-1.28e-01	4.28e-02	3.74e-01
SHC1 events in EGFR signaling	14	5.69e-02	1.12e-01	0.31900	-2.54e-01	1.92e-01	9.95e-02	2.13e-01
Mitochondrial protein import	54	5.18e-04	2.38e-03	0.31900	8.93e-02	3.06e-01	2.56e-01	1.01e-04
Lysine catabolism	12	2.33e-01	3.23e-01	0.31800	-1.96e-01	-2.50e-01	2.39e-01	1.34e-01
Erythropoietin activates RAS	14	6.02e-02	1.17e-01	0.31700	-2.67e-01	1.72e-01	8.38e-02	2.66e-01
Scavenging by Class A Receptors	19	1.04e-01	1.76e-01	0.31700	-2.16e-01	-2.32e-01	1.04e-01	7.98e-02
Integration of energy metabolism	106	8.74e-07	1.03e-05	0.31600	-2.94e-01	-1.16e-01	1.67e-07	3.90e-02
CD209 (DC-SIGN) signaling	20	8.67e-02	1.54e-01	0.31600	-2.65e-01	-1.72e-01	3.99e-02	1.84e-01
Prolonged ERK activation events	14	1.76e-01	2.61e-01	0.31500	-2.75e-01	-1.55e-01	7.51e-02	3.15e-01
The phototransduction cascade	32	2.34e-02	5.85e-02	0.31400	-2.14e-01	-2.30e-01	3.61e-02	2.43e-02
RAF activation	33	8.52e-03	2.62e-02	0.31400	-3.09e-01	-5.39e-02	2.11e-03	5.92e-01
tRNA Aminoacylation	24	1.10e-02	3.20e-02	0.31400	-1.21e-01	2.89e-01	3.03e-01	1.42e-02
SARS-CoV-1-host interactions	90	2.78e-05	1.94e-04	0.31300	2.06e-01	2.36e-01	7.29e-04	1.09e-04
Maturation of nucleoprotein 9683610	11	2.09e-01	2.98e-01	0.31300	-5.90e-02	-3.07e-01	7.35e-01	7.78e-02
Diseases of glycosylation	137	3.78e-08	6.35e-07	0.31300	-2.82e-01	-1.35e-01	1.16e-08	6.41e-03
Translocation of SLC2A4 (GLUT4) to the plasma membrane	51	1.80e-04	9.64e-04	0.31200	-3.09e-01	4.66e-02	1.34e-04	5.65e-01
Endogenous sterols	26	4.84e-02	9.98e-02	0.31200	-2.41e-01	-1.98e-01	3.31e-02	8.06e-02
Asymmetric localization of PCP proteins	62	7.95e-04	3.47e-03	0.31100	2.31e-01	2.09e-01	1.69e-03	4.36e-03
Diseases associated with glycosylation precursor biosynthesis	15	1.35e-01	2.13e-01	0.31100	8.81e-02	2.98e-01	5.54e-01	4.54e-02
Phospholipid metabolism	192	4.67e-12	2.00e-10	0.31000	-3.02e-01	-7.07e-02	5.17e-13	9.09e-02
Nucleotide biosynthesis	14	7.99e-02	1.46e-01	0.31000	-1.06e-01	2.91e-01	4.91e-01	5.95e-02
Formation of the beta-catenin:TCF transactivating complex	32	2.67e-02	6.50e-02	0.30800	-2.01e-01	-2.34e-01	4.95e-02	2.20e-02
Aspirin ADME	44	1.66e-03	6.56e-03	0.30800	-2.82e-02	-3.07e-01	7.46e-01	4.27e-04
JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1	15	1.03e-01	1.76e-01	0.30800	-3.08e-01	-3.29e-03	3.91e-02	9.82e-01
Conversion from APC/C:Cdc20 to APC/C:Cdh1 in late anaphase	20	6.16e-02	1.19e-01	0.30700	4.82e-02	3.03e-01	7.09e-01	1.89e-02
SHC1 events in ERBB4 signaling	14	8.20e-02	1.49e-01	0.30600	-2.84e-01	1.16e-01	6.62e-02	4.54e-01
Neurotransmitter receptors and postsynaptic signal transmission	175	1.05e-09	2.41e-08	0.30600	-2.73e-01	-1.39e-01	4.61e-10	1.55e-03
Synthesis of active ubiquitin: roles of E1 and E2 enzymes	27	4.75e-02	9.86e-02	0.30600	1.81e-01	2.47e-01	1.04e-01	2.65e-02
Infection with Mycobacterium tuberculosis	25	5.21e-02	1.06e-01	0.30600	1.40e-01	2.72e-01	2.25e-01	1.87e-02
ERBB2 Regulates Cell Motility	15	1.79e-01	2.63e-01	0.30500	-2.59e-01	-1.61e-01	8.20e-02	2.79e-01
APC truncation mutants have impaired AXIN binding	13	1.74e-01	2.59e-01	0.30500	-2.99e-01	-6.16e-02	6.21e-02	7.01e-01
AXIN missense mutants destabilize the destruction complex	13	1.74e-01	2.59e-01	0.30500	-2.99e-01	-6.16e-02	6.21e-02	7.01e-01
Signaling by AMER1 mutants	13	1.74e-01	2.59e-01	0.30500	-2.99e-01	-6.16e-02	6.21e-02	7.01e-01
Signaling by APC mutants	13	1.74e-01	2.59e-01	0.30500	-2.99e-01	-6.16e-02	6.21e-02	7.01e-01
Signaling by AXIN mutants	13	1.74e-01	2.59e-01	0.30500	-2.99e-01	-6.16e-02	6.21e-02	7.01e-01
Truncations of AMER1 destabilize the destruction complex	13	1.74e-01	2.59e-01	0.30500	-2.99e-01	-6.16e-02	6.21e-02	7.01e-01
Lewis blood group biosynthesis	18	1.21e-01	1.95e-01	0.30500	-2.70e-01	-1.42e-01	4.72e-02	2.98e-01
Thromboxane signalling through TP receptor	24	1.21e-02	3.44e-02	0.30500	-2.61e-01	1.57e-01	2.66e-02	1.84e-01
Nucleotide salvage	21	2.32e-02	5.81e-02	0.30500	-2.76e-01	1.28e-01	2.83e-02	3.10e-01
Transmission across Chemical Synapses	237	1.95e-12	8.87e-11	0.30400	-2.61e-01	-1.57e-01	4.19e-12	3.21e-05
Folding of actin by CCT/TriC	10	2.92e-01	3.83e-01	0.30400	2.84e-01	1.09e-01	1.20e-01	5.52e-01
Inactivation, recovery and regulation of the phototransduction cascade	31	3.32e-02	7.67e-02	0.30400	-2.19e-01	-2.11e-01	3.45e-02	4.23e-02
Activation of AMPK downstream of NMDARs	10	2.55e-01	3.45e-01	0.30400	-3.00e-01	-4.57e-02	1.00e-01	8.02e-01
p130Cas linkage to MAPK signaling for integrins	15	1.87e-01	2.74e-01	0.30400	-2.48e-01	-1.76e-01	9.68e-02	2.39e-01
rRNA modification in the nucleus and cytosol	55	2.02e-03	7.77e-03	0.30300	1.62e-01	2.56e-01	3.75e-02	1.01e-03
Cell death signalling via NRAGE, NRIF and NADE	69	3.46e-04	1.68e-03	0.30300	-2.67e-01	-1.43e-01	1.21e-04	4.03e-02
Estrogen-dependent nuclear events downstream of ESR-membrane signaling	23	5.40e-02	1.08e-01	0.30300	-2.91e-01	-8.29e-02	1.57e-02	4.91e-01
ADP signalling through P2Y purinoceptor 1	25	1.58e-02	4.28e-02	0.30200	-2.92e-01	7.73e-02	1.15e-02	5.04e-01
Heme degradation	16	9.12e-02	1.61e-01	0.30200	1.15e-02	-3.02e-01	9.36e-01	3.67e-02
HDACs deacetylate histones	29	4.81e-03	1.63e-02	0.30200	-2.35e-01	1.89e-01	2.85e-02	7.76e-02
TRAF6 mediated IRF7 activation	26	6.02e-02	1.17e-01	0.30200	2.22e-01	2.04e-01	5.02e-02	7.15e-02
Signaling by MET	66	1.34e-04	7.39e-04	0.30100	-2.98e-01	-4.36e-02	2.76e-05	5.40e-01
Potassium Channels	102	1.23e-05	9.36e-05	0.30100	-2.53e-01	-1.63e-01	9.65e-06	4.50e-03
Gastrin-CREB signalling pathway via PKC and MAPK	17	1.04e-01	1.76e-01	0.30100	-2.97e-01	-4.92e-02	3.41e-02	7.26e-01
Glycogen breakdown (glycogenolysis)	11	2.55e-01	3.45e-01	0.30000	-2.88e-01	-8.57e-02	9.84e-02	6.23e-01
Diseases associated with visual transduction	11	3.02e-01	3.91e-01	0.30000	-2.44e-01	-1.74e-01	1.61e-01	3.17e-01
Diseases of the neuronal system	11	3.02e-01	3.91e-01	0.30000	-2.44e-01	-1.74e-01	1.61e-01	3.17e-01
Retinoid cycle disease events	11	3.02e-01	3.91e-01	0.30000	-2.44e-01	-1.74e-01	1.61e-01	3.17e-01
Inwardly rectifying K+ channels	35	2.41e-02	5.99e-02	0.29900	-2.14e-01	-2.09e-01	2.81e-02	3.24e-02
Synthesis of bile acids and bile salts via 7alpha-hydroxycholesterol	24	7.37e-02	1.38e-01	0.29900	-2.45e-01	-1.72e-01	3.76e-02	1.45e-01
TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertain	13	1.00e-01	1.72e-01	0.29900	-2.59e-01	1.50e-01	1.06e-01	3.50e-01
Platelet sensitization by LDL	17	1.04e-01	1.76e-01	0.29900	-2.96e-01	-4.24e-02	3.48e-02	7.62e-01
Antimicrobial peptides	78	2.36e-05	1.68e-04	0.29800	2.97e-01	2.62e-02	5.56e-06	6.89e-01
SHC-mediated cascade:FGFR3	17	5.27e-02	1.06e-01	0.29800	-1.33e-01	2.67e-01	3.42e-01	5.68e-02
Polo-like kinase mediated events	16	8.46e-02	1.52e-01	0.29800	-4.57e-02	2.95e-01	7.52e-01	4.13e-02
Sphingolipid de novo biosynthesis	41	7.63e-03	2.37e-02	0.29800	-2.80e-01	-1.01e-01	1.89e-03	2.61e-01
Processing and activation of SUMO	10	2.09e-01	2.98e-01	0.29800	-5.58e-02	2.92e-01	7.60e-01	1.09e-01
Regulation of PTEN gene transcription	59	2.63e-05	1.84e-04	0.29800	-2.32e-01	1.86e-01	2.06e-03	1.32e-02
Uptake and actions of bacterial toxins	29	3.59e-02	8.06e-02	0.29700	-2.72e-01	-1.20e-01	1.12e-02	2.64e-01
DNA Damage/Telomere Stress Induced Senescence	28	7.44e-03	2.33e-02	0.29700	-1.55e-01	2.53e-01	1.56e-01	2.02e-02
Fatty acyl-CoA biosynthesis	36	2.30e-02	5.77e-02	0.29700	-2.21e-01	-1.98e-01	2.15e-02	4.00e-02
Synthesis of PE	12	1.21e-01	1.96e-01	0.29700	-2.48e-01	1.63e-01	1.37e-01	3.27e-01
Translation of Replicase and Assembly of the Replication Transcription Complex 9679504	13	1.21e-01	1.95e-01	0.29700	-8.74e-02	2.84e-01	5.85e-01	7.67e-02
Cytochrome c-mediated apoptotic response	12	1.36e-01	2.14e-01	0.29600	1.10e-01	-2.74e-01	5.08e-01	9.99e-02
Formation of apoptosome	10	1.73e-01	2.59e-01	0.29500	1.73e-01	-2.39e-01	3.42e-01	1.91e-01
Regulation of the apoptosome activity	10	1.73e-01	2.59e-01	0.29500	1.73e-01	-2.39e-01	3.42e-01	1.91e-01
Amino acid transport across the plasma membrane	30	4.04e-02	8.82e-02	0.29500	-2.50e-01	-1.58e-01	1.80e-02	1.35e-01
N-Glycan antennae elongation	15	1.16e-01	1.91e-01	0.29500	-2.95e-01	1.42e-02	4.82e-02	9.24e-01
Oncogenic MAPK signaling	76	1.11e-04	6.27e-04	0.29500	-2.83e-01	-8.27e-02	2.00e-05	2.12e-01
Apoptotic execution phase	43	3.15e-03	1.15e-02	0.29500	-2.94e-01	-2.28e-02	8.55e-04	7.95e-01
CD28 dependent PI3K/Akt signaling	22	8.60e-02	1.53e-01	0.29500	-2.67e-01	-1.25e-01	3.03e-02	3.10e-01
Activation of BAD and translocation to mitochondria	15	1.76e-01	2.61e-01	0.29400	-2.76e-01	-1.01e-01	6.37e-02	4.99e-01
EPH-Ephrin signaling	90	2.97e-05	2.04e-04	0.29400	-2.77e-01	-9.91e-02	5.52e-06	1.04e-01
Nuclear events mediated by NFE2L2	76	2.68e-04	1.35e-03	0.29400	1.42e-01	2.58e-01	3.27e-02	1.02e-04
Binding and Uptake of Ligands by Scavenger Receptors	41	1.47e-02	4.05e-02	0.29400	-2.22e-01	-1.92e-01	1.37e-02	3.33e-02
Organic anion transporters	10	2.79e-01	3.69e-01	0.29400	-4.60e-02	-2.90e-01	8.01e-01	1.12e-01
Synthesis of PC	27	1.81e-02	4.74e-02	0.29400	-2.91e-01	3.92e-02	8.80e-03	7.24e-01
HDMs demethylate histones	18	1.03e-01	1.76e-01	0.29400	-2.89e-01	-5.20e-02	3.37e-02	7.02e-01
Aquaporin-mediated transport	51	4.48e-03	1.53e-02	0.29300	-2.50e-01	-1.54e-01	2.01e-03	5.73e-02
Transcriptional Regulation by E2F6	32	5.49e-03	1.82e-02	0.29300	-2.74e-01	1.04e-01	7.27e-03	3.06e-01
Interleukin-35 Signalling	12	2.94e-01	3.83e-01	0.29300	-2.06e-01	-2.09e-01	2.16e-01	2.11e-01
GRB2 events in EGFR signaling	13	1.13e-01	1.86e-01	0.29300	-2.61e-01	1.34e-01	1.04e-01	4.02e-01
SARS-CoV-1 activates/modulates innate immune responses	37	1.49e-02	4.08e-02	0.29300	1.06e-01	2.73e-01	2.66e-01	4.01e-03
tRNA processing in the nucleus	55	1.86e-03	7.17e-03	0.29300	1.01e-01	2.75e-01	1.93e-01	4.23e-04
Keratan sulfate biosynthesis	28	3.30e-02	7.63e-02	0.29300	-2.85e-01	-6.59e-02	9.03e-03	5.46e-01
SUMOylation of immune response proteins	10	2.53e-01	3.43e-01	0.29200	7.78e-05	2.92e-01	1.00e+00	1.09e-01
Platelet Aggregation (Plug Formation)	37	7.06e-03	2.24e-02	0.29200	-2.91e-01	-1.19e-02	2.16e-03	9.00e-01
Voltage gated Potassium channels	42	6.87e-03	2.20e-02	0.29100	-2.81e-01	-7.56e-02	1.60e-03	3.97e-01
Response of Mtb to phagocytosis	22	9.39e-02	1.65e-01	0.29100	1.33e-01	2.59e-01	2.80e-01	3.53e-02
TNFR2 non-canonical NF-kB pathway	94	7.94e-05	4.83e-04	0.29100	2.07e-01	2.05e-01	5.19e-04	5.98e-04
Signal transduction by L1	20	9.93e-02	1.71e-01	0.29100	-2.77e-01	-8.79e-02	3.19e-02	4.96e-01
Cell-extracellular matrix interactions	14	2.39e-01	3.28e-01	0.29000	-2.39e-01	-1.65e-01	1.22e-01	2.86e-01
p75 NTR receptor-mediated signalling	89	9.87e-05	5.71e-04	0.29000	-2.48e-01	-1.51e-01	5.26e-05	1.40e-02
Signaling by PDGFRA extracellular domain mutants	12	2.18e-01	3.07e-01	0.28900	-2.88e-01	-3.35e-02	8.46e-02	8.41e-01
Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants	12	2.18e-01	3.07e-01	0.28900	-2.88e-01	-3.35e-02	8.46e-02	8.41e-01
RUNX2 regulates bone development	29	4.78e-02	9.90e-02	0.28800	-2.55e-01	-1.35e-01	1.75e-02	2.08e-01
Cyclin E associated events during G1/S transition	81	2.43e-04	1.23e-03	0.28800	1.44e-01	2.49e-01	2.48e-02	1.06e-04
Transcriptional regulation of testis differentiation	12	1.37e-01	2.15e-01	0.28800	-1.59e-01	2.39e-01	3.39e-01	1.51e-01
Factors involved in megakaryocyte development and platelet production	128	1.05e-07	1.55e-06	0.28700	-2.86e-01	-2.88e-02	2.27e-08	5.74e-01
COPI-independent Golgi-to-ER retrograde traffic	34	3.56e-02	8.05e-02	0.28700	-2.11e-01	-1.95e-01	3.31e-02	4.93e-02
GRB2 events in ERBB2 signaling	16	1.37e-01	2.15e-01	0.28700	-2.85e-01	-3.61e-02	4.84e-02	8.03e-01
Synthesis of PA	35	3.17e-02	7.42e-02	0.28700	-2.23e-01	-1.80e-01	2.21e-02	6.50e-02
Inactivation of APC/C via direct inhibition of the APC/C complex	21	8.48e-02	1.52e-01	0.28600	6.18e-02	2.80e-01	6.24e-01	2.65e-02
Inhibition of the proteolytic activity of APC/C required for the onset of anaphase by mitotic spindle checkpoint components	21	8.48e-02	1.52e-01	0.28600	6.18e-02	2.80e-01	6.24e-01	2.65e-02
TRAF6-mediated induction of TAK1 complex within TLR4 complex	15	1.69e-01	2.54e-01	0.28600	5.66e-02	2.81e-01	7.04e-01	5.97e-02
Thrombin signalling through proteinase activated receptors (PARs)	32	6.29e-03	2.04e-02	0.28600	-2.58e-01	1.23e-01	1.14e-02	2.29e-01
Caspase activation via Death Receptors in the presence of ligand	16	2.05e-01	2.95e-01	0.28600	2.34e-01	1.64e-01	1.05e-01	2.57e-01
Glucocorticoid biosynthesis	10	2.16e-01	3.05e-01	0.28600	9.62e-02	-2.69e-01	5.98e-01	1.41e-01
RUNX1 regulates transcription of genes involved in differentiation of HSCs	68	1.02e-03	4.36e-03	0.28500	1.40e-01	2.48e-01	4.62e-02	3.95e-04
Regulation of insulin secretion	77	3.38e-04	1.65e-03	0.28500	-2.57e-01	-1.23e-01	9.62e-05	6.14e-02
Pre-NOTCH Expression and Processing	61	6.89e-05	4.25e-04	0.28500	-2.57e-01	1.23e-01	5.12e-04	9.72e-02
Pyrimidine catabolism	12	2.65e-01	3.56e-01	0.28500	-2.71e-01	-8.62e-02	1.04e-01	6.05e-01
Glucagon-like Peptide-1 (GLP1) regulates insulin secretion	42	1.05e-02	3.08e-02	0.28400	-2.68e-01	-9.50e-02	2.64e-03	2.87e-01
Cyclin A:Cdk2-associated events at S phase entry	83	2.37e-04	1.21e-03	0.28400	1.40e-01	2.47e-01	2.71e-02	9.77e-05
Serotonin receptors	11	3.46e-01	4.30e-01	0.28400	-2.18e-01	-1.83e-01	2.11e-01	2.94e-01
Transport of organic anions	10	3.82e-01	4.69e-01	0.28400	-2.13e-01	-1.88e-01	2.43e-01	3.04e-01
Phase 4 - resting membrane potential	19	1.60e-01	2.44e-01	0.28400	-2.23e-01	-1.75e-01	9.19e-02	1.87e-01
Mitochondrial tRNA aminoacylation	18	5.96e-02	1.16e-01	0.28300	-1.28e-01	2.53e-01	3.48e-01	6.31e-02
Depolymerisation of the Nuclear Lamina	14	1.59e-01	2.43e-01	0.28300	-2.83e-01	9.13e-03	6.66e-02	9.53e-01
WNT5A-dependent internalization of FZD2, FZD5 and ROR2	13	2.16e-01	3.04e-01	0.28300	-2.79e-01	-4.71e-02	8.12e-02	7.69e-01
G beta:gamma signalling through PI3Kgamma	25	3.57e-02	8.05e-02	0.28300	-2.82e-01	1.86e-02	1.45e-02	8.72e-01
GABA synthesis, release, reuptake and degradation	19	1.57e-01	2.41e-01	0.28300	-1.60e-01	-2.33e-01	2.27e-01	7.83e-02
Smooth Muscle Contraction	43	1.71e-02	4.57e-02	0.28200	-2.05e-01	-1.94e-01	1.98e-02	2.78e-02
Endosomal/Vacuolar pathway	12	2.36e-01	3.25e-01	0.28200	2.80e-01	3.42e-02	9.27e-02	8.38e-01
Interleukin receptor SHC signaling	24	8.02e-02	1.47e-01	0.28200	-2.63e-01	-1.01e-01	2.58e-02	3.91e-01
Transcriptional Regulation by NPAS4	33	3.37e-02	7.70e-02	0.28100	-2.58e-01	-1.13e-01	1.04e-02	2.60e-01
G alpha (z) signalling events	48	6.89e-03	2.20e-02	0.28100	-2.60e-01	-1.08e-01	1.83e-03	1.96e-01
TNFR1-induced proapoptotic signaling	13	2.34e-01	3.24e-01	0.28000	6.51e-02	2.73e-01	6.85e-01	8.86e-02
Diseases associated with the TLR signaling cascade	29	1.11e-02	3.22e-02	0.28000	-1.40e-01	2.43e-01	1.92e-01	2.36e-02
Diseases of Immune System	29	1.11e-02	3.22e-02	0.28000	-1.40e-01	2.43e-01	1.92e-01	2.36e-02
TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest	18	1.21e-01	1.95e-01	0.28000	3.81e-02	2.78e-01	7.80e-01	4.14e-02
Unwinding of DNA	12	2.13e-01	3.01e-01	0.28000	-1.01e-02	2.80e-01	9.52e-01	9.29e-02
Glutamate binding, activation of AMPA receptors and synaptic plasticity	29	6.71e-02	1.28e-01	0.28000	-1.92e-01	-2.04e-01	7.42e-02	5.68e-02
Trafficking of AMPA receptors	29	6.71e-02	1.28e-01	0.28000	-1.92e-01	-2.04e-01	7.42e-02	5.68e-02
Extra-nuclear estrogen signaling	73	1.79e-04	9.64e-04	0.28000	-2.78e-01	-3.29e-02	3.99e-05	6.27e-01
Cellular response to hypoxia	71	1.29e-03	5.28e-03	0.28000	1.72e-01	2.20e-01	1.21e-02	1.31e-03
Miscellaneous substrates	12	1.64e-01	2.48e-01	0.28000	2.54e-01	-1.16e-01	1.27e-01	4.85e-01
DNA Replication	125	4.40e-06	3.90e-05	0.27900	1.25e-01	2.49e-01	1.55e-02	1.44e-06
NF-kB is activated and signals survival	12	3.21e-01	4.07e-01	0.27900	2.31e-01	1.56e-01	1.65e-01	3.50e-01
Signaling by NTRK3 (TRKC)	17	1.26e-01	2.02e-01	0.27800	-2.78e-01	-1.08e-02	4.73e-02	9.39e-01
SHC1 events in ERBB2 signaling	22	7.90e-02	1.45e-01	0.27800	-2.75e-01	-3.89e-02	2.54e-02	7.52e-01
ER Quality Control Compartment (ERQC)	20	1.31e-01	2.09e-01	0.27800	1.03e-01	2.58e-01	4.24e-01	4.60e-02
The citric acid (TCA) cycle and respiratory electron transport	143	1.94e-07	2.72e-06	0.27800	6.78e-02	2.69e-01	1.61e-01	2.70e-08
G1/S-Specific Transcription	28	1.87e-02	4.88e-02	0.27800	-8.12e-02	2.65e-01	4.57e-01	1.51e-02
G alpha (s) signalling events	153	7.42e-07	8.89e-06	0.27700	-2.21e-01	-1.67e-01	2.22e-06	3.55e-04
ERK/MAPK targets	20	4.87e-02	1.00e-01	0.27700	-2.43e-01	1.34e-01	5.99e-02	3.01e-01
IRAK2 mediated activation of TAK1 complex upon TLR7/8 or 9 stimulation	14	2.53e-01	3.44e-01	0.27600	1.16e-01	2.50e-01	4.52e-01	1.05e-01
Downregulation of SMAD2/3:SMAD4 transcriptional activity	29	1.97e-02	5.09e-02	0.27600	-2.70e-01	5.67e-02	1.19e-02	5.97e-01
Nuclear signaling by ERBB4	32	5.58e-02	1.11e-01	0.27600	-1.93e-01	-1.96e-01	5.84e-02	5.44e-02
Inhibition of replication initiation of damaged DNA by RB1/E2F1	11	1.85e-01	2.72e-01	0.27500	-2.16e-01	1.71e-01	2.15e-01	3.26e-01
Xenobiotics	24	1.02e-01	1.74e-01	0.27500	-1.31e-01	-2.42e-01	2.67e-01	4.00e-02
Activation of G protein gated Potassium channels	29	7.34e-02	1.37e-01	0.27500	-2.05e-01	-1.83e-01	5.58e-02	8.74e-02
G protein gated Potassium channels	29	7.34e-02	1.37e-01	0.27500	-2.05e-01	-1.83e-01	5.58e-02	8.74e-02
Inhibition of voltage gated Ca2+ channels via Gbeta/gamma subunits	29	7.34e-02	1.37e-01	0.27500	-2.05e-01	-1.83e-01	5.58e-02	8.74e-02
Blood group systems biosynthesis	22	1.34e-01	2.13e-01	0.27400	-2.26e-01	-1.55e-01	6.66e-02	2.08e-01
Nuclear import of Rev protein	32	1.74e-02	4.64e-02	0.27400	-2.55e-02	2.73e-01	8.03e-01	7.58e-03
Biosynthesis of specialized proresolving mediators (SPMs)	19	5.58e-02	1.11e-01	0.27300	-1.98e-01	1.88e-01	1.35e-01	1.55e-01
Signaling by SCF-KIT	43	5.53e-03	1.83e-02	0.27300	-2.73e-01	3.58e-03	1.93e-03	9.68e-01
mRNA Splicing	184	8.25e-08	1.25e-06	0.27300	1.74e-01	2.11e-01	4.77e-05	7.98e-07
NOTCH1 Intracellular Domain Regulates Transcription	44	2.33e-03	8.85e-03	0.27300	-2.61e-01	8.13e-02	2.77e-03	3.51e-01
mTORC1-mediated signalling	23	3.46e-02	7.88e-02	0.27300	-1.30e-01	2.40e-01	2.79e-01	4.66e-02
Generation of second messenger molecules	30	3.46e-02	7.88e-02	0.27300	-3.33e-02	-2.71e-01	7.52e-01	1.03e-02
NGF-stimulated transcription	39	1.67e-02	4.49e-02	0.27300	6.59e-02	2.65e-01	4.76e-01	4.24e-03
Assembly Of The HIV Virion	16	1.06e-01	1.77e-01	0.27300	-9.45e-02	2.56e-01	5.13e-01	7.65e-02
RUNX2 regulates osteoblast differentiation	22	1.26e-01	2.02e-01	0.27200	-2.43e-01	-1.23e-01	4.86e-02	3.18e-01
IL-6-type cytokine receptor ligand interactions	17	2.21e-01	3.09e-01	0.27200	-1.69e-01	-2.13e-01	2.28e-01	1.28e-01
ATF4 activates genes in response to endoplasmic reticulum stress	28	4.58e-02	9.63e-02	0.27200	2.69e-01	3.96e-02	1.37e-02	7.17e-01
Processing of Capped Intronless Pre-mRNA	28	2.09e-02	5.35e-02	0.27100	-9.37e-02	2.54e-01	3.91e-01	1.99e-02
Degradation of cysteine and homocysteine	14	1.48e-01	2.29e-01	0.27100	-8.57e-02	2.57e-01	5.79e-01	9.60e-02
Pausing and recovery of Tat-mediated HIV elongation	27	9.51e-02	1.66e-01	0.27100	1.83e-01	1.99e-01	9.91e-02	7.31e-02
Tat-mediated HIV elongation arrest and recovery	27	9.51e-02	1.66e-01	0.27100	1.83e-01	1.99e-01	9.91e-02	7.31e-02
trans-Golgi Network Vesicle Budding	67	1.03e-04	5.92e-04	0.27100	-2.55e-01	8.98e-02	2.99e-04	2.03e-01
ER-Phagosome pathway	87	5.21e-04	2.38e-03	0.27100	1.83e-01	2.00e-01	3.24e-03	1.27e-03
Activation of NF-kappaB in B cells	64	3.84e-03	1.36e-02	0.27100	2.00e-01	1.82e-01	5.62e-03	1.17e-02
CTLA4 inhibitory signaling	21	1.48e-01	2.29e-01	0.27000	-2.35e-01	-1.34e-01	6.24e-02	2.88e-01
Interleukin-27 signaling	11	3.83e-01	4.69e-01	0.27000	-2.12e-01	-1.67e-01	2.23e-01	3.38e-01
p75NTR recruits signalling complexes	12	3.46e-01	4.30e-01	0.27000	2.22e-01	1.53e-01	1.83e-01	3.59e-01
Diseases of programmed cell death	43	1.13e-02	3.27e-02	0.26800	5.08e-02	2.63e-01	5.64e-01	2.83e-03
Signaling by Non-Receptor Tyrosine Kinases	55	1.67e-03	6.56e-03	0.26800	-2.67e-01	5.59e-03	5.99e-04	9.43e-01
Signaling by PTK6	55	1.67e-03	6.56e-03	0.26800	-2.67e-01	5.59e-03	5.99e-04	9.43e-01
Cytosolic sulfonation of small molecules	21	5.23e-02	1.06e-01	0.26700	-2.35e-01	1.28e-01	6.23e-02	3.10e-01
Signaling by Rho GTPases	589	8.46e-25	2.62e-22	0.26700	-2.52e-01	-8.76e-02	9.79e-26	2.72e-04
RAB GEFs exchange GTP for GDP on RABs	82	1.50e-04	8.13e-04	0.26700	-2.65e-01	-3.11e-02	3.32e-05	6.26e-01
Golgi Associated Vesicle Biogenesis	51	3.63e-03	1.31e-02	0.26700	-2.66e-01	-1.91e-02	1.01e-03	8.13e-01
Formation of Fibrin Clot (Clotting Cascade)	37	4.42e-02	9.47e-02	0.26700	-1.85e-01	-1.92e-01	5.15e-02	4.33e-02
Downstream signal transduction	29	3.23e-02	7.53e-02	0.26600	-2.66e-01	1.93e-02	1.33e-02	8.57e-01
Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex	13	2.22e-01	3.09e-01	0.26600	-7.85e-03	2.66e-01	9.61e-01	9.67e-02
RMTs methylate histone arginines	30	4.63e-02	9.70e-02	0.26600	-2.61e-01	-5.23e-02	1.34e-02	6.20e-01
Biosynthesis of DHA-derived SPMs	17	8.81e-02	1.57e-01	0.26600	-1.63e-01	2.11e-01	2.46e-01	1.33e-01
Deadenylation of mRNA	25	1.04e-01	1.76e-01	0.26600	-2.40e-01	-1.13e-01	3.75e-02	3.26e-01
Cellular response to starvation	147	4.67e-06	4.10e-05	0.26600	1.85e-01	1.91e-01	1.09e-04	6.30e-05
Diseases associated with N-glycosylation of proteins	19	7.23e-02	1.36e-01	0.26600	-1.24e-01	2.35e-01	3.48e-01	7.63e-02
Fertilization	26	3.30e-02	7.63e-02	0.26600	8.37e-02	-2.52e-01	4.60e-01	2.61e-02
Synthesis of PIPs at the Golgi membrane	17	1.49e-01	2.31e-01	0.26500	-2.65e-01	-6.35e-03	5.83e-02	9.64e-01
Signalling to ERKs	34	1.18e-02	3.38e-02	0.26500	-2.51e-01	8.35e-02	1.12e-02	4.00e-01
Hyaluronan metabolism	17	1.95e-01	2.84e-01	0.26500	-2.53e-01	-7.74e-02	7.08e-02	5.80e-01
Negative regulation of FGFR1 signaling	32	4.74e-02	9.84e-02	0.26400	8.09e-02	2.52e-01	4.28e-01	1.37e-02
Synthesis of DNA	118	2.90e-05	2.00e-04	0.26400	1.18e-01	2.36e-01	2.64e-02	9.08e-06
PERK regulates gene expression	32	3.86e-02	8.53e-02	0.26400	2.60e-01	4.66e-02	1.10e-02	6.48e-01
Signaling by Rho GTPases, Miro GTPases and RHOBTB3	603	7.97e-25	2.62e-22	0.26300	-2.50e-01	-8.15e-02	7.65e-26	6.12e-04
Metabolism of folate and pterines	16	2.60e-01	3.52e-01	0.26300	-2.18e-01	-1.47e-01	1.31e-01	3.09e-01
RHO GTPases activate CIT	19	2.11e-01	3.00e-01	0.26200	-2.00e-01	-1.69e-01	1.31e-01	2.03e-01
Regulation of glycolysis by fructose 2,6-bisphosphate metabolism	11	2.17e-01	3.06e-01	0.26100	-1.75e-01	1.94e-01	3.14e-01	2.65e-01
Signaling by RAF1 mutants	37	2.83e-02	6.81e-02	0.26100	-2.54e-01	-6.35e-02	7.58e-03	5.04e-01
Synaptic adhesion-like molecules	19	2.11e-01	3.00e-01	0.26100	-2.04e-01	-1.64e-01	1.24e-01	2.17e-01
Keratan sulfate/keratin metabolism	33	3.00e-02	7.09e-02	0.26100	-2.60e-01	-1.44e-02	9.62e-03	8.86e-01
Neurotoxicity of clostridium toxins	10	4.45e-01	5.27e-01	0.26100	-1.96e-01	-1.71e-01	2.82e-01	3.48e-01
Trafficking and processing of endosomal TLR	11	3.55e-01	4.40e-01	0.26100	7.19e-02	2.51e-01	6.80e-01	1.50e-01
Interactions of Vpr with host cellular proteins	33	1.57e-02	4.26e-02	0.26100	-7.98e-02	2.48e-01	4.27e-01	1.36e-02
Regulation of mRNA stability by proteins that bind AU-rich elements	87	8.70e-04	3.78e-03	0.26000	2.04e-01	1.62e-01	9.99e-04	9.16e-03
Activation of SMO	17	9.68e-02	1.68e-01	0.26000	-1.96e-01	1.72e-01	1.63e-01	2.20e-01
Insertion of tail-anchored proteins into the endoplasmic reticulum membrane	18	1.10e-01	1.83e-01	0.26000	-2.52e-01	6.39e-02	6.41e-02	6.39e-01
Processing of Capped Intron-Containing Pre-mRNA	232	6.96e-09	1.36e-07	0.26000	1.54e-01	2.09e-01	5.18e-05	3.75e-08
Antigen processing-Cross presentation	100	3.37e-04	1.64e-03	0.26000	1.81e-01	1.87e-01	1.79e-03	1.24e-03
Negative regulation of FGFR3 signaling	28	5.02e-02	1.03e-01	0.26000	7.74e-03	2.60e-01	9.43e-01	1.74e-02
Pyruvate metabolism	29	1.89e-02	4.92e-02	0.26000	-1.73e-01	1.94e-01	1.07e-01	7.09e-02
Activation of the TFAP2 (AP-2) family of transcription factors	11	4.08e-01	4.94e-01	0.25900	1.51e-01	2.11e-01	3.86e-01	2.26e-01
ERKs are inactivated	13	2.64e-01	3.55e-01	0.25800	2.34e-02	2.57e-01	8.84e-01	1.08e-01
Golgi-to-ER retrograde transport	115	4.86e-05	3.20e-04	0.25800	-2.37e-01	-1.03e-01	1.15e-05	5.62e-02
Glycerophospholipid biosynthesis	114	2.88e-05	2.00e-04	0.25800	-2.48e-01	-7.26e-02	4.87e-06	1.80e-01
Interactions of Rev with host cellular proteins	35	1.64e-02	4.41e-02	0.25800	-4.86e-02	2.53e-01	6.19e-01	9.45e-03
Regulation of gene expression by Hypoxia-inducible Factor	11	2.77e-01	3.68e-01	0.25800	-2.54e-01	4.53e-02	1.45e-01	7.95e-01
Growth hormone receptor signaling	24	1.47e-01	2.28e-01	0.25800	-1.55e-01	-2.06e-01	1.88e-01	8.11e-02
Branched-chain amino acid catabolism	20	6.98e-02	1.32e-01	0.25700	-1.52e-01	2.07e-01	2.38e-01	1.09e-01
Passive transport by Aquaporins	13	3.24e-01	4.09e-01	0.25600	-9.48e-02	-2.38e-01	5.54e-01	1.37e-01
G-protein activation	24	6.26e-02	1.21e-01	0.25600	-2.52e-01	4.54e-02	3.23e-02	7.00e-01
FGFR1c ligand binding and activation	11	3.97e-01	4.85e-01	0.25600	1.12e-01	2.30e-01	5.19e-01	1.86e-01
Signaling by activated point mutants of FGFR1	11	3.97e-01	4.85e-01	0.25600	1.12e-01	2.30e-01	5.19e-01	1.86e-01
G1/S Transition	126	1.22e-05	9.36e-05	0.25600	7.49e-02	2.45e-01	1.46e-01	2.02e-06
Signaling by high-kinase activity BRAF mutants	32	2.87e-02	6.89e-02	0.25600	-2.55e-01	2.54e-02	1.26e-02	8.04e-01
Organic cation/anion/zwitterion transport	15	2.89e-01	3.79e-01	0.25600	-2.26e-01	-1.19e-01	1.29e-01	4.23e-01
TRAF6 mediated NF-kB activation	24	5.88e-02	1.15e-01	0.25600	-6.13e-02	2.48e-01	6.03e-01	3.53e-02
Vpr-mediated nuclear import of PICs	32	1.90e-02	4.92e-02	0.25500	-9.47e-02	2.37e-01	3.54e-01	2.02e-02
Eicosanoid ligand-binding receptors	14	1.60e-01	2.44e-01	0.25500	-2.09e-01	1.46e-01	1.75e-01	3.43e-01
Telomere C-strand synthesis initiation	11	4.18e-01	5.01e-01	0.25500	1.45e-01	2.10e-01	4.06e-01	2.27e-01
G beta:gamma signalling through PLC beta	20	1.68e-01	2.54e-01	0.25500	-2.43e-01	-7.68e-02	5.95e-02	5.52e-01
Oxidative Stress Induced Senescence	66	2.03e-04	1.07e-03	0.25500	-2.18e-01	1.32e-01	2.14e-03	6.39e-02
Tandem pore domain potassium channels	12	3.32e-01	4.17e-01	0.25500	-2.47e-01	-6.17e-02	1.38e-01	7.11e-01
COPI-dependent Golgi-to-ER retrograde traffic	81	6.25e-04	2.80e-03	0.25500	-2.47e-01	-6.42e-02	1.22e-04	3.18e-01
Acetylcholine Neurotransmitter Release Cycle	16	2.86e-01	3.76e-01	0.25400	-1.48e-01	-2.06e-01	3.04e-01	1.53e-01
Glutathione conjugation	36	5.21e-02	1.06e-01	0.25400	1.14e-01	2.27e-01	2.37e-01	1.83e-02
XBP1(S) activates chaperone genes	47	2.55e-03	9.52e-03	0.25400	-1.28e-01	2.19e-01	1.30e-01	9.30e-03
SHC-mediated cascade:FGFR1	21	1.17e-01	1.91e-01	0.25300	5.06e-03	2.53e-01	9.68e-01	4.44e-02
Calnexin/calreticulin cycle	25	8.10e-02	1.47e-01	0.25300	1.33e-02	2.53e-01	9.08e-01	2.85e-02
Regulation of PTEN mRNA translation	25	3.89e-02	8.58e-02	0.25300	-1.95e-01	1.61e-01	9.06e-02	1.63e-01
N-glycan trimming in the ER and Calnexin/Calreticulin cycle	34	2.96e-02	7.04e-02	0.25300	-1.83e-03	2.53e-01	9.85e-01	1.06e-02
Regulation of signaling by NODAL	10	2.85e-01	3.75e-01	0.25300	2.24e-01	-1.18e-01	2.20e-01	5.18e-01
NEP/NS2 Interacts with the Cellular Export Machinery	30	3.70e-02	8.27e-02	0.25300	-3.29e-02	2.51e-01	7.55e-01	1.74e-02
SUMOylation of ubiquitinylation proteins	37	1.15e-02	3.30e-02	0.25300	-8.96e-02	2.37e-01	3.46e-01	1.28e-02
Signaling by FGFR4 in disease	11	4.27e-01	5.09e-01	0.25300	-2.06e-01	-1.46e-01	2.36e-01	4.01e-01
p75NTR signals via NF-kB	15	2.99e-01	3.88e-01	0.25300	2.24e-01	1.18e-01	1.34e-01	4.30e-01
Physiological factors	14	3.31e-01	4.17e-01	0.25200	-2.17e-01	-1.28e-01	1.59e-01	4.06e-01
Signaling by FLT3 ITD and TKD mutants	16	1.66e-01	2.51e-01	0.25200	-4.69e-02	2.48e-01	7.45e-01	8.62e-02
RNA Polymerase III Transcription Initiation From Type 3 Promoter	28	1.04e-01	1.76e-01	0.25200	1.13e-01	2.26e-01	3.02e-01	3.88e-02
Rab regulation of trafficking	113	2.05e-06	2.20e-05	0.25200	-2.43e-01	6.85e-02	8.30e-06	2.08e-01
GAB1 signalosome	17	1.60e-01	2.43e-01	0.25200	-2.51e-01	2.70e-02	7.36e-02	8.47e-01
DNA Damage Recognition in GG-NER	36	6.16e-02	1.19e-01	0.25200	1.38e-01	2.11e-01	1.53e-01	2.87e-02
Signaling by ALK fusions and activated point mutants	51	3.35e-03	1.21e-02	0.25100	-2.46e-01	4.92e-02	2.32e-03	5.43e-01
Signaling by ALK in cancer	51	3.35e-03	1.21e-02	0.25100	-2.46e-01	4.92e-02	2.32e-03	5.43e-01
Deposition of new CENPA-containing nucleosomes at the centromere	26	8.56e-02	1.53e-01	0.25100	3.32e-02	2.49e-01	7.70e-01	2.80e-02
Nucleosome assembly	26	8.56e-02	1.53e-01	0.25100	3.32e-02	2.49e-01	7.70e-01	2.80e-02
ATF6 (ATF6-alpha) activates chaperone genes	10	4.59e-01	5.40e-01	0.25100	1.30e-01	2.15e-01	4.77e-01	2.39e-01
Meiotic synapsis	32	3.94e-02	8.67e-02	0.25100	-2.51e-01	-1.96e-03	1.39e-02	9.85e-01
FLT3 signaling in disease	28	4.10e-02	8.94e-02	0.25100	-6.15e-02	2.43e-01	5.73e-01	2.58e-02
HIV elongation arrest and recovery	29	1.14e-01	1.87e-01	0.25000	1.99e-01	1.51e-01	6.37e-02	1.59e-01
Pausing and recovery of HIV elongation	29	1.14e-01	1.87e-01	0.25000	1.99e-01	1.51e-01	6.37e-02	1.59e-01
Glutamate and glutamine metabolism	12	2.21e-01	3.09e-01	0.25000	-1.55e-01	1.95e-01	3.52e-01	2.41e-01
activated TAK1 mediates p38 MAPK activation	16	1.72e-01	2.58e-01	0.24900	-2.45e-01	4.86e-02	9.02e-02	7.37e-01
Transport of Mature mRNAs Derived from Intronless Transcripts	41	8.74e-03	2.68e-02	0.24900	-7.90e-02	2.36e-01	3.81e-01	8.83e-03
Translesion Synthesis by POLH	19	2.01e-01	2.91e-01	0.24900	7.69e-02	2.37e-01	5.62e-01	7.37e-02
Methylation	14	2.92e-01	3.83e-01	0.24900	2.42e-01	5.76e-02	1.17e-01	7.09e-01
Interconversion of nucleotide di- and triphosphates	29	2.95e-02	7.04e-02	0.24800	-1.22e-01	2.16e-01	2.56e-01	4.38e-02
Acyl chain remodelling of PS	21	2.07e-01	2.96e-01	0.24800	-1.35e-01	-2.08e-01	2.85e-01	9.93e-02
mRNA Splicing - Major Pathway	174	3.25e-06	3.14e-05	0.24700	1.53e-01	1.94e-01	5.08e-04	1.01e-05
G2/M Checkpoints	129	4.23e-05	2.83e-04	0.24700	1.04e-01	2.24e-01	4.17e-02	1.12e-05
Calcitonin-like ligand receptors	10	4.82e-01	5.60e-01	0.24700	-1.94e-01	-1.52e-01	2.88e-01	4.04e-01
GPVI-mediated activation cascade	32	2.38e-02	5.91e-02	0.24600	-2.24e-01	1.02e-01	2.81e-02	3.18e-01
Retinoid metabolism and transport	42	4.34e-02	9.35e-02	0.24600	-1.29e-01	-2.10e-01	1.48e-01	1.86e-02
The NLRP3 inflammasome	16	1.63e-01	2.48e-01	0.24600	-8.09e-02	2.32e-01	5.75e-01	1.08e-01
Interleukin-20 family signaling	24	1.13e-01	1.86e-01	0.24600	-3.06e-02	-2.44e-01	7.96e-01	3.85e-02
IRE1alpha activates chaperones	49	2.96e-03	1.09e-02	0.24600	-1.19e-01	2.15e-01	1.48e-01	9.21e-03
Vitamin D (calciferol) metabolism	12	3.95e-01	4.83e-01	0.24600	-2.22e-01	-1.04e-01	1.82e-01	5.32e-01
Transport of Mature mRNA Derived from an Intronless Transcript	40	1.10e-02	3.20e-02	0.24500	-8.18e-02	2.31e-01	3.71e-01	1.13e-02
Visual phototransduction	93	1.33e-03	5.40e-03	0.24500	-1.66e-01	-1.80e-01	5.61e-03	2.65e-03
Signaling by ALK	26	1.57e-01	2.41e-01	0.24500	-1.75e-01	-1.71e-01	1.23e-01	1.30e-01
DARPP-32 events	24	1.64e-01	2.48e-01	0.24300	-2.18e-01	-1.08e-01	6.45e-02	3.58e-01
Fcgamma receptor (FCGR) dependent phagocytosis	82	7.75e-04	3.40e-03	0.24300	-2.40e-01	-3.76e-02	1.68e-04	5.56e-01
Negative regulation of the PI3K/AKT network	111	8.58e-05	5.08e-04	0.24300	-2.37e-01	-5.25e-02	1.53e-05	3.39e-01
Rev-mediated nuclear export of HIV RNA	33	2.76e-02	6.66e-02	0.24300	-7.01e-02	2.33e-01	4.86e-01	2.07e-02
Diseases of metabolism	234	2.56e-08	4.45e-07	0.24300	-2.19e-01	-1.05e-01	8.16e-09	5.46e-03
Beta-catenin phosphorylation cascade	16	2.08e-01	2.98e-01	0.24300	-2.42e-01	1.61e-02	9.37e-02	9.11e-01
RUNX3 regulates p14-ARF	10	3.03e-01	3.92e-01	0.24200	-1.63e-01	1.79e-01	3.72e-01	3.26e-01
Retrograde neurotrophin signalling	14	3.51e-01	4.36e-01	0.24200	-2.17e-01	-1.08e-01	1.60e-01	4.84e-01
KEAP1-NFE2L2 pathway	103	3.35e-04	1.64e-03	0.24200	8.40e-02	2.27e-01	1.40e-01	7.02e-05
Presynaptic function of Kainate receptors	21	2.13e-01	3.01e-01	0.24100	-2.15e-01	-1.10e-01	8.85e-02	3.83e-01
alpha-linolenic (omega3) and linoleic (omega6) acid metabolism	12	2.94e-01	3.83e-01	0.24100	-2.37e-01	4.46e-02	1.56e-01	7.89e-01
alpha-linolenic acid (ALA) metabolism	12	2.94e-01	3.83e-01	0.24100	-2.37e-01	4.46e-02	1.56e-01	7.89e-01
Frs2-mediated activation	12	4.16e-01	5.00e-01	0.24000	-2.13e-01	-1.11e-01	2.01e-01	5.05e-01
NRIF signals cell death from the nucleus	16	3.34e-01	4.19e-01	0.24000	1.69e-01	1.71e-01	2.43e-01	2.36e-01
Activation of Matrix Metalloproteinases	31	9.43e-02	1.65e-01	0.24000	-8.78e-02	-2.23e-01	3.97e-01	3.13e-02
Transcriptional Regulation by VENTX	41	8.80e-03	2.69e-02	0.24000	-1.96e-01	1.39e-01	3.02e-02	1.24e-01
Membrane binding and targetting of GAG proteins	14	2.25e-01	3.13e-01	0.24000	-7.22e-02	2.29e-01	6.40e-01	1.38e-01
Synthesis And Processing Of GAG, GAGPOL Polyproteins	14	2.25e-01	3.13e-01	0.24000	-7.22e-02	2.29e-01	6.40e-01	1.38e-01
Processive synthesis on the C-strand of the telomere	19	1.50e-01	2.31e-01	0.24000	-2.37e-01	3.72e-02	7.39e-02	7.79e-01
Activation of gene expression by SREBF (SREBP)	42	1.35e-02	3.74e-02	0.23900	-2.33e-01	5.43e-02	9.03e-03	5.42e-01
mRNA Splicing - Minor Pathway	51	2.58e-02	6.33e-02	0.23900	2.11e-01	1.13e-01	9.27e-03	1.63e-01
Signaling by Receptor Tyrosine Kinases	493	2.08e-17	2.14e-15	0.23800	-2.30e-01	-6.29e-02	1.88e-18	1.66e-02
Export of Viral Ribonucleoproteins from Nucleus	31	5.89e-02	1.15e-01	0.23800	-1.95e-04	2.38e-01	9.99e-01	2.17e-02
SUMOylation of SUMOylation proteins	33	4.79e-02	9.90e-02	0.23800	-5.74e-03	2.38e-01	9.55e-01	1.81e-02
Regulation of RAS by GAPs	65	1.27e-02	3.60e-02	0.23700	1.54e-01	1.81e-01	3.22e-02	1.16e-02
Hemostasis	555	3.09e-20	5.97e-18	0.23700	-2.34e-01	-4.09e-02	3.72e-21	9.89e-02
TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition)	16	1.76e-01	2.61e-01	0.23700	-2.16e-01	9.84e-02	1.35e-01	4.95e-01
TRAF3-dependent IRF activation pathway	15	3.60e-01	4.45e-01	0.23700	1.36e-01	1.94e-01	3.62e-01	1.93e-01
MAPK targets/ Nuclear events mediated by MAP kinases	29	4.03e-02	8.82e-02	0.23700	-2.06e-01	1.17e-01	5.47e-02	2.75e-01
Resolution of Abasic Sites (AP sites)	37	1.54e-02	4.18e-02	0.23700	-1.40e-01	1.91e-01	1.41e-01	4.40e-02
EPHB-mediated forward signaling	34	6.58e-02	1.26e-01	0.23700	-2.31e-01	-5.25e-02	1.97e-02	5.96e-01
Interleukin-3, Interleukin-5 and GM-CSF signaling	41	4.88e-02	1.00e-01	0.23600	-2.20e-01	-8.66e-02	1.49e-02	3.37e-01
Defects in vitamin and cofactor metabolism	20	2.30e-01	3.19e-01	0.23600	-2.19e-01	-8.73e-02	8.95e-02	4.99e-01
Maturation of nucleoprotein 9694631	15	2.80e-01	3.70e-01	0.23500	-2.16e-02	-2.34e-01	8.85e-01	1.16e-01
PPARA activates gene expression	114	6.71e-05	4.17e-04	0.23500	-2.34e-01	-2.26e-02	1.55e-05	6.76e-01
FCERI mediated NF-kB activation	74	7.84e-03	2.42e-02	0.23500	1.71e-01	1.61e-01	1.10e-02	1.64e-02
Chylomicron remodeling	10	4.36e-01	5.19e-01	0.23500	-2.97e-02	-2.33e-01	8.71e-01	2.02e-01
Cyclin D associated events in G1	46	9.55e-03	2.86e-02	0.23500	-6.51e-02	2.26e-01	4.45e-01	8.08e-03
G1 Phase	46	9.55e-03	2.86e-02	0.23500	-6.51e-02	2.26e-01	4.45e-01	8.08e-03
Presynaptic nicotinic acetylcholine receptors	12	3.21e-01	4.08e-01	0.23400	-3.12e-02	2.32e-01	8.51e-01	1.63e-01
Post-translational protein phosphorylation	100	1.13e-03	4.75e-03	0.23400	-2.01e-01	-1.20e-01	4.96e-04	3.84e-02
Activated NTRK2 signals through FRS2 and FRS3	11	3.14e-01	4.03e-01	0.23400	-9.33e-02	2.15e-01	5.92e-01	2.17e-01
Base Excision Repair	45	7.27e-03	2.28e-02	0.23400	-1.28e-01	1.96e-01	1.38e-01	2.26e-02
Metabolism of RNA	639	1.76e-18	1.96e-16	0.23400	1.47e-01	1.82e-01	2.16e-10	3.41e-15
Late SARS-CoV-2 Infection Events	67	5.66e-03	1.87e-02	0.23400	-2.27e-01	-5.55e-02	1.30e-03	4.32e-01
Negative regulation of MET activity	20	1.15e-01	1.90e-01	0.23400	-2.02e-01	1.17e-01	1.17e-01	3.64e-01
Alpha-protein kinase 1 signaling pathway	10	5.23e-01	5.98e-01	0.23300	1.56e-01	1.74e-01	3.94e-01	3.41e-01
UCH proteinases	81	5.28e-03	1.76e-02	0.23300	1.79e-01	1.50e-01	5.46e-03	1.96e-02
Common Pathway of Fibrin Clot Formation	21	2.52e-01	3.43e-01	0.23300	-1.90e-01	-1.35e-01	1.32e-01	2.84e-01
Signaling by NOTCH1	69	3.69e-03	1.31e-02	0.23300	-2.31e-01	-3.04e-02	9.11e-04	6.62e-01
RHO GTPases activate PKNs	34	7.99e-02	1.46e-01	0.23200	-2.23e-01	-6.71e-02	2.47e-02	4.98e-01
Adrenaline,noradrenaline inhibits insulin secretion	28	1.65e-01	2.50e-01	0.23200	-1.78e-01	-1.49e-01	1.03e-01	1.72e-01
ADP signalling through P2Y purinoceptor 12	22	1.42e-01	2.22e-01	0.23200	-2.32e-01	1.11e-02	6.01e-02	9.28e-01
Cell recruitment (pro-inflammatory response)	25	9.43e-02	1.65e-01	0.23200	-4.17e-02	2.28e-01	7.18e-01	4.85e-02
Purinergic signaling in leishmaniasis infection	25	9.43e-02	1.65e-01	0.23200	-4.17e-02	2.28e-01	7.18e-01	4.85e-02
TP53 Regulates Metabolic Genes	83	2.13e-04	1.11e-03	0.23200	-8.65e-02	2.15e-01	1.73e-01	7.10e-04
Mitotic G1 phase and G1/S transition	144	9.68e-06	7.68e-05	0.23100	2.89e-02	2.30e-01	5.50e-01	1.96e-06
Signaling by NTRK2 (TRKB)	25	9.82e-02	1.69e-01	0.23100	-2.28e-01	3.67e-02	4.85e-02	7.51e-01
GRB2:SOS provides linkage to MAPK signaling for Integrins	15	3.18e-01	4.05e-01	0.23000	-2.25e-01	-4.78e-02	1.31e-01	7.49e-01
Sialic acid metabolism	33	8.07e-02	1.47e-01	0.23000	-2.25e-01	-4.57e-02	2.51e-02	6.50e-01
TP53 Regulates Transcription of Caspase Activators and Caspases	12	4.12e-01	4.96e-01	0.22900	-2.22e-01	-5.69e-02	1.83e-01	7.33e-01
Signaling by NOTCH4	79	7.46e-03	2.33e-02	0.22900	1.62e-01	1.62e-01	1.30e-02	1.28e-02
Platelet activation, signaling and aggregation	245	5.37e-09	1.09e-07	0.22800	-2.27e-01	-2.97e-02	9.66e-10	4.23e-01
Zinc influx into cells by the SLC39 gene family	10	4.60e-01	5.41e-01	0.22800	3.33e-02	2.26e-01	8.55e-01	2.16e-01
Hyaluronan uptake and degradation	12	4.71e-01	5.49e-01	0.22800	-1.82e-01	-1.38e-01	2.76e-01	4.06e-01
mitochondrial fatty acid beta-oxidation of saturated fatty acids	11	3.13e-01	4.02e-01	0.22800	-1.52e-01	1.71e-01	3.84e-01	3.27e-01
Glutathione synthesis and recycling	12	2.83e-01	3.73e-01	0.22800	-1.52e-01	1.69e-01	3.60e-01	3.10e-01
Paradoxical activation of RAF signaling by kinase inactive BRAF	41	4.59e-02	9.63e-02	0.22700	-2.23e-01	-4.23e-02	1.33e-02	6.40e-01
Signaling by RAS mutants	41	4.59e-02	9.63e-02	0.22700	-2.23e-01	-4.23e-02	1.33e-02	6.40e-01
Signaling by moderate kinase activity BRAF mutants	41	4.59e-02	9.63e-02	0.22700	-2.23e-01	-4.23e-02	1.33e-02	6.40e-01
Signaling downstream of RAS mutants	41	4.59e-02	9.63e-02	0.22700	-2.23e-01	-4.23e-02	1.33e-02	6.40e-01
TP53 Regulates Transcription of Genes Involved in Cytochrome C Release	19	1.86e-01	2.73e-01	0.22700	-2.25e-01	2.87e-02	8.89e-02	8.29e-01
Nuclear Pore Complex (NPC) Disassembly	34	3.55e-02	8.02e-02	0.22700	-8.85e-02	2.09e-01	3.72e-01	3.52e-02
SLC-mediated transmembrane transport	238	5.64e-07	6.97e-06	0.22700	-1.57e-01	-1.63e-01	2.81e-05	1.48e-05
Plasma lipoprotein assembly	19	2.70e-01	3.61e-01	0.22600	-2.13e-01	-7.61e-02	1.07e-01	5.66e-01
NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10	12	4.15e-01	5.00e-01	0.22600	4.98e-02	2.21e-01	7.65e-01	1.85e-01
Regulation of lipid metabolism by PPARalpha	116	1.07e-04	6.08e-04	0.22600	-2.26e-01	-1.73e-02	2.67e-05	7.47e-01
RNA Polymerase III Transcription Initiation	36	6.74e-02	1.28e-01	0.22600	3.96e-02	2.23e-01	6.81e-01	2.07e-02
Potential therapeutics for SARS	92	1.14e-04	6.36e-04	0.22600	-2.05e-01	9.64e-02	6.90e-04	1.10e-01
ABC transporter disorders	75	9.07e-03	2.74e-02	0.22600	1.91e-01	1.20e-01	4.14e-03	7.15e-02
Creation of C4 and C2 activators	14	3.36e-01	4.21e-01	0.22600	-2.31e-02	-2.25e-01	8.81e-01	1.45e-01
Interleukin-6 family signaling	24	2.23e-01	3.10e-01	0.22600	-1.21e-01	-1.91e-01	3.03e-01	1.06e-01
Cargo concentration in the ER	32	3.80e-02	8.42e-02	0.22600	-1.29e-01	1.85e-01	2.05e-01	7.02e-02
Cellular Senescence	130	1.59e-06	1.77e-05	0.22500	-1.49e-01	1.70e-01	3.44e-03	8.30e-04
Acyl chain remodelling of PI	16	2.74e-01	3.65e-01	0.22500	-4.60e-03	-2.25e-01	9.75e-01	1.18e-01
Nuclear Events (kinase and transcription factor activation)	60	4.97e-03	1.67e-02	0.22500	-3.69e-02	2.22e-01	6.21e-01	2.91e-03
KSRP (KHSRP) binds and destabilizes mRNA	17	1.77e-01	2.62e-01	0.22500	1.79e-01	-1.36e-01	2.01e-01	3.32e-01
SUMOylation of chromatin organization proteins	54	3.98e-03	1.37e-02	0.22500	-1.68e-01	1.49e-01	3.27e-02	5.76e-02
mRNA decay by 5’ to 3’ exoribonuclease	15	2.18e-01	3.07e-01	0.22500	-1.30e-01	1.84e-01	3.84e-01	2.18e-01
NPAS4 regulates expression of target genes	21	2.69e-01	3.60e-01	0.22400	-1.93e-01	-1.14e-01	1.25e-01	3.65e-01
Oncogene Induced Senescence	35	3.98e-02	8.74e-02	0.22400	-6.20e-02	2.15e-01	5.25e-01	2.74e-02
Expression and translocation of olfactory receptors	356	3.30e-16	2.55e-14	0.22400	1.38e-01	-1.77e-01	7.56e-06	1.00e-08
Initial triggering of complement	21	1.30e-01	2.07e-01	0.22400	9.82e-02	-2.01e-01	4.36e-01	1.11e-01
Striated Muscle Contraction	33	1.41e-01	2.21e-01	0.22300	-1.48e-01	-1.67e-01	1.40e-01	9.73e-02
TNF receptor superfamily (TNFSF) members mediating non-canonical NF-kB pathway	16	3.84e-01	4.71e-01	0.22300	1.76e-01	1.38e-01	2.24e-01	3.40e-01
PI3K/AKT Signaling in Cancer	103	8.57e-04	3.73e-03	0.22300	-2.14e-01	-6.16e-02	1.72e-04	2.80e-01
GPCR downstream signalling	603	4.26e-16	2.99e-14	0.22300	-1.81e-01	-1.30e-01	2.75e-14	4.89e-08
Removal of the Flap Intermediate from the C-strand	17	2.44e-01	3.33e-01	0.22300	-2.22e-01	1.69e-02	1.13e-01	9.04e-01
Tristetraprolin (TTP, ZFP36) binds and destabilizes mRNA	17	3.16e-01	4.05e-01	0.22200	2.12e-01	6.37e-02	1.29e-01	6.49e-01
FGFRL1 modulation of FGFR1 signaling	13	3.29e-01	4.15e-01	0.22100	-2.18e-01	3.64e-02	1.73e-01	8.20e-01
Olfactory Signaling Pathway	363	4.45e-16	2.99e-14	0.22100	1.32e-01	-1.78e-01	1.58e-05	5.66e-09
Nuclear Envelope Breakdown	50	7.15e-03	2.26e-02	0.22100	-1.64e-01	1.48e-01	4.46e-02	7.09e-02
Signaling by Erythropoietin	25	1.21e-01	1.95e-01	0.22100	-2.18e-01	3.37e-02	5.90e-02	7.71e-01
Chromatin modifying enzymes	186	3.55e-07	4.65e-06	0.22100	-2.20e-01	1.04e-02	2.10e-07	8.07e-01
Chromatin organization	186	3.55e-07	4.65e-06	0.22100	-2.20e-01	1.04e-02	2.10e-07	8.07e-01
Peptide hormone biosynthesis	11	4.44e-01	5.27e-01	0.22100	-2.19e-01	-2.46e-02	2.08e-01	8.88e-01
Regulation of TNFR1 signaling	37	9.69e-02	1.68e-01	0.22000	8.74e-02	2.02e-01	3.57e-01	3.34e-02
YAP1- and WWTR1 (TAZ)-stimulated gene expression	15	4.09e-01	4.94e-01	0.22000	-1.18e-01	-1.86e-01	4.30e-01	2.12e-01
TP53 Regulates Transcription of Cell Death Genes	42	1.75e-02	4.64e-02	0.22000	-1.20e-01	1.84e-01	1.80e-01	3.86e-02
Tight junction interactions	28	1.98e-01	2.88e-01	0.22000	-1.37e-01	-1.71e-01	2.08e-01	1.16e-01
Transport of Ribonucleoproteins into the Host Nucleus	30	8.49e-02	1.52e-01	0.21900	-2.59e-02	2.18e-01	8.06e-01	3.88e-02
Defective Intrinsic Pathway for Apoptosis	25	2.20e-01	3.08e-01	0.21900	1.00e-01	1.95e-01	3.86e-01	9.22e-02
FGFR2c ligand binding and activation	12	3.76e-01	4.64e-01	0.21900	-2.43e-02	2.17e-01	8.84e-01	1.92e-01
Neutrophil degranulation	458	3.61e-19	5.08e-17	0.21900	-1.08e-01	1.90e-01	7.80e-05	2.66e-12
MASTL Facilitates Mitotic Progression	10	4.72e-01	5.49e-01	0.21900	-2.18e-01	-1.04e-02	2.32e-01	9.55e-01
Cobalamin (Cbl, vitamin B12) transport and metabolism	20	3.22e-01	4.08e-01	0.21800	-1.48e-01	-1.60e-01	2.50e-01	2.15e-01
Acyl chain remodelling of PC	26	2.09e-01	2.98e-01	0.21800	-9.99e-02	-1.94e-01	3.78e-01	8.71e-02
Killing mechanisms	11	3.57e-01	4.42e-01	0.21800	-1.07e-01	1.90e-01	5.40e-01	2.75e-01
WNT5:FZD7-mediated leishmania damping	11	3.57e-01	4.42e-01	0.21800	-1.07e-01	1.90e-01	5.40e-01	2.75e-01
Downregulation of ERBB2:ERBB3 signaling	13	3.05e-01	3.94e-01	0.21800	-9.03e-02	1.98e-01	5.73e-01	2.16e-01
Gene and protein expression by JAK-STAT signaling after Interleukin-12 stimulation	35	9.30e-02	1.64e-01	0.21700	4.50e-02	2.13e-01	6.45e-01	2.95e-02
Transcription of E2F targets under negative control by p107 (RBL1) and p130 (RBL2) in complex with HDAC1	16	2.39e-01	3.28e-01	0.21700	-8.00e-02	2.02e-01	5.80e-01	1.62e-01
Mitotic Telophase/Cytokinesis	10	4.10e-01	4.95e-01	0.21700	-2.02e-01	7.79e-02	2.68e-01	6.70e-01
FRS-mediated FGFR3 signaling	19	1.78e-01	2.63e-01	0.21600	-9.30e-02	1.95e-01	4.83e-01	1.40e-01
Nuclear events stimulated by ALK signaling in cancer	18	2.85e-01	3.75e-01	0.21600	3.07e-02	2.14e-01	8.22e-01	1.16e-01
Host Interactions of HIV factors	122	5.57e-04	2.52e-03	0.21600	7.96e-02	2.01e-01	1.28e-01	1.26e-04
Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha)	14	2.65e-01	3.56e-01	0.21600	-1.61e-01	1.44e-01	2.96e-01	3.52e-01
Sensory Perception	567	1.58e-18	1.96e-16	0.21600	-7.56e-03	-2.16e-01	7.58e-01	1.22e-18
Regulated Necrosis	53	4.01e-02	8.79e-02	0.21600	8.41e-02	1.99e-01	2.90e-01	1.24e-02
Vesicle-mediated transport	623	1.40e-19	2.41e-17	0.21500	-2.15e-01	-1.93e-02	4.63e-20	4.11e-01
Triglyceride catabolism	23	2.63e-01	3.54e-01	0.21500	-1.04e-01	-1.89e-01	3.89e-01	1.17e-01
Pentose phosphate pathway	12	3.31e-01	4.16e-01	0.21500	-1.81e-01	1.17e-01	2.79e-01	4.84e-01
Interleukin-37 signaling	20	2.32e-01	3.21e-01	0.21400	-2.14e-01	-4.70e-03	9.73e-02	9.71e-01
NoRC negatively regulates rRNA expression	43	4.18e-02	9.04e-02	0.21400	-3.78e-04	2.14e-01	9.97e-01	1.51e-02
Transport of small molecules	689	1.22e-16	1.05e-14	0.21400	-1.59e-01	-1.44e-01	1.12e-12	1.07e-10
Metabolism of porphyrins	27	1.41e-01	2.21e-01	0.21400	-5.84e-03	-2.14e-01	9.58e-01	5.45e-02
SARS-CoV-1 targets host intracellular signalling and regulatory pathways	16	3.39e-01	4.24e-01	0.21400	-2.11e-01	-3.30e-02	1.44e-01	8.19e-01
Costimulation by the CD28 family	65	2.74e-02	6.62e-02	0.21400	-1.76e-01	-1.21e-01	1.41e-02	9.14e-02
G0 and Early G1	27	8.37e-02	1.51e-01	0.21300	-1.29e-01	1.70e-01	2.46e-01	1.26e-01
Epigenetic regulation of gene expression	83	4.80e-04	2.22e-03	0.21300	-1.40e-01	1.61e-01	2.79e-02	1.10e-02
Positive epigenetic regulation of rRNA expression	43	2.81e-02	6.78e-02	0.21300	-5.74e-02	2.05e-01	5.15e-01	1.98e-02
Leishmania infection	156	1.85e-05	1.35e-04	0.21300	-2.12e-01	-1.62e-02	4.57e-06	7.27e-01
Translocation of ZAP-70 to Immunological synapse	17	2.26e-01	3.14e-01	0.21300	8.80e-02	-1.94e-01	5.30e-01	1.66e-01
G alpha (q) signalling events	206	5.54e-06	4.70e-05	0.21300	-1.96e-01	-8.38e-02	1.24e-06	3.80e-02
MyD88:MAL(TIRAP) cascade initiated on plasma membrane	106	6.52e-05	4.08e-04	0.21200	-1.65e-01	1.34e-01	3.40e-03	1.70e-02
Toll Like Receptor 2 (TLR2) Cascade	106	6.52e-05	4.08e-04	0.21200	-1.65e-01	1.34e-01	3.40e-03	1.70e-02
Toll Like Receptor TLR1:TLR2 Cascade	106	6.52e-05	4.08e-04	0.21200	-1.65e-01	1.34e-01	3.40e-03	1.70e-02
Toll Like Receptor TLR6:TLR2 Cascade	106	6.52e-05	4.08e-04	0.21200	-1.65e-01	1.34e-01	3.40e-03	1.70e-02
Membrane Trafficking	585	1.78e-18	1.96e-16	0.21200	-2.12e-01	-5.44e-03	1.62e-18	8.22e-01
Sphingolipid metabolism	81	3.38e-03	1.22e-02	0.21200	-2.12e-01	-1.05e-02	9.86e-04	8.70e-01
AKT phosphorylates targets in the cytosol	14	2.84e-01	3.74e-01	0.21200	-1.72e-01	1.24e-01	2.66e-01	4.24e-01
Negative regulation of FGFR4 signaling	30	1.30e-01	2.07e-01	0.21200	2.21e-02	2.10e-01	8.34e-01	4.61e-02
SARS-CoV-1 Infection	134	3.93e-04	1.85e-03	0.21100	7.94e-02	1.96e-01	1.12e-01	8.96e-05
SHC-mediated cascade:FGFR4	19	1.91e-01	2.79e-01	0.21100	-9.57e-02	1.88e-01	4.70e-01	1.55e-01
Neurotransmitter release cycle	47	7.91e-02	1.45e-01	0.21100	-1.21e-01	-1.73e-01	1.50e-01	4.04e-02
Signal Transduction	2409	2.81e-58	4.35e-55	0.21100	-2.00e-01	-6.70e-02	2.90e-59	5.92e-08
NS1 Mediated Effects on Host Pathways	39	7.13e-02	1.35e-01	0.21100	2.14e-02	2.10e-01	8.17e-01	2.34e-02
Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta)	14	3.16e-01	4.05e-01	0.21100	-2.01e-01	6.29e-02	1.92e-01	6.84e-01
Signaling by Nuclear Receptors	237	4.75e-08	7.65e-07	0.21100	-2.11e-01	1.71e-03	2.25e-08	9.64e-01
Metabolism of cofactors	19	2.03e-01	2.94e-01	0.21000	-7.66e-02	1.96e-01	5.63e-01	1.39e-01
Initiation of Nuclear Envelope (NE) Reformation	18	2.01e-01	2.91e-01	0.21000	-1.66e-01	1.29e-01	2.23e-01	3.43e-01
Budding and maturation of HIV virion	28	1.26e-01	2.02e-01	0.21000	-1.70e-02	2.09e-01	8.76e-01	5.51e-02
G beta:gamma signalling through CDC42	19	2.76e-01	3.67e-01	0.21000	-2.09e-01	-1.74e-02	1.15e-01	8.95e-01
HCMV Early Events	55	1.02e-02	3.00e-02	0.21000	-1.95e-01	7.74e-02	1.24e-02	3.21e-01
Gap junction assembly	18	2.12e-01	3.00e-01	0.21000	1.01e-01	-1.84e-01	4.59e-01	1.77e-01
PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling	104	1.27e-03	5.21e-03	0.21000	-2.06e-01	-3.63e-02	2.75e-04	5.23e-01
Interleukin-17 signaling	66	3.98e-03	1.37e-02	0.20900	-1.92e-01	8.27e-02	6.91e-03	2.45e-01
MAP2K and MAPK activation	36	5.08e-02	1.04e-01	0.20900	-1.94e-01	7.68e-02	4.36e-02	4.25e-01
Signaling by TGF-beta Receptor Complex	90	2.42e-03	9.08e-03	0.20800	-2.07e-01	-1.31e-02	6.74e-04	8.29e-01
FGFR2b ligand binding and activation	10	4.40e-01	5.23e-01	0.20700	8.11e-02	-1.91e-01	6.57e-01	2.97e-01
SUMOylation of DNA replication proteins	44	4.18e-02	9.04e-02	0.20700	-1.84e-02	2.06e-01	8.33e-01	1.79e-02
Intra-Golgi and retrograde Golgi-to-ER traffic	181	5.06e-05	3.30e-04	0.20700	-1.87e-01	-8.77e-02	1.36e-05	4.17e-02
The role of Nef in HIV-1 replication and disease pathogenesis	27	2.44e-01	3.33e-01	0.20700	-1.73e-01	-1.13e-01	1.19e-01	3.10e-01
Mitotic Prophase	78	1.33e-03	5.40e-03	0.20600	-1.73e-01	1.13e-01	8.24e-03	8.49e-02
SHC-mediated cascade:FGFR2	22	1.55e-01	2.39e-01	0.20600	-1.12e-01	1.73e-01	3.63e-01	1.60e-01
Disassembly of the destruction complex and recruitment of AXIN to the membrane	30	1.01e-01	1.74e-01	0.20600	-2.00e-01	4.74e-02	5.73e-02	6.53e-01
Cellular response to chemical stress	187	1.76e-05	1.29e-04	0.20600	5.55e-02	1.98e-01	1.90e-01	2.89e-06
Gap junction trafficking and regulation	29	2.20e-01	3.08e-01	0.20600	-1.08e-01	-1.75e-01	3.16e-01	1.02e-01
SUMOylation of RNA binding proteins	45	2.57e-02	6.31e-02	0.20600	-8.43e-02	1.88e-01	3.28e-01	2.94e-02
FGFR1 ligand binding and activation	15	4.68e-01	5.47e-01	0.20600	1.29e-01	1.60e-01	3.88e-01	2.82e-01
IRS-related events triggered by IGF1R	50	4.68e-02	9.77e-02	0.20600	-2.02e-01	-3.91e-02	1.36e-02	6.32e-01
SUMO E3 ligases SUMOylate target proteins	158	3.18e-06	3.09e-05	0.20500	-1.89e-01	7.95e-02	3.98e-05	8.46e-02
Cooperation of Prefoldin and TriC/CCT in actin and tubulin folding	32	2.01e-01	2.91e-01	0.20500	1.57e-01	1.31e-01	1.23e-01	1.98e-01
SUMOylation	164	1.75e-06	1.91e-05	0.20500	-1.85e-01	8.79e-02	4.28e-05	5.20e-02
mRNA decay by 3’ to 5’ exoribonuclease	16	2.81e-01	3.71e-01	0.20500	1.91e-01	-7.37e-02	1.86e-01	6.10e-01
Downstream TCR signaling	92	7.10e-03	2.24e-02	0.20400	1.87e-01	8.19e-02	1.97e-03	1.74e-01
Negative epigenetic regulation of rRNA expression	45	4.91e-02	1.01e-01	0.20300	-2.35e-03	2.03e-01	9.78e-01	1.82e-02
TGF-beta receptor signaling activates SMADs	45	1.02e-01	1.74e-01	0.20300	-1.72e-01	-1.08e-01	4.57e-02	2.08e-01
Metabolism of steroid hormones	33	1.05e-01	1.76e-01	0.20300	1.14e-02	-2.03e-01	9.10e-01	4.35e-02
Signaling by FGFR1 in disease	37	5.25e-02	1.06e-01	0.20300	-1.83e-01	8.73e-02	5.39e-02	3.58e-01
Transcription of E2F targets under negative control by DREAM complex	19	2.12e-01	3.00e-01	0.20300	-1.06e-01	1.73e-01	4.23e-01	1.92e-01
Metabolism of fat-soluble vitamins	46	9.29e-02	1.64e-01	0.20300	-9.57e-02	-1.79e-01	2.61e-01	3.60e-02
IGF1R signaling cascade	51	4.16e-02	9.04e-02	0.20200	-2.01e-01	-1.98e-02	1.29e-02	8.07e-01
Amine ligand-binding receptors	41	6.10e-02	1.18e-01	0.20200	-2.01e-01	1.61e-02	2.58e-02	8.58e-01
Prostacyclin signalling through prostacyclin receptor	19	2.69e-01	3.60e-01	0.20100	-2.00e-01	2.22e-02	1.31e-01	8.67e-01
Regulation of cholesterol biosynthesis by SREBP (SREBF)	54	1.69e-02	4.54e-02	0.20100	-1.90e-01	6.57e-02	1.57e-02	4.03e-01
Detoxification of Reactive Oxygen Species	35	1.84e-01	2.71e-01	0.20100	1.26e-01	1.56e-01	1.96e-01	1.09e-01
Transport of the SLBP Dependant Mature mRNA	34	9.13e-02	1.61e-01	0.20100	-3.28e-02	1.98e-01	7.40e-01	4.55e-02
Formation of tubulin folding intermediates by CCT/TriC	26	2.49e-01	3.39e-01	0.20100	1.87e-01	7.20e-02	9.80e-02	5.25e-01
Insulin receptor signalling cascade	53	4.18e-02	9.04e-02	0.20100	-1.99e-01	-2.88e-02	1.24e-02	7.16e-01
Metalloprotease DUBs	19	2.26e-01	3.14e-01	0.20100	-8.90e-02	1.80e-01	5.02e-01	1.75e-01
Signaling by ERBB2	49	5.33e-02	1.07e-01	0.20000	-1.98e-01	-2.79e-02	1.63e-02	7.36e-01
FCGR activation	12	5.15e-01	5.90e-01	0.20000	-5.67e-02	-1.92e-01	7.34e-01	2.50e-01
S Phase	157	1.83e-04	9.79e-04	0.20000	5.77e-02	1.92e-01	2.12e-01	3.39e-05
Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs)	117	3.95e-03	1.37e-02	0.20000	-1.41e-01	-1.42e-01	8.54e-03	7.91e-03
Post-translational modification: synthesis of GPI-anchored proteins	89	8.98e-03	2.73e-02	0.19900	-6.94e-02	-1.87e-01	2.58e-01	2.28e-03
RNA Polymerase I Transcription	47	2.72e-02	6.60e-02	0.19900	-8.34e-02	1.81e-01	3.22e-01	3.17e-02
Metabolism of non-coding RNA	50	2.99e-02	7.08e-02	0.19900	-3.82e-02	1.96e-01	6.41e-01	1.66e-02
snRNP Assembly	50	2.99e-02	7.08e-02	0.19900	-3.82e-02	1.96e-01	6.41e-01	1.66e-02
STING mediated induction of host immune responses	13	5.07e-01	5.83e-01	0.19900	1.85e-01	7.20e-02	2.48e-01	6.53e-01
Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)	52	5.10e-02	1.04e-01	0.19800	-1.95e-01	-3.69e-02	1.50e-02	6.45e-01
HSF1 activation	27	2.76e-01	3.67e-01	0.19800	1.15e-01	1.62e-01	3.02e-01	1.45e-01
ESR-mediated signaling	160	3.85e-05	2.60e-04	0.19800	-1.98e-01	3.01e-03	1.47e-05	9.48e-01
Negative regulation of FGFR2 signaling	33	1.25e-01	2.01e-01	0.19800	4.64e-04	1.98e-01	9.96e-01	4.89e-02
FRS-mediated FGFR1 signaling	23	2.61e-01	3.52e-01	0.19700	2.63e-02	1.96e-01	8.27e-01	1.04e-01
Signaling by GPCR	670	2.33e-14	1.39e-12	0.19700	-1.69e-01	-1.02e-01	8.22e-14	6.38e-06
Negative regulation of MAPK pathway	41	4.54e-02	9.63e-02	0.19700	-8.88e-02	1.76e-01	3.25e-01	5.17e-02
NOTCH4 Intracellular Domain Regulates Transcription	19	3.49e-01	4.34e-01	0.19700	-1.92e-01	-4.29e-02	1.47e-01	7.46e-01
Attenuation phase	25	3.15e-01	4.05e-01	0.19600	1.24e-01	1.52e-01	2.82e-01	1.88e-01
mRNA 3’-end processing	53	6.92e-02	1.31e-01	0.19600	7.64e-02	1.81e-01	3.36e-01	2.26e-02
HCMV Infection	79	2.24e-03	8.54e-03	0.19600	-1.61e-01	1.12e-01	1.32e-02	8.43e-02
Class I peroxisomal membrane protein import	19	4.18e-01	5.01e-01	0.19600	1.48e-01	1.29e-01	2.64e-01	3.30e-01
Activation of HOX genes during differentiation	61	9.02e-03	2.73e-02	0.19600	-1.61e-01	1.12e-01	2.97e-02	1.29e-01
Activation of anterior HOX genes in hindbrain development during early embryogenesis	61	9.02e-03	2.73e-02	0.19600	-1.61e-01	1.12e-01	2.97e-02	1.29e-01
RNA Polymerase I Promoter Clearance	46	3.30e-02	7.63e-02	0.19600	-8.20e-02	1.78e-01	3.36e-01	3.65e-02
Gap junction trafficking	27	2.35e-01	3.24e-01	0.19600	-5.10e-02	-1.89e-01	6.46e-01	8.86e-02
Metabolism of lipids	696	1.93e-16	1.57e-14	0.19600	-1.89e-01	-5.27e-02	1.80e-17	1.76e-02
Interleukin-10 signaling	45	1.06e-01	1.77e-01	0.19500	1.80e-01	7.52e-02	3.65e-02	3.83e-01
Processing of SMDT1	15	4.91e-01	5.69e-01	0.19500	-9.83e-02	-1.69e-01	5.10e-01	2.58e-01
Protein localization	147	4.12e-04	1.92e-03	0.19500	4.98e-02	1.89e-01	2.97e-01	7.87e-05
tRNA processing	98	6.13e-03	2.01e-02	0.19500	5.57e-02	1.86e-01	3.40e-01	1.42e-03
Caspase-mediated cleavage of cytoskeletal proteins	12	4.66e-01	5.45e-01	0.19400	-1.94e-01	1.66e-02	2.45e-01	9.21e-01
IRS-mediated signalling	47	7.41e-02	1.38e-01	0.19400	-1.92e-01	-3.32e-02	2.31e-02	6.94e-01
Acyl chain remodelling of PE	24	3.17e-01	4.05e-01	0.19400	-8.85e-02	-1.73e-01	4.53e-01	1.42e-01
Transport of the SLBP independent Mature mRNA	33	1.12e-01	1.86e-01	0.19400	-3.48e-02	1.91e-01	7.30e-01	5.75e-02
Basigin interactions	24	2.20e-01	3.08e-01	0.19400	-1.93e-01	1.58e-02	1.01e-01	8.94e-01
Heme biosynthesis	13	4.95e-01	5.71e-01	0.19400	-3.91e-02	-1.90e-01	8.07e-01	2.36e-01
Signaling by FGFR3	39	6.92e-02	1.31e-01	0.19400	-5.22e-02	1.86e-01	5.73e-01	4.39e-02
PTEN Regulation	150	1.68e-05	1.24e-04	0.19300	-9.37e-02	1.69e-01	4.76e-02	3.42e-04
Macroautophagy	111	2.49e-04	1.26e-03	0.19300	-1.21e-01	1.49e-01	2.70e-02	6.52e-03
Surfactant metabolism	28	1.94e-01	2.83e-01	0.19200	-1.92e-01	-3.38e-03	7.93e-02	9.75e-01
Amino acids regulate mTORC1	52	2.27e-02	5.71e-02	0.19200	-1.63e-01	1.00e-01	4.18e-02	2.11e-01
Clathrin-mediated endocytosis	135	2.88e-04	1.42e-03	0.19100	-1.91e-01	1.21e-02	1.30e-04	8.08e-01
SUMOylation of DNA damage response and repair proteins	71	6.18e-03	2.02e-02	0.19100	-1.67e-01	9.27e-02	1.49e-02	1.77e-01
Mitochondrial biogenesis	69	6.78e-03	2.17e-02	0.19100	-1.62e-01	1.01e-01	2.02e-02	1.45e-01
Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors	34	9.27e-02	1.63e-01	0.19000	-1.73e-01	7.93e-02	8.05e-02	4.23e-01
PI3K Cascade	43	1.26e-01	2.03e-01	0.19000	-1.78e-01	-6.81e-02	4.36e-02	4.40e-01
Butyrate Response Factor 1 (BRF1) binds and destabilizes mRNA	17	3.27e-01	4.14e-01	0.19000	1.84e-01	-4.85e-02	1.90e-01	7.29e-01
Metallothioneins bind metals	11	6.20e-01	6.84e-01	0.18900	1.09e-01	1.55e-01	5.33e-01	3.73e-01
Autophagy	125	1.20e-04	6.67e-04	0.18900	-1.25e-01	1.42e-01	1.59e-02	6.08e-03
COPII-mediated vesicle transport	66	8.47e-03	2.61e-02	0.18900	-1.25e-01	1.41e-01	7.81e-02	4.70e-02
Synthesis, secretion, and inactivation of Glucose-dependent Insulinotropic Polypeptide (GIP)	12	5.66e-01	6.39e-01	0.18900	6.76e-02	1.76e-01	6.85e-01	2.90e-01
Intracellular signaling by second messengers	313	6.13e-09	1.23e-07	0.18800	-1.87e-01	2.48e-02	1.26e-08	4.50e-01
Toll Like Receptor 4 (TLR4) Cascade	135	6.88e-05	4.25e-04	0.18800	-1.44e-01	1.21e-01	3.93e-03	1.54e-02
Regulation of PTEN stability and activity	66	5.30e-02	1.06e-01	0.18800	8.53e-02	1.67e-01	2.31e-01	1.89e-02
Pre-NOTCH Transcription and Translation	45	4.59e-02	9.63e-02	0.18800	-1.67e-01	8.44e-02	5.19e-02	3.27e-01
Condensation of Prophase Chromosomes	12	5.08e-01	5.84e-01	0.18700	-1.87e-01	-6.48e-06	2.61e-01	1.00e+00
Signaling by ROBO receptors	203	2.21e-04	1.14e-03	0.18700	1.43e-01	1.20e-01	4.25e-04	3.16e-03
Inhibition of DNA recombination at telomere	20	3.77e-01	4.65e-01	0.18700	1.80e-01	4.96e-02	1.63e-01	7.01e-01
Regulation of gene expression in late stage (branching morphogenesis) pancreatic bud precursor cells	15	3.79e-01	4.66e-01	0.18700	-1.77e-01	5.82e-02	2.34e-01	6.96e-01
SLBP Dependent Processing of Replication-Dependent Histone Pre-mRNAs	11	4.63e-01	5.42e-01	0.18700	-1.11e-01	1.50e-01	5.23e-01	3.90e-01
Signaling by KIT in disease	20	3.17e-01	4.05e-01	0.18600	-1.86e-01	9.71e-03	1.49e-01	9.40e-01
Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants	20	3.17e-01	4.05e-01	0.18600	-1.86e-01	9.71e-03	1.49e-01	9.40e-01
E3 ubiquitin ligases ubiquitinate target proteins	43	8.33e-02	1.51e-01	0.18600	-1.19e-02	1.86e-01	8.93e-01	3.47e-02
LDL clearance	19	4.55e-01	5.37e-01	0.18600	-1.40e-01	-1.23e-01	2.90e-01	3.53e-01
Signaling by ERBB2 KD Mutants	24	3.09e-01	3.98e-01	0.18600	-1.81e-01	-4.57e-02	1.26e-01	6.99e-01
Interleukin-2 family signaling	40	1.76e-01	2.61e-01	0.18600	-1.63e-01	-8.98e-02	7.41e-02	3.26e-01
Early SARS-CoV-2 Infection Events	34	9.49e-02	1.66e-01	0.18600	-1.55e-01	1.04e-01	1.19e-01	2.95e-01
TNF signaling	45	1.12e-01	1.86e-01	0.18600	4.56e-02	1.80e-01	5.97e-01	3.64e-02
Synthesis of glycosylphosphatidylinositol (GPI)	17	3.03e-01	3.92e-01	0.18600	-1.35e-01	1.28e-01	3.35e-01	3.61e-01
Butyrophilin (BTN) family interactions	12	4.60e-01	5.41e-01	0.18600	1.75e-01	-6.18e-02	2.94e-01	7.11e-01
RNA Polymerase II Transcription Termination	62	5.71e-02	1.13e-01	0.18600	6.21e-02	1.75e-01	3.97e-01	1.72e-02
Interleukin-7 signaling	21	4.24e-01	5.06e-01	0.18600	-1.29e-01	-1.34e-01	3.07e-01	2.89e-01
Hedgehog ‘on’ state	83	3.05e-02	7.15e-02	0.18500	9.87e-02	1.57e-01	1.20e-01	1.35e-02
Phospholipase C-mediated cascade: FGFR1	16	5.20e-01	5.94e-01	0.18500	1.20e-01	1.41e-01	4.07e-01	3.28e-01
TP53 Regulates Transcription of Cell Cycle Genes	49	3.35e-02	7.68e-02	0.18500	-1.22e-01	1.39e-01	1.41e-01	9.14e-02
Transport of bile salts and organic acids, metal ions and amine compounds	84	3.39e-02	7.73e-02	0.18400	-1.44e-01	-1.14e-01	2.26e-02	7.09e-02
HCMV Late Events	54	3.24e-02	7.54e-02	0.18300	-6.79e-02	1.70e-01	3.88e-01	3.08e-02
Protein methylation	16	3.37e-01	4.22e-01	0.18300	-1.29e-01	1.30e-01	3.71e-01	3.69e-01
SUMOylation of transcription cofactors	43	7.18e-02	1.35e-01	0.18300	-1.75e-01	5.11e-02	4.65e-02	5.62e-01
RAB geranylgeranylation	57	3.34e-02	7.68e-02	0.18200	-4.16e-02	1.77e-01	5.87e-01	2.04e-02
Mismatch Repair	15	3.64e-01	4.50e-01	0.18200	-1.38e-01	1.19e-01	3.55e-01	4.25e-01
FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes	29	3.19e-01	4.05e-01	0.18200	-1.36e-01	-1.21e-01	2.04e-01	2.60e-01
Downstream signaling events of B Cell Receptor (BCR)	78	4.69e-02	9.77e-02	0.18200	1.26e-01	1.31e-01	5.40e-02	4.52e-02
Resolution of AP sites via the multiple-nucleotide patch replacement pathway	24	2.10e-01	2.98e-01	0.18200	-1.59e-01	8.85e-02	1.78e-01	4.53e-01
Transport of Mature Transcript to Cytoplasm	76	3.09e-02	7.25e-02	0.18200	4.98e-02	1.75e-01	4.53e-01	8.39e-03
Formation of HIV-1 elongation complex containing HIV-1 Tat	38	2.05e-01	2.95e-01	0.18200	8.45e-02	1.61e-01	3.67e-01	8.61e-02
HIV Transcription Elongation	38	2.05e-01	2.95e-01	0.18200	8.45e-02	1.61e-01	3.67e-01	8.61e-02
Tat-mediated elongation of the HIV-1 transcript	38	2.05e-01	2.95e-01	0.18200	8.45e-02	1.61e-01	3.67e-01	8.61e-02
Regulation of pyruvate dehydrogenase (PDH) complex	14	4.17e-01	5.01e-01	0.18200	-1.69e-01	6.57e-02	2.73e-01	6.70e-01
Signaling by Insulin receptor	77	1.59e-02	4.31e-02	0.18200	-1.82e-01	5.15e-03	5.87e-03	9.38e-01
Incretin synthesis, secretion, and inactivation	23	2.39e-01	3.28e-01	0.18100	-1.70e-01	6.46e-02	1.59e-01	5.92e-01
Constitutive Signaling by Aberrant PI3K in Cancer	77	3.33e-02	7.67e-02	0.18100	-1.71e-01	-6.00e-02	9.40e-03	3.62e-01
Transport to the Golgi and subsequent modification	165	1.85e-04	9.85e-04	0.18100	-1.81e-01	-3.42e-03	5.81e-05	9.40e-01
Keratan sulfate degradation	12	5.96e-01	6.64e-01	0.18100	-1.68e-01	-6.87e-02	3.15e-01	6.80e-01
Transport of Mature mRNA derived from an Intron-Containing Transcript	67	6.33e-02	1.22e-01	0.18100	8.61e-02	1.59e-01	2.23e-01	2.40e-02
Diseases of signal transduction by growth factor receptors and second messengers	410	9.21e-11	2.91e-09	0.18100	-1.79e-01	2.91e-02	4.93e-10	3.12e-01
Keratinization	213	1.29e-06	1.47e-05	0.18100	8.59e-02	-1.59e-01	3.06e-02	6.25e-05
Signaling by ERBB2 TMD/JMD mutants	21	2.93e-01	3.83e-01	0.18100	-1.76e-01	3.97e-02	1.62e-01	7.53e-01
WNT ligand biogenesis and trafficking	25	2.04e-01	2.94e-01	0.18100	-8.18e-02	1.61e-01	4.79e-01	1.63e-01
MAP kinase activation	58	2.42e-02	6.00e-02	0.18100	-1.57e-01	8.90e-02	3.85e-02	2.41e-01
Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell	120	2.68e-03	9.95e-03	0.18000	1.79e-01	1.83e-02	6.85e-04	7.28e-01
PD-1 signaling	21	2.52e-01	3.43e-01	0.18000	1.14e-01	-1.40e-01	3.67e-01	2.67e-01
G beta:gamma signalling through BTK	17	4.20e-01	5.03e-01	0.18000	-1.80e-01	-7.26e-03	1.99e-01	9.59e-01
G alpha (i) signalling events	305	8.93e-06	7.23e-05	0.18000	-1.34e-01	-1.20e-01	5.33e-05	3.20e-04
HIV Life Cycle	139	1.03e-03	4.38e-03	0.18000	1.58e-02	1.79e-01	7.47e-01	2.63e-04
Peptide hormone metabolism	83	2.23e-02	5.65e-02	0.18000	-1.75e-01	-4.18e-02	5.84e-03	5.11e-01
Plasma lipoprotein assembly, remodeling, and clearance	73	6.17e-02	1.19e-01	0.17900	-1.24e-01	-1.30e-01	6.76e-02	5.49e-02
Metabolism of nucleotides	95	2.17e-03	8.33e-03	0.17900	-1.44e-01	1.07e-01	1.51e-02	7.25e-02
NOD1/2 Signaling Pathway	29	1.70e-01	2.55e-01	0.17900	-1.66e-01	6.74e-02	1.21e-01	5.30e-01
Cytoprotection by HMOX1	58	2.66e-02	6.47e-02	0.17900	-8.24e-02	1.59e-01	2.78e-01	3.62e-02
Class B/2 (Secretin family receptors)	94	4.19e-03	1.44e-02	0.17800	-1.71e-01	5.00e-02	4.11e-03	4.02e-01
Signaling by Retinoic Acid	41	7.76e-02	1.43e-01	0.17800	-1.57e-01	8.52e-02	8.28e-02	3.45e-01
Sealing of the nuclear envelope (NE) by ESCRT-III	31	3.08e-01	3.98e-01	0.17800	1.11e-01	1.39e-01	2.86e-01	1.79e-01
Abortive elongation of HIV-1 transcript in the absence of Tat	23	4.20e-01	5.03e-01	0.17800	1.15e-01	1.36e-01	3.41e-01	2.59e-01
Translation of Structural Proteins 9694635	55	4.79e-02	9.90e-02	0.17800	-1.75e-01	2.99e-02	2.45e-02	7.01e-01
Toll-like Receptor Cascades	154	5.35e-05	3.46e-04	0.17800	-1.30e-01	1.21e-01	5.32e-03	9.38e-03
Activation of the pre-replicative complex	31	1.56e-01	2.40e-01	0.17800	-6.53e-02	1.65e-01	5.29e-01	1.11e-01
Defective TPR may confer susceptibility towards thyroid papillary carcinoma (TPC)	30	2.04e-01	2.94e-01	0.17800	-1.56e-02	1.77e-01	8.83e-01	9.36e-02
Regulation of Glucokinase by Glucokinase Regulatory Protein	30	2.04e-01	2.94e-01	0.17800	-1.56e-02	1.77e-01	8.83e-01	9.36e-02
Intra-Golgi traffic	43	1.85e-01	2.71e-01	0.17700	-1.55e-01	-8.53e-02	7.81e-02	3.33e-01
Prefoldin mediated transfer of substrate to CCT/TriC	27	3.43e-01	4.29e-01	0.17600	1.58e-01	7.85e-02	1.55e-01	4.80e-01
Interferon alpha/beta signaling	69	5.99e-02	1.17e-01	0.17600	1.63e-01	6.54e-02	1.88e-02	3.48e-01
Metabolism of carbohydrates	275	3.90e-06	3.64e-05	0.17600	-1.74e-01	-2.77e-02	6.95e-07	4.28e-01
Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer	49	6.19e-02	1.19e-01	0.17600	-1.68e-01	5.06e-02	4.16e-02	5.40e-01
Recruitment of NuMA to mitotic centrosomes	75	2.24e-02	5.66e-02	0.17500	-1.75e-01	1.02e-02	8.90e-03	8.79e-01
Drug ADME	104	1.75e-02	4.64e-02	0.17500	-7.69e-02	-1.57e-01	1.75e-01	5.64e-03
FGFR1 mutant receptor activation	30	1.57e-01	2.41e-01	0.17500	-1.35e-01	1.11e-01	2.00e-01	2.94e-01
SLBP independent Processing of Histone Pre-mRNAs	10	5.38e-01	6.14e-01	0.17500	-1.25e-01	1.22e-01	4.92e-01	5.06e-01
Protein ubiquitination	61	5.55e-02	1.10e-01	0.17400	7.33e-03	1.74e-01	9.21e-01	1.90e-02
IRF3-mediated induction of type I IFN	11	5.94e-01	6.62e-01	0.17400	1.73e-01	8.10e-03	3.19e-01	9.63e-01
Regulation of RUNX2 expression and activity	71	7.82e-02	1.44e-01	0.17400	1.12e-01	1.33e-01	1.04e-01	5.28e-02
Platelet degranulation	115	1.20e-02	3.42e-02	0.17300	-1.57e-01	-7.37e-02	3.63e-03	1.72e-01
HIV Infection	216	1.86e-04	9.89e-04	0.17300	5.99e-02	1.62e-01	1.29e-01	3.79e-05
Meiosis	56	1.02e-01	1.74e-01	0.17300	-1.65e-01	-5.02e-02	3.26e-02	5.16e-01
Selective autophagy	59	4.52e-02	9.63e-02	0.17200	-3.28e-02	1.69e-01	6.63e-01	2.44e-02
Defects in cobalamin (B12) metabolism	12	6.31e-01	6.92e-01	0.17200	-1.57e-01	-7.07e-02	3.47e-01	6.71e-01
Glucagon-type ligand receptors	33	2.94e-01	3.83e-01	0.17200	-1.51e-01	-8.19e-02	1.33e-01	4.15e-01
Apoptotic factor-mediated response	17	3.98e-01	4.85e-01	0.17200	1.65e-01	-4.75e-02	2.38e-01	7.34e-01
Signaling by ERBB2 ECD mutants	15	4.72e-01	5.49e-01	0.17200	-1.71e-01	1.82e-02	2.52e-01	9.03e-01
MyD88 cascade initiated on plasma membrane	91	5.23e-03	1.75e-02	0.17100	-1.50e-01	8.39e-02	1.37e-02	1.67e-01
Toll Like Receptor 10 (TLR10) Cascade	91	5.23e-03	1.75e-02	0.17100	-1.50e-01	8.39e-02	1.37e-02	1.67e-01
Toll Like Receptor 5 (TLR5) Cascade	91	5.23e-03	1.75e-02	0.17100	-1.50e-01	8.39e-02	1.37e-02	1.67e-01
TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation	95	3.94e-03	1.37e-02	0.17100	-1.45e-01	9.15e-02	1.47e-02	1.23e-01
MyD88 dependent cascade initiated on endosome	96	3.64e-03	1.31e-02	0.17100	-1.40e-01	9.81e-02	1.77e-02	9.64e-02
Toll Like Receptor 7/8 (TLR7/8) Cascade	96	3.64e-03	1.31e-02	0.17100	-1.40e-01	9.81e-02	1.77e-02	9.64e-02
Pyruvate metabolism and Citric Acid (TCA) cycle	52	4.66e-02	9.75e-02	0.17000	-1.19e-01	1.22e-01	1.37e-01	1.29e-01
FOXO-mediated transcription of cell cycle genes	16	5.72e-01	6.42e-01	0.17000	-1.03e-01	-1.36e-01	4.75e-01	3.47e-01
Purine catabolism	17	5.48e-01	6.21e-01	0.17000	1.41e-01	9.50e-02	3.12e-01	4.98e-01
MAPK3 (ERK1) activation	10	7.09e-01	7.64e-01	0.17000	-1.13e-01	-1.27e-01	5.36e-01	4.87e-01
Metabolism of steroids	148	6.29e-03	2.04e-02	0.17000	-1.29e-01	-1.10e-01	6.54e-03	2.08e-02
Transport of nucleosides and free purine and pyrimidine bases across the plasma membrane	10	5.71e-01	6.42e-01	0.16900	-1.50e-01	7.79e-02	4.11e-01	6.70e-01
PIP3 activates AKT signaling	275	2.94e-07	3.95e-06	0.16900	-1.53e-01	7.19e-02	1.25e-05	4.00e-02
Deactivation of the beta-catenin transactivating complex	39	1.87e-01	2.74e-01	0.16900	-1.68e-01	-2.09e-02	7.01e-02	8.22e-01
Postmitotic nuclear pore complex (NPC) reformation	26	3.09e-01	3.98e-01	0.16900	4.28e-03	1.69e-01	9.70e-01	1.37e-01
Mitotic Metaphase and Anaphase	222	2.04e-04	1.07e-03	0.16800	5.12e-02	1.60e-01	1.89e-01	3.86e-05
Biosynthesis of the N-glycan precursor (dolichol lipid-linked oligosaccharide, LLO) and transfer to a nascent protein	74	1.44e-02	3.99e-02	0.16800	-1.14e-01	1.24e-01	9.05e-02	6.56e-02
RNA polymerase II transcribes snRNA genes	77	6.39e-02	1.22e-01	0.16700	7.22e-02	1.51e-01	2.73e-01	2.21e-02
Signaling by FGFR4	40	1.45e-01	2.26e-01	0.16700	-2.37e-02	1.65e-01	7.95e-01	7.02e-02
B-WICH complex positively regulates rRNA expression	29	3.43e-01	4.28e-01	0.16700	6.01e-02	1.56e-01	5.75e-01	1.47e-01
Glyoxylate metabolism and glycine degradation	30	1.88e-01	2.75e-01	0.16700	-9.42e-02	1.38e-01	3.72e-01	1.92e-01
Mitochondrial Fatty Acid Beta-Oxidation	35	1.49e-01	2.30e-01	0.16700	-1.47e-01	7.84e-02	1.32e-01	4.22e-01
Cell surface interactions at the vascular wall	127	1.38e-03	5.58e-03	0.16700	-1.57e-01	5.58e-02	2.24e-03	2.77e-01
Anchoring of the basal body to the plasma membrane	92	3.53e-02	8.01e-02	0.16600	-1.55e-01	-6.06e-02	1.04e-02	3.15e-01
Response to elevated platelet cytosolic Ca2+	120	1.51e-02	4.11e-02	0.16600	-1.49e-01	-7.18e-02	4.73e-03	1.74e-01
Insulin receptor recycling	26	2.66e-01	3.56e-01	0.16600	-1.57e-01	5.13e-02	1.65e-01	6.51e-01
RNA Polymerase III Transcription Initiation From Type 1 Promoter	28	3.42e-01	4.27e-01	0.16500	4.21e-02	1.60e-01	7.00e-01	1.43e-01
Cell Cycle Checkpoints	248	4.55e-05	3.02e-04	0.16500	2.43e-02	1.64e-01	5.09e-01	8.97e-06
RNA Polymerase II Pre-transcription Events	73	8.87e-02	1.58e-01	0.16500	9.16e-02	1.37e-01	1.76e-01	4.24e-02
Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants	54	7.66e-02	1.42e-01	0.16500	-1.62e-01	2.85e-02	3.90e-02	7.17e-01
Constitutive Signaling by NOTCH1 PEST Domain Mutants	54	7.66e-02	1.42e-01	0.16500	-1.62e-01	2.85e-02	3.90e-02	7.17e-01
Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer	54	7.66e-02	1.42e-01	0.16500	-1.62e-01	2.85e-02	3.90e-02	7.17e-01
Signaling by NOTCH1 PEST Domain Mutants in Cancer	54	7.66e-02	1.42e-01	0.16500	-1.62e-01	2.85e-02	3.90e-02	7.17e-01
Signaling by NOTCH1 in Cancer	54	7.66e-02	1.42e-01	0.16500	-1.62e-01	2.85e-02	3.90e-02	7.17e-01
Mitotic Anaphase	221	2.79e-04	1.38e-03	0.16500	4.79e-02	1.58e-01	2.19e-01	5.30e-05
Transcriptional regulation by small RNAs	46	1.67e-01	2.52e-01	0.16500	3.44e-02	1.61e-01	6.86e-01	5.89e-02
Transcriptional Regulation by TP53	346	1.16e-08	2.21e-07	0.16400	-8.55e-02	1.40e-01	6.23e-03	7.32e-06
Toll Like Receptor 9 (TLR9) Cascade	100	4.54e-03	1.54e-02	0.16400	-1.32e-01	9.78e-02	2.30e-02	9.09e-02
RHO GTPase Effectors	232	1.04e-04	5.96e-04	0.16400	-1.62e-01	-2.37e-02	2.11e-05	5.34e-01
FCGR3A-mediated phagocytosis	57	1.06e-01	1.76e-01	0.16400	-1.61e-01	-2.61e-02	3.49e-02	7.33e-01
Leishmania phagocytosis	57	1.06e-01	1.76e-01	0.16400	-1.61e-01	-2.61e-02	3.49e-02	7.33e-01
Parasite infection	57	1.06e-01	1.76e-01	0.16400	-1.61e-01	-2.61e-02	3.49e-02	7.33e-01
MyD88-independent TLR4 cascade	103	3.90e-03	1.36e-02	0.16300	-1.04e-01	1.26e-01	6.88e-02	2.68e-02
TRIF(TICAM1)-mediated TLR4 signaling	103	3.90e-03	1.36e-02	0.16300	-1.04e-01	1.26e-01	6.88e-02	2.68e-02
Interleukin-12 signaling	43	1.36e-01	2.15e-01	0.16300	-2.57e-02	1.61e-01	7.70e-01	6.74e-02
Centrosome maturation	76	3.75e-02	8.34e-02	0.16300	-1.63e-01	3.40e-03	1.39e-02	9.59e-01
Recruitment of mitotic centrosome proteins and complexes	76	3.75e-02	8.34e-02	0.16300	-1.63e-01	3.40e-03	1.39e-02	9.59e-01
Glycosphingolipid metabolism	40	1.22e-01	1.97e-01	0.16300	-1.41e-01	8.26e-02	1.24e-01	3.66e-01
Synthesis of bile acids and bile salts via 24-hydroxycholesterol	14	5.88e-01	6.56e-01	0.16300	-3.62e-02	-1.59e-01	8.15e-01	3.03e-01
Formation of HIV elongation complex in the absence of HIV Tat	40	2.81e-01	3.71e-01	0.16300	1.01e-01	1.28e-01	2.70e-01	1.62e-01
Reversible hydration of carbon dioxide	11	5.60e-01	6.33e-01	0.16300	-8.72e-02	1.37e-01	6.16e-01	4.30e-01
Signaling by TGFB family members	118	1.86e-02	4.85e-02	0.16300	-1.47e-01	-7.04e-02	5.88e-03	1.86e-01
Signaling by EGFR in Cancer	25	3.19e-01	4.06e-01	0.16300	-2.31e-02	1.61e-01	8.41e-01	1.64e-01
Signaling by NTRK1 (TRKA)	114	2.54e-03	9.50e-03	0.16200	-1.37e-01	8.75e-02	1.16e-02	1.06e-01
Regulation of TP53 Activity	154	4.98e-04	2.29e-03	0.16200	-1.51e-01	5.78e-02	1.18e-03	2.16e-01
RUNX3 regulates NOTCH signaling	13	6.63e-01	7.22e-01	0.16200	-9.48e-02	-1.31e-01	5.54e-01	4.13e-01
HDR through MMEJ (alt-NHEJ)	11	5.58e-01	6.32e-01	0.16200	-1.13e-01	1.15e-01	5.15e-01	5.08e-01
Cytosolic iron-sulfur cluster assembly	10	6.91e-01	7.49e-01	0.16200	3.83e-02	1.57e-01	8.34e-01	3.90e-01
Synthesis of substrates in N-glycan biosythesis	60	4.41e-02	9.47e-02	0.16100	-1.32e-01	9.27e-02	7.75e-02	2.14e-01
Processing of DNA double-strand break ends	61	8.59e-02	1.53e-01	0.16100	1.00e-02	1.61e-01	8.93e-01	3.00e-02
Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer’s disease models	22	4.46e-01	5.28e-01	0.16100	3.74e-02	1.56e-01	7.61e-01	2.04e-01
Neurodegenerative Diseases	22	4.46e-01	5.28e-01	0.16100	3.74e-02	1.56e-01	7.61e-01	2.04e-01
Response to metal ions	14	6.23e-01	6.86e-01	0.16100	6.11e-02	1.48e-01	6.92e-01	3.36e-01
Transcription of the HIV genome	62	1.50e-01	2.31e-01	0.16000	1.07e-01	1.20e-01	1.47e-01	1.02e-01
Triglyceride metabolism	36	3.15e-01	4.04e-01	0.16000	-7.76e-02	-1.40e-01	4.20e-01	1.45e-01
RNA Polymerase I Transcription Initiation	42	1.13e-01	1.87e-01	0.16000	-1.01e-01	1.24e-01	2.56e-01	1.64e-01
Regulation of TP53 Degradation	36	2.25e-01	3.13e-01	0.16000	-1.60e-01	2.60e-03	9.69e-02	9.78e-01
NOTCH4 Activation and Transmission of Signal to the Nucleus	11	6.08e-01	6.73e-01	0.16000	3.22e-02	-1.56e-01	8.53e-01	3.69e-01
Late Phase of HIV Life Cycle	126	7.67e-03	2.38e-02	0.16000	1.64e-02	1.59e-01	7.50e-01	2.07e-03
mRNA Editing	10	5.97e-01	6.64e-01	0.15900	1.21e-01	-1.04e-01	5.09e-01	5.68e-01
Metabolism of water-soluble vitamins and cofactors	118	1.67e-02	4.49e-02	0.15900	-1.52e-01	-4.72e-02	4.28e-03	3.76e-01
DAP12 signaling	28	2.78e-01	3.69e-01	0.15900	-1.55e-01	3.71e-02	1.56e-01	7.34e-01
Signaling by WNT	263	3.80e-05	2.58e-04	0.15900	-1.59e-01	-1.32e-02	9.16e-06	7.12e-01
Metabolic disorders of biological oxidation enzymes	32	3.80e-01	4.68e-01	0.15900	-1.04e-01	-1.20e-01	3.08e-01	2.38e-01
Regulation of TP53 Activity through Methylation	18	5.61e-01	6.34e-01	0.15900	7.24e-02	1.42e-01	5.95e-01	2.98e-01
Signaling by NTRKs	133	1.84e-03	7.11e-03	0.15900	-1.50e-01	5.39e-02	2.85e-03	2.83e-01
Glutamate Neurotransmitter Release Cycle	23	4.85e-01	5.62e-01	0.15900	-7.94e-02	-1.38e-01	5.10e-01	2.53e-01
Endosomal Sorting Complex Required For Transport (ESCRT)	31	2.46e-01	3.35e-01	0.15900	-3.54e-02	1.55e-01	7.33e-01	1.35e-01
Activation of ATR in response to replication stress	37	2.20e-01	3.08e-01	0.15900	-2.86e-03	1.59e-01	9.76e-01	9.49e-02
Death Receptor Signalling	134	9.99e-03	2.97e-02	0.15900	-1.52e-01	-4.66e-02	2.43e-03	3.51e-01
PCP/CE pathway	90	5.62e-02	1.11e-01	0.15800	6.62e-02	1.43e-01	2.78e-01	1.88e-02
Listeria monocytogenes entry into host cells	19	4.74e-01	5.51e-01	0.15700	-1.57e-01	-2.44e-03	2.37e-01	9.85e-01
Nuclear Envelope (NE) Reassembly	73	5.69e-02	1.12e-01	0.15700	1.69e-03	1.57e-01	9.80e-01	2.05e-02
RNA Polymerase III Transcription Initiation From Type 2 Promoter	27	4.04e-01	4.91e-01	0.15700	4.72e-02	1.49e-01	6.71e-01	1.79e-01
RNA Polymerase III Abortive And Retractive Initiation	41	1.49e-01	2.31e-01	0.15700	-5.65e-02	1.46e-01	5.31e-01	1.06e-01
RNA Polymerase III Transcription	41	1.49e-01	2.31e-01	0.15700	-5.65e-02	1.46e-01	5.31e-01	1.06e-01
WNT5A-dependent internalization of FZD4	15	6.27e-01	6.89e-01	0.15600	-1.40e-01	-6.78e-02	3.46e-01	6.49e-01
Translesion synthesis by Y family DNA polymerases bypasses lesions on DNA template	38	1.78e-01	2.63e-01	0.15600	-5.07e-02	1.47e-01	5.89e-01	1.16e-01
Phenylalanine and tyrosine metabolism	10	7.27e-01	7.80e-01	0.15600	-1.44e-01	-5.86e-02	4.29e-01	7.48e-01
Cooperation of PDCL (PhLP1) and TRiC/CCT in G-protein beta folding	38	2.39e-01	3.29e-01	0.15500	-1.55e-01	-9.09e-03	9.80e-02	9.23e-01
Signaling by EGFR	49	1.15e-01	1.89e-01	0.15500	-1.49e-01	4.31e-02	7.07e-02	6.01e-01
Translation of Structural Proteins 9683701	29	3.29e-01	4.15e-01	0.15500	-1.55e-01	-2.10e-03	1.49e-01	9.84e-01
Formation of Incision Complex in GG-NER	40	1.75e-01	2.60e-01	0.15500	-4.01e-02	1.49e-01	6.61e-01	1.02e-01
Formation of RNA Pol II elongation complex	53	2.08e-01	2.98e-01	0.15500	7.81e-02	1.33e-01	3.25e-01	9.28e-02
RNA Polymerase II Transcription Elongation	53	2.08e-01	2.98e-01	0.15500	7.81e-02	1.33e-01	3.25e-01	9.28e-02
Degradation of beta-catenin by the destruction complex	81	9.48e-02	1.66e-01	0.15500	8.54e-02	1.29e-01	1.84e-01	4.50e-02
Signaling by FGFR3 in disease	21	4.05e-01	4.91e-01	0.15400	-1.49e-01	3.82e-02	2.36e-01	7.62e-01
MAPK6/MAPK4 signaling	89	8.13e-02	1.48e-01	0.15400	1.00e-01	1.17e-01	1.03e-01	5.62e-02
G2/M DNA damage checkpoint	58	8.29e-02	1.50e-01	0.15300	-4.23e-02	1.47e-01	5.78e-01	5.24e-02
Toll Like Receptor 3 (TLR3) Cascade	99	9.58e-03	2.86e-02	0.15300	-8.97e-02	1.24e-01	1.23e-01	3.29e-02
RNA Polymerase III Chain Elongation	18	6.07e-01	6.73e-01	0.15300	1.07e-01	1.09e-01	4.32e-01	4.22e-01
Ethanol oxidation	12	5.67e-01	6.39e-01	0.15300	1.01e-01	-1.15e-01	5.45e-01	4.92e-01
FGFR3 mutant receptor activation	11	6.27e-01	6.89e-01	0.15200	-4.00e-02	1.47e-01	8.18e-01	3.98e-01
Signaling by activated point mutants of FGFR3	11	6.27e-01	6.89e-01	0.15200	-4.00e-02	1.47e-01	8.18e-01	3.98e-01
Downstream signaling of activated FGFR3	24	3.23e-01	4.09e-01	0.15200	-1.08e-01	1.08e-01	3.61e-01	3.61e-01
CLEC7A (Dectin-1) signaling	96	5.25e-02	1.06e-01	0.15200	5.21e-02	1.43e-01	3.77e-01	1.58e-02
TP53 Regulates Transcription of DNA Repair Genes	57	2.12e-01	3.00e-01	0.15100	9.93e-02	1.14e-01	1.94e-01	1.36e-01
PCNA-Dependent Long Patch Base Excision Repair	21	3.81e-01	4.68e-01	0.15100	-1.20e-01	9.17e-02	3.42e-01	4.67e-01
Signaling by ERBB4	57	1.82e-01	2.68e-01	0.15100	-1.40e-01	-5.64e-02	6.77e-02	4.61e-01
Nervous system development	527	6.36e-07	7.80e-06	0.15000	-1.27e-01	-8.05e-02	6.34e-07	1.53e-03
Synthesis, secretion, and inactivation of Glucagon-like Peptide-1 (GLP-1)	20	4.12e-01	4.96e-01	0.15000	-1.29e-01	7.64e-02	3.19e-01	5.54e-01
ROS and RNS production in phagocytes	35	2.32e-01	3.21e-01	0.14900	-1.41e-01	4.88e-02	1.48e-01	6.17e-01
Cholesterol biosynthesis	24	4.23e-01	5.05e-01	0.14900	-1.52e-04	1.49e-01	9.99e-01	2.05e-01
Acyl chain remodelling of PG	18	5.81e-01	6.50e-01	0.14900	-4.72e-02	-1.41e-01	7.29e-01	2.99e-01
Formation of TC-NER Pre-Incision Complex	51	2.61e-01	3.52e-01	0.14900	1.07e-01	1.03e-01	1.85e-01	2.01e-01
FRS-mediated FGFR2 signaling	24	3.46e-01	4.30e-01	0.14900	-8.21e-02	1.24e-01	4.86e-01	2.92e-01
ER to Golgi Anterograde Transport	134	6.36e-03	2.05e-02	0.14800	-1.47e-01	2.00e-02	3.28e-03	6.89e-01
Signaling by ERBB2 in Cancer	25	4.67e-01	5.46e-01	0.14800	-1.43e-01	-4.03e-02	2.17e-01	7.27e-01
ISG15 antiviral mechanism	71	9.55e-02	1.66e-01	0.14800	1.72e-02	1.47e-01	8.02e-01	3.21e-02
Regulation of NF-kappa B signaling	17	6.38e-01	6.99e-01	0.14800	1.20e-01	8.57e-02	3.90e-01	5.41e-01
Separation of Sister Chromatids	161	1.19e-02	3.40e-02	0.14800	6.67e-02	1.32e-01	1.44e-01	3.89e-03
Interleukin-15 signaling	13	6.12e-01	6.77e-01	0.14700	-1.46e-01	2.25e-02	3.63e-01	8.88e-01
DNA Damage Bypass	46	1.62e-01	2.46e-01	0.14700	-3.86e-02	1.42e-01	6.50e-01	9.49e-02
Unfolded Protein Response (UPR)	90	5.82e-02	1.14e-01	0.14700	2.65e-02	1.45e-01	6.63e-01	1.75e-02
Antiviral mechanism by IFN-stimulated genes	78	9.71e-02	1.68e-01	0.14700	3.92e-02	1.41e-01	5.50e-01	3.08e-02
Loss of Nlp from mitotic centrosomes	65	9.67e-02	1.68e-01	0.14700	-1.46e-01	1.16e-02	4.15e-02	8.72e-01
Loss of proteins required for interphase microtubule organization from the centrosome	65	9.67e-02	1.68e-01	0.14700	-1.46e-01	1.16e-02	4.15e-02	8.72e-01
Processive synthesis on the lagging strand	14	5.73e-01	6.43e-01	0.14700	-1.40e-01	4.45e-02	3.66e-01	7.73e-01
Estrogen-dependent gene expression	91	3.39e-02	7.73e-02	0.14600	-1.44e-01	2.33e-02	1.72e-02	7.00e-01
Fanconi Anemia Pathway	36	3.36e-01	4.21e-01	0.14600	3.25e-02	1.42e-01	7.36e-01	1.40e-01
Activated NOTCH1 Transmits Signal to the Nucleus	30	4.50e-01	5.32e-01	0.14600	-7.00e-02	-1.28e-01	5.07e-01	2.26e-01
FRS-mediated FGFR4 signaling	21	4.22e-01	5.05e-01	0.14600	-6.30e-02	1.31e-01	6.17e-01	2.98e-01
Regulation of FZD by ubiquitination	21	4.08e-01	4.94e-01	0.14500	-1.16e-01	8.83e-02	3.59e-01	4.83e-01
Chylomicron assembly	10	7.70e-01	8.16e-01	0.14500	-7.46e-02	-1.25e-01	6.83e-01	4.95e-01
Interleukin-2 signaling	11	6.44e-01	7.04e-01	0.14500	5.32e-02	-1.35e-01	7.60e-01	4.38e-01
Transcriptional regulation of white adipocyte differentiation	81	3.23e-02	7.54e-02	0.14500	-8.86e-02	1.15e-01	1.68e-01	7.38e-02
Regulation of IFNG signaling	14	5.80e-01	6.49e-01	0.14500	-1.39e-01	4.28e-02	3.69e-01	7.81e-01
Plasma lipoprotein clearance	37	2.76e-01	3.67e-01	0.14500	-1.45e-01	7.85e-03	1.27e-01	9.34e-01
MHC class II antigen presentation	104	4.43e-02	9.48e-02	0.14400	-1.41e-01	-2.91e-02	1.27e-02	6.08e-01
Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways	49	1.27e-01	2.03e-01	0.14400	-1.05e-01	9.89e-02	2.04e-01	2.31e-01
Beta-oxidation of very long chain fatty acids	10	6.57e-01	7.17e-01	0.14400	-1.11e-01	9.13e-02	5.42e-01	6.17e-01
Axon guidance	503	3.02e-06	3.04e-05	0.14400	-1.25e-01	-7.18e-02	1.63e-06	5.75e-03
Regulation of actin dynamics for phagocytic cup formation	59	1.32e-01	2.10e-01	0.14400	-1.43e-01	9.14e-03	5.67e-02	9.03e-01
Activation of PPARGC1A (PGC-1alpha) by phosphorylation	10	6.65e-01	7.24e-01	0.14300	-1.23e-01	7.33e-02	5.00e-01	6.88e-01
Asparagine N-linked glycosylation	278	1.42e-05	1.07e-04	0.14300	-1.25e-01	7.08e-02	3.42e-04	4.19e-02
Phosphorylation of CD3 and TCR zeta chains	20	4.34e-01	5.17e-01	0.14300	1.06e-01	-9.62e-02	4.11e-01	4.56e-01
Reproduction	82	1.33e-01	2.10e-01	0.14300	-8.62e-02	-1.14e-01	1.77e-01	7.32e-02
Cargo recognition for clathrin-mediated endocytosis	98	3.81e-02	8.43e-02	0.14300	-1.43e-01	4.06e-03	1.44e-02	9.45e-01
Viral Messenger RNA Synthesis	42	3.17e-01	4.05e-01	0.14300	4.95e-02	1.34e-01	5.79e-01	1.32e-01
Azathioprine ADME	22	4.28e-01	5.11e-01	0.14300	-1.34e-01	4.96e-02	2.76e-01	6.87e-01
Transferrin endocytosis and recycling	30	3.09e-01	3.98e-01	0.14300	-1.31e-01	5.68e-02	2.13e-01	5.90e-01
TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain	21	5.92e-01	6.61e-01	0.14300	-1.19e-01	-7.92e-02	3.45e-01	5.30e-01
Downregulation of TGF-beta receptor signaling	26	5.05e-01	5.81e-01	0.14300	-1.30e-01	-5.94e-02	2.52e-01	6.00e-01
Diseases of carbohydrate metabolism	30	4.59e-01	5.41e-01	0.14200	-1.29e-01	-5.91e-02	2.21e-01	5.75e-01
Metabolism of vitamins and cofactors	181	8.53e-03	2.62e-02	0.14200	-1.32e-01	-5.26e-02	2.24e-03	2.22e-01
FGFR3 ligand binding and activation	12	6.14e-01	6.78e-01	0.14200	-9.00e-02	1.09e-01	5.89e-01	5.11e-01
FGFR3c ligand binding and activation	12	6.14e-01	6.78e-01	0.14200	-9.00e-02	1.09e-01	5.89e-01	5.11e-01
Aflatoxin activation and detoxification	19	5.81e-01	6.50e-01	0.14100	-2.78e-02	-1.38e-01	8.34e-01	2.98e-01
DNA strand elongation	31	2.97e-01	3.87e-01	0.14000	-7.83e-02	1.16e-01	4.50e-01	2.64e-01
Response of EIF2AK1 (HRI) to heme deficiency	14	6.96e-01	7.52e-01	0.14000	5.06e-02	1.30e-01	7.43e-01	3.99e-01
Regulation of HSF1-mediated heat shock response	78	1.04e-01	1.76e-01	0.13900	1.87e-02	1.38e-01	7.75e-01	3.47e-02
Ribavirin ADME	11	7.02e-01	7.58e-01	0.13900	-1.39e-01	9.12e-03	4.26e-01	9.58e-01
RNA Polymerase I Promoter Escape	28	5.17e-01	5.92e-01	0.13900	7.69e-02	1.16e-01	4.81e-01	2.89e-01
Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants	19	6.30e-01	6.91e-01	0.13900	6.29e-02	1.23e-01	6.35e-01	3.52e-01
Signaling by Ligand-Responsive EGFR Variants in Cancer	19	6.30e-01	6.91e-01	0.13900	6.29e-02	1.23e-01	6.35e-01	3.52e-01
Regulation of TP53 Activity through Phosphorylation	88	8.58e-02	1.53e-01	0.13800	2.52e-02	1.36e-01	6.83e-01	2.72e-02
ATF6 (ATF6-alpha) activates chaperones	11	7.63e-01	8.10e-01	0.13800	5.88e-02	1.25e-01	7.36e-01	4.72e-01
Cellular responses to stimuli	696	3.94e-10	1.05e-08	0.13800	-1.02e-02	1.38e-01	6.46e-01	5.15e-10
COPI-mediated anterograde transport	83	1.14e-01	1.88e-01	0.13800	-1.32e-01	-4.03e-02	3.74e-02	5.26e-01
Cellular responses to stress	682	5.80e-10	1.47e-08	0.13800	-1.17e-02	1.37e-01	6.02e-01	8.45e-10
Acetylcholine binding and downstream events	14	6.86e-01	7.43e-01	0.13700	3.05e-02	1.34e-01	8.43e-01	3.85e-01
Postsynaptic nicotinic acetylcholine receptors	14	6.86e-01	7.43e-01	0.13700	3.05e-02	1.34e-01	8.43e-01	3.85e-01
Transcriptional regulation by RUNX1	183	2.42e-03	9.08e-03	0.13700	-1.35e-01	2.43e-02	1.60e-03	5.71e-01
Transcriptional activation of mitochondrial biogenesis	51	1.47e-01	2.28e-01	0.13700	-1.14e-01	7.62e-02	1.58e-01	3.47e-01
Nef-mediates down modulation of cell surface receptors by recruiting them to clathrin adapters	20	6.06e-01	6.72e-01	0.13700	-1.28e-01	-4.82e-02	3.20e-01	7.09e-01
Cilium Assembly	174	1.58e-02	4.28e-02	0.13700	-1.23e-01	-5.89e-02	4.94e-03	1.80e-01
Cell Cycle, Mitotic	476	6.72e-08	1.04e-06	0.13600	-5.41e-02	1.24e-01	4.27e-02	3.20e-06
Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation	10	6.94e-01	7.51e-01	0.13600	-7.03e-02	1.16e-01	7.00e-01	5.26e-01
Organelle biogenesis and maintenance	243	1.16e-03	4.86e-03	0.13600	-1.35e-01	-1.33e-02	2.90e-04	7.21e-01
Telomere C-strand (Lagging Strand) Synthesis	32	3.19e-01	4.05e-01	0.13500	-1.19e-01	6.31e-02	2.42e-01	5.37e-01
BBSome-mediated cargo-targeting to cilium	23	6.04e-01	6.71e-01	0.13500	7.83e-02	1.09e-01	5.16e-01	3.64e-01
Constitutive Signaling by EGFRvIII	15	6.51e-01	7.11e-01	0.13400	-1.34e-01	-2.70e-03	3.69e-01	9.86e-01
Signaling by EGFRvIII in Cancer	15	6.51e-01	7.11e-01	0.13400	-1.34e-01	-2.70e-03	3.69e-01	9.86e-01
RA biosynthesis pathway	22	4.70e-01	5.48e-01	0.13400	-5.47e-02	1.22e-01	6.57e-01	3.22e-01
Ovarian tumor domain proteases	36	2.76e-01	3.67e-01	0.13300	-9.53e-02	9.25e-02	3.22e-01	3.37e-01
RNA Polymerase I Transcription Termination	27	5.46e-01	6.20e-01	0.13300	5.82e-02	1.19e-01	6.01e-01	2.84e-01
Nucleotide catabolism	35	4.61e-01	5.41e-01	0.13300	-1.17e-01	-6.20e-02	2.30e-01	5.25e-01
Interleukin-12 family signaling	53	1.73e-01	2.59e-01	0.13300	-4.70e-02	1.24e-01	5.54e-01	1.19e-01
SLC transporter disorders	92	1.23e-01	1.99e-01	0.13200	-1.21e-01	-5.32e-02	4.42e-02	3.78e-01
Interleukin-1 signaling	109	8.20e-02	1.49e-01	0.13200	4.93e-02	1.23e-01	3.74e-01	2.69e-02
Mitotic Prometaphase	174	4.05e-03	1.39e-02	0.13200	-1.27e-01	3.50e-02	3.72e-03	4.26e-01
Purine salvage	12	6.60e-01	7.19e-01	0.13200	-7.22e-02	1.10e-01	6.65e-01	5.09e-01
Disease	1567	6.23e-21	1.38e-18	0.13100	-1.27e-01	3.48e-02	3.52e-17	2.07e-02
Post-translational protein modification	1289	3.49e-16	2.57e-14	0.13100	-1.31e-01	1.09e-02	1.97e-15	5.10e-01
Regulation of IFNA/IFNB signaling	22	4.94e-01	5.71e-01	0.13000	1.22e-01	-4.51e-02	3.20e-01	7.14e-01
HIV Transcription Initiation	43	4.05e-01	4.91e-01	0.13000	1.12e-01	6.62e-02	2.03e-01	4.53e-01
RNA Polymerase II HIV Promoter Escape	43	4.05e-01	4.91e-01	0.13000	1.12e-01	6.62e-02	2.03e-01	4.53e-01
RNA Polymerase II Promoter Escape	43	4.05e-01	4.91e-01	0.13000	1.12e-01	6.62e-02	2.03e-01	4.53e-01
RNA Polymerase II Transcription Initiation	43	4.05e-01	4.91e-01	0.13000	1.12e-01	6.62e-02	2.03e-01	4.53e-01
RNA Polymerase II Transcription Initiation And Promoter Clearance	43	4.05e-01	4.91e-01	0.13000	1.12e-01	6.62e-02	2.03e-01	4.53e-01
RNA Polymerase II Transcription Pre-Initiation And Promoter Opening	43	4.05e-01	4.91e-01	0.13000	1.12e-01	6.62e-02	2.03e-01	4.53e-01
Negative regulation of FLT3	15	7.04e-01	7.60e-01	0.13000	3.42e-02	1.25e-01	8.19e-01	4.02e-01
Regulation of TP53 Expression and Degradation	37	3.69e-01	4.56e-01	0.12900	-1.29e-01	-1.79e-05	1.73e-01	1.00e+00
NOTCH3 Activation and Transmission of Signal to the Nucleus	25	4.74e-01	5.51e-01	0.12900	1.26e-01	-2.76e-02	2.74e-01	8.11e-01
Metal ion SLC transporters	25	4.38e-01	5.21e-01	0.12900	-1.10e-01	6.73e-02	3.41e-01	5.60e-01
Phospholipase C-mediated cascade; FGFR3	12	6.94e-01	7.51e-01	0.12800	-3.79e-02	1.23e-01	8.20e-01	4.62e-01
M Phase	335	4.52e-05	3.01e-04	0.12800	-3.68e-02	1.23e-01	2.46e-01	1.11e-04
FLT3 Signaling	38	3.46e-01	4.30e-01	0.12800	-1.27e-01	1.51e-02	1.75e-01	8.72e-01
SARS-CoV-2-host interactions	183	2.13e-02	5.43e-02	0.12800	5.09e-02	1.17e-01	2.35e-01	6.31e-03
Signaling by CSF3 (G-CSF)	28	5.17e-01	5.92e-01	0.12700	2.19e-02	1.25e-01	8.41e-01	2.52e-01
TNFR1-induced NFkappaB signaling pathway	22	5.65e-01	6.37e-01	0.12700	-1.14e-03	1.27e-01	9.93e-01	3.03e-01
Cytosolic sensors of pathogen-associated DNA	60	3.18e-01	4.05e-01	0.12600	7.89e-02	9.88e-02	2.90e-01	1.86e-01
Dual Incision in GG-NER	39	2.85e-01	3.75e-01	0.12600	-7.89e-02	9.87e-02	3.94e-01	2.86e-01
Inflammasomes	21	5.47e-01	6.21e-01	0.12600	-3.02e-02	1.22e-01	8.10e-01	3.31e-01
Gene expression (Transcription)	1420	1.60e-19	2.47e-17	0.12600	-8.03e-02	9.72e-02	3.49e-07	6.78e-10
Antigen Presentation: Folding, assembly and peptide loading of class I MHC	29	5.76e-01	6.46e-01	0.12600	-7.96e-02	-9.78e-02	4.58e-01	3.62e-01
Gene Silencing by RNA	80	8.45e-02	1.52e-01	0.12600	-1.12e-01	5.74e-02	8.29e-02	3.75e-01
TCR signaling	112	8.56e-02	1.53e-01	0.12600	1.21e-01	3.32e-02	2.66e-02	5.44e-01
Glycogen metabolism	22	5.61e-01	6.34e-01	0.12500	-1.25e-01	8.76e-03	3.10e-01	9.43e-01
TNFs bind their physiological receptors	25	5.43e-01	6.18e-01	0.12500	1.25e-01	7.76e-03	2.79e-01	9.46e-01
HDR through Homologous Recombination (HRR) or Single Strand Annealing (SSA)	93	5.47e-02	1.09e-01	0.12500	-7.13e-02	1.03e-01	2.34e-01	8.70e-02
Cell Cycle	601	1.99e-08	3.54e-07	0.12500	-5.52e-02	1.12e-01	2.06e-02	2.79e-06
HATs acetylate histones	71	1.19e-01	1.93e-01	0.12400	-1.08e-01	5.98e-02	1.15e-01	3.83e-01
Formation of the Early Elongation Complex	32	5.44e-01	6.18e-01	0.12300	6.01e-02	1.08e-01	5.56e-01	2.91e-01
Formation of the HIV-1 Early Elongation Complex	32	5.44e-01	6.18e-01	0.12300	6.01e-02	1.08e-01	5.56e-01	2.91e-01
PECAM1 interactions	12	8.06e-01	8.47e-01	0.12300	-9.33e-02	-7.97e-02	5.76e-01	6.33e-01
Homology Directed Repair	99	5.22e-02	1.06e-01	0.12300	-6.60e-02	1.03e-01	2.56e-01	7.57e-02
Nicotinamide salvaging	17	6.17e-01	6.81e-01	0.12300	4.44e-02	-1.14e-01	7.51e-01	4.15e-01
The canonical retinoid cycle in rods (twilight vision)	23	6.53e-01	7.13e-01	0.12300	-1.05e-01	-6.38e-02	3.85e-01	5.96e-01
Lagging Strand Synthesis	19	6.20e-01	6.84e-01	0.12200	-1.21e-01	1.21e-02	3.60e-01	9.27e-01
DDX58/IFIH1-mediated induction of interferon-alpha/beta	75	1.60e-01	2.44e-01	0.12100	-7.24e-03	1.21e-01	9.14e-01	6.93e-02
Peroxisomal protein import	62	3.06e-01	3.95e-01	0.12100	4.93e-02	1.11e-01	5.02e-01	1.31e-01
AURKA Activation by TPX2	68	1.61e-01	2.44e-01	0.12100	-1.16e-01	3.41e-02	9.74e-02	6.27e-01
Chaperone Mediated Autophagy	19	6.41e-01	7.02e-01	0.12100	1.21e-01	1.37e-03	3.62e-01	9.92e-01
Other interleukin signaling	24	4.94e-01	5.71e-01	0.12100	-9.68e-02	7.22e-02	4.12e-01	5.40e-01
Cytochrome P450 - arranged by substrate type	64	3.03e-01	3.92e-01	0.12000	-4.92e-02	-1.10e-01	4.96e-01	1.29e-01
PIWI-interacting RNA (piRNA) biogenesis	29	5.79e-01	6.49e-01	0.12000	-4.73e-02	-1.10e-01	6.59e-01	3.03e-01
Global Genome Nucleotide Excision Repair (GG-NER)	81	1.31e-01	2.09e-01	0.12000	-2.05e-02	1.18e-01	7.50e-01	6.63e-02
Negative regulators of DDX58/IFIH1 signaling	34	3.96e-01	4.84e-01	0.11800	-5.19e-02	1.06e-01	6.01e-01	2.83e-01
Complement cascade	56	2.62e-01	3.53e-01	0.11800	1.43e-02	-1.17e-01	8.53e-01	1.28e-01
Cyclin A/B1/B2 associated events during G2/M transition	24	5.09e-01	5.85e-01	0.11800	-7.13e-02	9.42e-02	5.45e-01	4.24e-01
Ub-specific processing proteases	153	5.26e-02	1.06e-01	0.11800	3.24e-02	1.14e-01	4.89e-01	1.52e-02
RNA Pol II CTD phosphorylation and interaction with CE	26	5.68e-01	6.39e-01	0.11800	1.18e-01	5.93e-03	2.99e-01	9.58e-01
RNA Pol II CTD phosphorylation and interaction with CE during HIV infection	26	5.68e-01	6.39e-01	0.11800	1.18e-01	5.93e-03	2.99e-01	9.58e-01
Mitochondrial calcium ion transport	22	6.75e-01	7.34e-01	0.11800	-1.07e-01	-4.96e-02	3.86e-01	6.87e-01
SARS-CoV Infections	387	2.43e-05	1.71e-04	0.11800	-7.07e-02	9.39e-02	1.68e-02	1.49e-03
Polymerase switching on the C-strand of the telomere	24	5.52e-01	6.26e-01	0.11700	-2.94e-02	1.13e-01	8.03e-01	3.38e-01
RNA Polymerase II Transcription	1284	2.90e-15	1.87e-13	0.11700	-6.95e-02	9.37e-02	2.62e-05	1.45e-08
Regulation of Complement cascade	45	3.34e-01	4.19e-01	0.11600	2.94e-02	-1.12e-01	7.33e-01	1.93e-01
Fatty acid metabolism	167	1.80e-02	4.73e-02	0.11600	-1.13e-01	2.72e-02	1.20e-02	5.44e-01
Regulation of PLK1 Activity at G2/M Transition	83	1.24e-01	2.00e-01	0.11600	-1.08e-01	4.07e-02	8.84e-02	5.22e-01
Downstream signaling of activated FGFR2	29	4.63e-01	5.42e-01	0.11500	-9.61e-02	6.38e-02	3.71e-01	5.52e-01
Signaling by FGFR2	72	2.65e-01	3.56e-01	0.11500	3.14e-02	1.11e-01	6.45e-01	1.03e-01
Pyroptosis	26	4.96e-01	5.71e-01	0.11500	-7.87e-02	8.43e-02	4.87e-01	4.57e-01
Carboxyterminal post-translational modifications of tubulin	40	4.64e-01	5.43e-01	0.11500	-2.26e-02	-1.13e-01	8.05e-01	2.16e-01
Generic Transcription Pathway	1163	1.01e-13	5.79e-12	0.11500	-7.64e-02	8.62e-02	1.03e-05	6.57e-07
Advanced glycosylation endproduct receptor signaling	13	7.29e-01	7.80e-01	0.11500	-3.34e-02	1.10e-01	8.35e-01	4.93e-01
Nonhomologous End-Joining (NHEJ)	32	4.26e-01	5.08e-01	0.11500	-8.85e-02	7.32e-02	3.86e-01	4.74e-01
Cellular response to heat stress	95	1.29e-01	2.05e-01	0.11400	-7.23e-03	1.14e-01	9.03e-01	5.50e-02
Cargo trafficking to the periciliary membrane	49	4.68e-01	5.47e-01	0.11400	-8.87e-02	-7.12e-02	2.83e-01	3.88e-01
Developmental Biology	1027	1.05e-07	1.55e-06	0.11400	-1.01e-01	-5.28e-02	4.49e-08	4.10e-03
Antigen processing: Ubiquitination & Proteasome degradation	293	6.72e-04	3.00e-03	0.11400	-1.01e-01	5.23e-02	2.97e-03	1.23e-01
Negative regulation of activity of TFAP2 (AP-2) family transcription factors	10	8.48e-01	8.84e-01	0.11300	4.85e-02	1.03e-01	7.90e-01	5.74e-01
FGFR2 ligand binding and activation	19	7.33e-01	7.84e-01	0.11300	1.02e-01	4.99e-02	4.44e-01	7.06e-01
Intrinsic Pathway for Apoptosis	52	4.44e-01	5.27e-01	0.11300	-9.62e-02	-5.86e-02	2.30e-01	4.65e-01
Late endosomal microautophagy	32	4.44e-01	5.27e-01	0.11200	-6.67e-02	9.03e-02	5.14e-01	3.76e-01
Signaling by FGFR1	49	3.29e-01	4.15e-01	0.11200	-2.60e-02	1.09e-01	7.53e-01	1.86e-01
Mitotic G2-G2/M phases	177	3.37e-02	7.70e-02	0.11100	7.68e-03	1.11e-01	8.60e-01	1.07e-02
Neddylation	228	9.87e-03	2.94e-02	0.11100	-5.63e-03	1.11e-01	8.83e-01	3.84e-03
Metabolism of amino acids and derivatives	344	6.99e-03	2.23e-02	0.11100	7.29e-02	8.33e-02	1.99e-02	7.84e-03
Activation of the AP-1 family of transcription factors	10	7.99e-01	8.41e-01	0.11100	-1.06e-01	3.04e-02	5.60e-01	8.68e-01
RHO GTPases Activate Formins	114	9.14e-02	1.61e-01	0.11100	-1.10e-01	1.46e-02	4.29e-02	7.88e-01
Signaling by NOTCH	182	1.29e-02	3.63e-02	0.11100	-9.69e-02	5.33e-02	2.40e-02	2.14e-01
Metabolism	1963	4.34e-17	3.94e-15	0.11000	-1.09e-01	1.33e-02	7.37e-16	3.26e-01
Cellular hexose transport	21	5.98e-01	6.65e-01	0.11000	8.32e-02	-7.18e-02	5.09e-01	5.69e-01
EML4 and NUDC in mitotic spindle formation	93	1.45e-01	2.25e-01	0.11000	-1.09e-01	1.59e-02	7.01e-02	7.90e-01
G2/M Transition	175	4.05e-02	8.83e-02	0.10900	9.06e-03	1.09e-01	8.36e-01	1.28e-02
TP53 Regulates Transcription of Death Receptors and Ligands	12	7.47e-01	7.96e-01	0.10900	-8.18e-02	7.27e-02	6.24e-01	6.63e-01
DNA Repair	276	1.80e-03	7.00e-03	0.10900	-4.66e-02	9.89e-02	1.82e-01	4.65e-03
MAPK family signaling cascades	311	6.32e-03	2.04e-02	0.10900	-1.05e-01	-2.95e-02	1.46e-03	3.71e-01
Regulation of beta-cell development	41	3.94e-01	4.82e-01	0.10800	-9.80e-02	4.64e-02	2.78e-01	6.07e-01
HDR through Single Strand Annealing (SSA)	36	4.61e-01	5.41e-01	0.10800	-3.01e-02	1.04e-01	7.55e-01	2.80e-01
RIP-mediated NFkB activation via ZBP1	16	6.96e-01	7.52e-01	0.10800	-4.81e-02	9.66e-02	7.39e-01	5.03e-01
Signaling by FGFR in disease	61	3.22e-01	4.08e-01	0.10800	-1.08e-01	-7.81e-04	1.45e-01	9.92e-01
Intraflagellar transport	36	6.03e-01	6.70e-01	0.10700	-6.06e-02	-8.88e-02	5.29e-01	3.56e-01
Peroxisomal lipid metabolism	28	5.33e-01	6.08e-01	0.10700	-4.80e-02	9.61e-02	6.60e-01	3.78e-01
Transcriptional regulation by RUNX3	93	2.78e-01	3.68e-01	0.10600	5.89e-02	8.87e-02	3.26e-01	1.39e-01
Gap-filling DNA repair synthesis and ligation in GG-NER	25	5.85e-01	6.53e-01	0.10600	-4.12e-02	9.76e-02	7.22e-01	3.98e-01
Sulfur amino acid metabolism	27	5.45e-01	6.20e-01	0.10600	-8.74e-02	5.99e-02	4.32e-01	5.90e-01
Constitutive Signaling by NOTCH1 HD Domain Mutants	15	7.28e-01	7.80e-01	0.10600	9.91e-02	-3.75e-02	5.06e-01	8.01e-01
Signaling by NOTCH1 HD Domain Mutants in Cancer	15	7.28e-01	7.80e-01	0.10600	9.91e-02	-3.75e-02	5.06e-01	8.01e-01
Phase I - Functionalization of compounds	100	1.65e-01	2.50e-01	0.10600	1.09e-03	-1.06e-01	9.85e-01	6.79e-02
Class I MHC mediated antigen processing & presentation	361	3.79e-04	1.80e-03	0.10500	-8.94e-02	5.59e-02	3.50e-03	6.76e-02
Resolution of Sister Chromatid Cohesion	98	1.26e-01	2.02e-01	0.10500	-9.71e-02	4.10e-02	9.67e-02	4.83e-01
Innate Immune System	999	4.16e-10	1.09e-08	0.10500	-6.79e-02	8.05e-02	2.69e-04	1.55e-05
Gamma carboxylation, hypusine formation and arylsulfatase activation	34	5.12e-01	5.87e-01	0.10500	-1.03e-01	2.16e-02	2.98e-01	8.27e-01
Termination of translesion DNA synthesis	31	5.13e-01	5.88e-01	0.10500	-5.10e-02	9.14e-02	6.23e-01	3.79e-01
Diseases of DNA repair	49	3.77e-01	4.65e-01	0.10400	-3.08e-02	9.91e-02	7.09e-01	2.30e-01
Interferon gamma signaling	89	2.13e-01	3.02e-01	0.10400	-1.04e-01	8.27e-04	9.06e-02	9.89e-01
ABC-family proteins mediated transport	98	2.85e-01	3.75e-01	0.10300	8.19e-02	6.31e-02	1.61e-01	2.80e-01
Retrograde transport at the Trans-Golgi-Network	47	4.54e-01	5.36e-01	0.10300	-1.03e-01	-4.15e-03	2.21e-01	9.61e-01
Downstream signaling of activated FGFR4	26	5.72e-01	6.42e-01	0.10300	-8.22e-02	6.25e-02	4.68e-01	5.81e-01
Extension of Telomeres	48	3.71e-01	4.58e-01	0.10300	-9.16e-02	4.70e-02	2.72e-01	5.73e-01
VLDLR internalisation and degradation	16	7.51e-01	7.99e-01	0.10300	-1.14e-02	1.02e-01	9.37e-01	4.80e-01
Post-chaperonin tubulin folding pathway	23	7.50e-01	7.98e-01	0.10200	6.30e-02	8.04e-02	6.01e-01	5.04e-01
Zinc transporters	17	7.97e-01	8.41e-01	0.10100	3.93e-02	9.32e-02	7.79e-01	5.06e-01
Translesion synthesis by POLK	17	7.17e-01	7.71e-01	0.10000	-4.57e-02	8.92e-02	7.44e-01	5.24e-01
Glycolysis	68	2.60e-01	3.52e-01	0.10000	-5.19e-02	8.55e-02	4.59e-01	2.23e-01
Protein folding	96	1.59e-01	2.43e-01	0.09880	-8.64e-02	4.79e-02	1.43e-01	4.18e-01
Chromosome Maintenance	86	2.58e-01	3.49e-01	0.09870	-1.30e-03	9.87e-02	9.83e-01	1.14e-01
Removal of the Flap Intermediate	13	8.21e-01	8.61e-01	0.09850	-9.83e-02	-5.84e-03	5.39e-01	9.71e-01
Infectious disease	830	1.56e-07	2.24e-06	0.09820	-6.17e-02	7.63e-02	2.45e-03	1.78e-04
DAP12 interactions	40	4.85e-01	5.62e-01	0.09750	-9.03e-02	3.66e-02	3.23e-01	6.88e-01
Recognition of DNA damage by PCNA-containing replication complex	29	6.54e-01	7.14e-01	0.09710	6.47e-03	9.69e-02	9.52e-01	3.67e-01
PI-3K cascade:FGFR3	17	7.54e-01	8.01e-01	0.09650	-9.43e-02	2.06e-02	5.01e-01	8.83e-01
Synthesis of Leukotrienes (LT) and Eoxins (EX)	21	7.26e-01	7.79e-01	0.09610	9.60e-02	-4.87e-03	4.46e-01	9.69e-01
RAS processing	19	7.40e-01	7.90e-01	0.09600	-9.52e-02	1.23e-02	4.72e-01	9.26e-01
TAK1-dependent IKK and NF-kappa-B activation	41	4.86e-01	5.62e-01	0.09510	-4.29e-02	8.49e-02	6.34e-01	3.47e-01
Iron uptake and transport	57	4.12e-01	4.96e-01	0.09440	-1.57e-02	9.31e-02	8.37e-01	2.24e-01
NOTCH2 intracellular domain regulates transcription	11	8.27e-01	8.66e-01	0.09430	-4.23e-02	8.42e-02	8.08e-01	6.28e-01
CYP2E1 reactions	11	8.78e-01	9.10e-01	0.09420	-3.21e-02	-8.85e-02	8.54e-01	6.11e-01
RAF-independent MAPK1/3 activation	22	7.25e-01	7.79e-01	0.09410	-4.76e-03	9.40e-02	9.69e-01	4.45e-01
Amplification of signal from unattached kinetochores via a MAD2 inhibitory signal	89	2.40e-01	3.29e-01	0.09280	-8.79e-02	2.97e-02	1.52e-01	6.28e-01
Amplification of signal from the kinetochores	89	2.40e-01	3.29e-01	0.09280	-8.79e-02	2.97e-02	1.52e-01	6.28e-01
Transport of vitamins, nucleosides, and related molecules	38	6.23e-01	6.86e-01	0.09270	-9.09e-02	-1.78e-02	3.32e-01	8.50e-01
Inactivation of CSF3 (G-CSF) signaling	23	7.47e-01	7.96e-01	0.09260	9.14e-02	1.45e-02	4.48e-01	9.04e-01
NOTCH3 Intracellular Domain Regulates Transcription	24	7.62e-01	8.10e-01	0.09200	-8.63e-02	-3.18e-02	4.64e-01	7.88e-01
DNA Double-Strand Break Repair	129	1.18e-01	1.93e-01	0.09110	-7.54e-02	5.11e-02	1.39e-01	3.16e-01
Mitotic Spindle Checkpoint	106	1.73e-01	2.59e-01	0.09090	-5.40e-02	7.31e-02	3.36e-01	1.93e-01
GPCR ligand binding	443	1.31e-02	3.66e-02	0.09050	-7.43e-02	-5.17e-02	7.21e-03	6.18e-02
Synthesis of Prostaglandins (PG) and Thromboxanes (TX)	14	8.50e-01	8.85e-01	0.09050	2.08e-02	8.81e-02	8.93e-01	5.68e-01
Deadenylation-dependent mRNA decay	56	5.26e-01	6.00e-01	0.09050	-8.76e-02	-2.26e-02	2.57e-01	7.70e-01
Chaperonin-mediated protein folding	90	2.36e-01	3.25e-01	0.09000	-7.63e-02	4.77e-02	2.11e-01	4.34e-01
MAPK1/MAPK3 signaling	270	4.82e-02	9.95e-02	0.09000	-8.70e-02	-2.30e-02	1.38e-02	5.15e-01
Beta-catenin independent WNT signaling	144	1.72e-01	2.58e-01	0.08960	-8.92e-02	-8.63e-03	6.44e-02	8.58e-01
Gluconeogenesis	32	7.39e-01	7.90e-01	0.08910	-6.08e-02	-6.52e-02	5.52e-01	5.23e-01
SARS-CoV-2 activates/modulates innate and adaptive immune responses	110	2.42e-01	3.31e-01	0.08860	-3.87e-03	8.85e-02	9.44e-01	1.09e-01
RAF/MAP kinase cascade	264	5.39e-02	1.08e-01	0.08840	-8.63e-02	-1.95e-02	1.57e-02	5.86e-01
Regulated proteolysis of p75NTR	11	8.97e-01	9.20e-01	0.08830	-7.84e-02	-4.06e-02	6.53e-01	8.16e-01
TCF dependent signaling in response to WNT	168	8.09e-02	1.47e-01	0.08810	-7.96e-02	3.80e-02	7.51e-02	3.96e-01
Nucleotide Excision Repair	107	2.72e-01	3.63e-01	0.08800	3.44e-03	8.80e-02	9.51e-01	1.16e-01
Adaptive Immune System	709	1.90e-04	1.00e-03	0.08690	-8.68e-02	3.53e-03	7.81e-05	8.72e-01
Immune System	1870	1.01e-11	3.88e-10	0.08680	-7.87e-02	3.68e-02	1.38e-08	8.00e-03
Metabolism of proteins	1767	4.45e-11	1.50e-09	0.08680	-7.94e-02	3.49e-02	2.38e-08	1.41e-02
RHO GTPases Activate WASPs and WAVEs	34	7.16e-01	7.71e-01	0.08480	2.56e-02	8.09e-02	7.96e-01	4.14e-01
PI-3K cascade:FGFR2	22	8.00e-01	8.42e-01	0.08390	-8.20e-02	-1.74e-02	5.05e-01	8.88e-01
Meiotic recombination	26	7.98e-01	8.41e-01	0.08270	-3.68e-02	-7.40e-02	7.46e-01	5.13e-01
Deubiquitination	226	5.41e-02	1.08e-01	0.08230	-3.32e-02	7.53e-02	3.90e-01	5.09e-02
FOXO-mediated transcription	65	5.97e-01	6.64e-01	0.08190	-5.86e-02	-5.72e-02	4.14e-01	4.25e-01
Interleukin-1 family signaling	145	2.42e-01	3.30e-01	0.08090	1.02e-02	8.03e-02	8.32e-01	9.50e-02
Impaired BRCA2 binding to RAD51	33	7.40e-01	7.90e-01	0.08030	1.87e-02	7.81e-02	8.53e-01	4.38e-01
Programmed Cell Death	192	9.06e-02	1.60e-01	0.08020	-3.77e-02	7.07e-02	3.68e-01	9.07e-02
Signaling by Leptin	11	9.15e-01	9.32e-01	0.07950	-7.15e-02	-3.48e-02	6.81e-01	8.42e-01
RNA Polymerase III Transcription Termination	23	7.97e-01	8.41e-01	0.07910	-7.90e-02	-3.02e-03	5.12e-01	9.80e-01
NOTCH2 Activation and Transmission of Signal to the Nucleus	22	8.27e-01	8.66e-01	0.07790	7.59e-02	1.74e-02	5.38e-01	8.88e-01
Translesion synthesis by REV1	16	8.39e-01	8.77e-01	0.07770	-2.01e-02	7.51e-02	8.89e-01	6.03e-01
Interferon Signaling	191	2.06e-01	2.96e-01	0.07720	2.05e-02	7.45e-02	6.25e-01	7.57e-02
Peptide ligand-binding receptors	190	1.02e-01	1.75e-01	0.07720	5.82e-02	-5.07e-02	1.66e-01	2.28e-01
Transcription-Coupled Nucleotide Excision Repair (TC-NER)	76	4.69e-01	5.47e-01	0.07620	-9.92e-03	7.56e-02	8.81e-01	2.54e-01
SARS-CoV-2 Infection	276	4.69e-02	9.77e-02	0.07560	-3.53e-02	6.69e-02	3.12e-01	5.56e-02
HDR through Homologous Recombination (HRR)	64	4.96e-01	5.71e-01	0.07550	-3.09e-02	6.89e-02	6.69e-01	3.40e-01
RHOBTB2 GTPase cycle	22	8.47e-01	8.84e-01	0.07540	7.03e-02	2.71e-02	5.68e-01	8.26e-01
mRNA Capping	28	8.02e-01	8.43e-01	0.07530	7.26e-02	2.01e-02	5.06e-01	8.54e-01
Telomere Extension By Telomerase	22	7.90e-01	8.34e-01	0.07400	-3.48e-02	6.53e-02	7.78e-01	5.96e-01
Resolution of D-Loop Structures	31	7.80e-01	8.24e-01	0.07370	-7.27e-02	-1.18e-02	4.83e-01	9.09e-01
Synthesis, secretion, and deacylation of Ghrelin	19	8.87e-01	9.14e-01	0.07250	4.35e-02	5.80e-02	7.43e-01	6.61e-01
Signaling by NODAL	21	8.33e-01	8.72e-01	0.07180	6.31e-03	-7.16e-02	9.60e-01	5.70e-01
Regulation of gene expression in beta cells	21	8.82e-01	9.13e-01	0.07080	-4.42e-02	-5.53e-02	7.26e-01	6.61e-01
C-type lectin receptors (CLRs)	137	2.61e-01	3.52e-01	0.07000	-5.69e-02	4.08e-02	2.50e-01	4.09e-01
PI-3K cascade:FGFR4	19	8.93e-01	9.18e-01	0.06880	-6.09e-02	-3.19e-02	6.46e-01	8.10e-01
Activated point mutants of FGFR2	16	8.60e-01	8.94e-01	0.06840	-4.01e-02	5.54e-02	7.81e-01	7.01e-01
Glycogen storage diseases	14	9.19e-01	9.35e-01	0.06820	6.19e-02	2.86e-02	6.88e-01	8.53e-01
Defective HDR through Homologous Recombination (HRR) due to BRCA1 loss-of-function	23	8.85e-01	9.13e-01	0.06670	5.07e-02	4.34e-02	6.74e-01	7.18e-01
Defective HDR through Homologous Recombination (HRR) due to PALB2 loss of function	23	8.85e-01	9.13e-01	0.06670	5.07e-02	4.34e-02	6.74e-01	7.18e-01
Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA1 binding function	23	8.85e-01	9.13e-01	0.06670	5.07e-02	4.34e-02	6.74e-01	7.18e-01
Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA2/RAD51/RAD51C binding function	23	8.85e-01	9.13e-01	0.06670	5.07e-02	4.34e-02	6.74e-01	7.18e-01
Impaired BRCA2 binding to PALB2	23	8.85e-01	9.13e-01	0.06670	5.07e-02	4.34e-02	6.74e-01	7.18e-01
Translesion synthesis by POLI	17	9.11e-01	9.28e-01	0.06600	3.07e-02	5.84e-02	8.26e-01	6.77e-01
tRNA modification in the nucleus and cytosol	38	7.29e-01	7.80e-01	0.06590	-2.64e-02	6.04e-02	7.78e-01	5.20e-01
PI-3K cascade:FGFR1	21	8.97e-01	9.20e-01	0.06530	3.66e-02	5.41e-02	7.72e-01	6.68e-01
Fc epsilon receptor (FCERI) signaling	126	3.44e-01	4.29e-01	0.06490	-4.02e-02	5.09e-02	4.36e-01	3.23e-01
Highly calcium permeable postsynaptic nicotinic acetylcholine receptors	11	9.35e-01	9.48e-01	0.06490	6.35e-02	1.32e-02	7.15e-01	9.40e-01
Transcriptional regulation by RUNX2	116	4.06e-01	4.91e-01	0.06440	-2.21e-02	6.05e-02	6.81e-01	2.60e-01
FGFR2 alternative splicing	26	8.79e-01	9.11e-01	0.06430	4.93e-02	4.13e-02	6.63e-01	7.15e-01
Signaling by Interleukins	434	2.85e-02	6.84e-02	0.06420	-4.03e-02	5.00e-02	1.50e-01	7.37e-02
Glucose metabolism	87	4.94e-01	5.71e-01	0.06380	-5.31e-02	3.54e-02	3.92e-01	5.68e-01
Triglyceride biosynthesis	13	9.39e-01	9.49e-01	0.06250	-3.11e-02	-5.42e-02	8.46e-01	7.35e-01
Arachidonic acid metabolism	56	7.73e-01	8.18e-01	0.06170	5.00e-02	3.61e-02	5.17e-01	6.40e-01
LGI-ADAM interactions	14	9.04e-01	9.25e-01	0.06100	-2.73e-02	5.45e-02	8.59e-01	7.24e-01
FOXO-mediated transcription of cell death genes	15	9.03e-01	9.24e-01	0.06000	5.58e-02	-2.19e-02	7.08e-01	8.83e-01
Biological oxidations	213	3.19e-01	4.05e-01	0.05980	-6.75e-03	-5.94e-02	8.65e-01	1.35e-01
Association of TriC/CCT with target proteins during biosynthesis	38	7.68e-01	8.14e-01	0.05960	-5.27e-02	2.80e-02	5.74e-01	7.65e-01
SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription	36	7.75e-01	8.20e-01	0.05930	-4.75e-02	3.55e-02	6.22e-01	7.13e-01
Metabolism of Angiotensinogen to Angiotensins	15	9.05e-01	9.25e-01	0.05850	-5.23e-02	2.62e-02	7.26e-01	8.61e-01
Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks	41	7.67e-01	8.14e-01	0.05840	-2.12e-02	5.44e-02	8.14e-01	5.47e-01
Cytokine Signaling in Immune system	670	1.34e-02	3.73e-02	0.05830	-2.57e-02	5.23e-02	2.55e-01	2.06e-02
Phospholipase C-mediated cascade; FGFR2	17	8.90e-01	9.16e-01	0.05820	-3.86e-02	4.36e-02	7.83e-01	7.56e-01
Downstream signaling of activated FGFR1	31	8.29e-01	8.67e-01	0.05740	-1.65e-02	5.50e-02	8.73e-01	5.96e-01
Aggrephagy	23	9.00e-01	9.23e-01	0.05710	-5.52e-02	-1.47e-02	6.47e-01	9.03e-01
Formation of the cornified envelope	73	6.68e-01	7.27e-01	0.05620	5.53e-02	-9.68e-03	4.13e-01	8.86e-01
Leading Strand Synthesis	13	9.38e-01	9.49e-01	0.05580	1.02e-03	5.58e-02	9.95e-01	7.28e-01
Polymerase switching	13	9.38e-01	9.49e-01	0.05580	1.02e-03	5.58e-02	9.95e-01	7.28e-01
Signaling by NOTCH2	32	8.89e-01	9.16e-01	0.05560	3.96e-02	3.90e-02	6.98e-01	7.03e-01
HSF1-dependent transactivation	35	8.60e-01	8.94e-01	0.05510	1.24e-02	5.37e-02	8.99e-01	5.82e-01
CD28 dependent Vav1 pathway	11	9.35e-01	9.48e-01	0.05490	3.60e-02	-4.15e-02	8.36e-01	8.12e-01
Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA)	25	8.70e-01	9.04e-01	0.05490	-1.69e-02	5.22e-02	8.84e-01	6.51e-01
Signaling by NOTCH3	48	7.69e-01	8.15e-01	0.05350	2.06e-02	-4.94e-02	8.05e-01	5.54e-01
Prolactin receptor signaling	15	9.18e-01	9.34e-01	0.05300	-3.41e-02	4.06e-02	8.19e-01	7.86e-01
Hedgehog ‘off’ state	97	7.11e-01	7.66e-01	0.05110	4.83e-02	1.68e-02	4.11e-01	7.75e-01
FGFR4 ligand binding and activation	13	9.48e-01	9.57e-01	0.05080	3.86e-04	5.08e-02	9.98e-01	7.51e-01
FGFR2 mutant receptor activation	32	9.08e-01	9.27e-01	0.04960	4.15e-02	2.72e-02	6.84e-01	7.90e-01
Apoptosis	164	4.55e-01	5.37e-01	0.04920	-2.63e-02	4.16e-02	5.61e-01	3.57e-01
ZBP1(DAI) mediated induction of type I IFNs	20	9.37e-01	9.49e-01	0.04910	1.60e-02	4.64e-02	9.02e-01	7.19e-01
Defective homologous recombination repair (HRR) due to BRCA2 loss of function	39	8.95e-01	9.19e-01	0.04890	3.26e-02	3.65e-02	7.25e-01	6.93e-01
Diseases of DNA Double-Strand Break Repair	39	8.95e-01	9.19e-01	0.04890	3.26e-02	3.65e-02	7.25e-01	6.93e-01
Resolution of D-loop Structures through Holliday Junction Intermediates	30	9.06e-01	9.26e-01	0.04890	-4.68e-02	-1.41e-02	6.57e-01	8.94e-01
Citric acid cycle (TCA cycle)	21	9.10e-01	9.28e-01	0.04890	-1.70e-02	4.58e-02	8.93e-01	7.16e-01
Presynaptic phase of homologous DNA pairing and strand exchange	38	8.87e-01	9.14e-01	0.04820	1.52e-02	4.57e-02	8.71e-01	6.26e-01
Downregulation of ERBB2 signaling	28	9.18e-01	9.34e-01	0.04780	-4.51e-02	-1.60e-02	6.80e-01	8.84e-01
EGFR downregulation	30	8.78e-01	9.11e-01	0.04650	-3.85e-02	2.60e-02	7.15e-01	8.05e-01
Signaling by Hedgehog	133	5.60e-01	6.33e-01	0.04640	-3.29e-02	3.28e-02	5.12e-01	5.14e-01
DNA Double Strand Break Response	42	8.45e-01	8.82e-01	0.04640	-1.51e-02	4.38e-02	8.66e-01	6.23e-01
Signaling by Activin	15	9.53e-01	9.59e-01	0.04370	4.35e-02	-4.64e-03	7.71e-01	9.75e-01
Homologous DNA Pairing and Strand Exchange	41	9.10e-01	9.28e-01	0.04170	1.51e-02	3.89e-02	8.67e-01	6.66e-01
Signaling by the B Cell Receptor (BCR)	105	7.19e-01	7.73e-01	0.04110	-1.32e-02	3.89e-02	8.15e-01	4.91e-01
Nicotinate metabolism	29	9.31e-01	9.45e-01	0.04050	-4.02e-02	-4.87e-03	7.08e-01	9.64e-01
Gap-filling DNA repair synthesis and ligation in TC-NER	62	8.53e-01	8.88e-01	0.03990	-1.51e-05	3.99e-02	1.00e+00	5.86e-01
Vitamin B5 (pantothenate) metabolism	16	9.52e-01	9.59e-01	0.03910	-3.21e-02	2.24e-02	8.24e-01	8.77e-01
Pregnenolone biosynthesis	10	9.76e-01	9.78e-01	0.03910	1.56e-05	3.91e-02	1.00e+00	8.30e-01
RHOBTB1 GTPase cycle	22	9.58e-01	9.64e-01	0.03880	1.57e-02	3.55e-02	8.98e-01	7.73e-01
InlB-mediated entry of Listeria monocytogenes into host cell	14	9.64e-01	9.68e-01	0.03810	-9.13e-03	3.70e-02	9.53e-01	8.11e-01
Phospholipase C-mediated cascade; FGFR4	14	9.70e-01	9.73e-01	0.03690	-6.39e-04	3.69e-02	9.97e-01	8.11e-01
Signaling by FGFR	85	8.42e-01	8.80e-01	0.03560	5.19e-04	3.56e-02	9.93e-01	5.70e-01
Caspase activation via extrinsic apoptotic signalling pathway	25	9.60e-01	9.66e-01	0.03450	-1.09e-02	-3.27e-02	9.25e-01	7.77e-01
Telomere Maintenance	62	8.75e-01	9.08e-01	0.03440	-9.56e-03	3.30e-02	8.96e-01	6.53e-01
Interleukin-4 and Interleukin-13 signaling	104	8.14e-01	8.55e-01	0.03430	-3.42e-02	3.14e-03	5.47e-01	9.56e-01
Signaling by FGFR2 IIIa TM	19	9.62e-01	9.67e-01	0.03260	2.95e-02	-1.38e-02	8.24e-01	9.17e-01
Signaling by FGFR2 in disease	42	9.30e-01	9.44e-01	0.03250	-3.25e-02	1.27e-03	7.15e-01	9.89e-01
Class A/1 (Rhodopsin-like receptors)	311	6.82e-01	7.41e-01	0.03170	-1.63e-02	-2.72e-02	6.20e-01	4.10e-01
Disorders of transmembrane transporters	167	8.21e-01	8.61e-01	0.03140	1.92e-02	2.49e-02	6.68e-01	5.79e-01
RHOBTB GTPase Cycle	34	9.48e-01	9.57e-01	0.03080	3.07e-02	-2.29e-03	7.57e-01	9.82e-01
Dual incision in TC-NER	63	8.94e-01	9.19e-01	0.03070	-1.04e-02	2.89e-02	8.86e-01	6.92e-01
MicroRNA (miRNA) biogenesis	26	9.74e-01	9.77e-01	0.02870	-2.46e-02	-1.49e-02	8.28e-01	8.95e-01
MAP3K8 (TPL2)-dependent MAPK1/3 activation	15	9.83e-01	9.85e-01	0.02540	-6.22e-03	2.46e-02	9.67e-01	8.69e-01
Amyloid fiber formation	53	9.52e-01	9.59e-01	0.02260	5.44e-03	-2.20e-02	9.45e-01	7.82e-01
Phase II - Conjugation of compounds	106	9.49e-01	9.58e-01	0.01850	-3.75e-03	-1.81e-02	9.47e-01	7.48e-01
Glycogen synthesis	13	9.96e-01	9.97e-01	0.01290	4.65e-03	-1.20e-02	9.77e-01	9.40e-01
Dissolution of Fibrin Clot	13	9.97e-01	9.97e-01	0.01210	-1.35e-03	1.20e-02	9.93e-01	9.40e-01
HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand	37	9.95e-01	9.97e-01	0.00876	1.34e-04	8.76e-03	9.99e-01	9.27e-01

---

Detailed Gene set reports

Activation of RAC1

Activation of RAC1

metric	value
setSize	11
pMANOVA	1.62e-05
p.adjustMANOVA	0.00012
s.dist	0.87
s.bl	-0.811
s.gu	-0.315
p.bl	3.2e-06
p.gu	0.0705

Top 20 genes

Gene	bl	gu
ROBO1	-20137	-15748.5
NCK2	-19953	-15765.5
SLIT2	-20991	-13718.5
PAK1	-18763	-13669.5
NCK1	-14946	-16200.5
PAK4	-15859	-14968.5
PAK2	-19545	-8414.5
SOS2	-19782	-5326.5
SOS1	-18679	-4590.5

Click HERE to show all gene set members

All member genes

	bl	gu
NCK1	-14946	-16200.5
NCK2	-19953	-15765.5
PAK1	-18763	-13669.5
PAK2	-19545	-8414.5
PAK4	-15859	-14968.5
PAK6	-18306	3665.5
RAC1	-19826	5665.5
ROBO1	-20137	-15748.5
SLIT2	-20991	-13718.5
SOS1	-18679	-4590.5
SOS2	-19782	-5326.5

---

---

Regulation of commissural axon pathfinding by SLIT and ROBO

Regulation of commissural axon pathfinding by SLIT and ROBO

metric	value
setSize	10
pMANOVA	0.000401
p.adjustMANOVA	0.00187
s.dist	0.81
s.bl	-0.535
s.gu	-0.608
p.bl	0.00336
p.gu	0.000868

Top 20 genes

Gene	bl	gu
ROBO2	-20891	-16996.5
ROBO1	-20137	-15748.5
SLIT3	-17464	-17307.5
SLIT2	-20991	-13718.5
DCC	-15511	-14790.5
NELL2	-12038	-16611.5
SLIT1	-18144	-10187.5
ROBO3	-6667	-11514.5
NTN1	-1878	-13809.5

Click HERE to show all gene set members

All member genes

	bl	gu
DCC	-15511	-14790.5
NELL2	-12038	-16611.5
NTN1	-1878	-13809.5
ROBO1	-20137	-15748.5
ROBO2	-20891	-16996.5
ROBO3	-6667	-11514.5
SLIT1	-18144	-10187.5
SLIT2	-20991	-13718.5
SLIT3	-17464	-17307.5
SRC	-18883	2938.5

---

---

cGMP effects

cGMP effects

metric	value
setSize	15
pMANOVA	5.18e-06
p.adjustMANOVA	4.47e-05
s.dist	0.796
s.bl	-0.343
s.gu	-0.718
p.bl	0.0213
p.gu	1.48e-06

Top 20 genes

Gene	bl	gu
KCNMB2	-20581	-17588.5
PDE1A	-19290	-17620.5
PDE11A	-17065	-17733.5
PDE10A	-17778	-16980.5
KCNMB3	-16704	-16685.5
KCNMA1	-13573	-17709.5
PRKG1	-12589	-16324.5
PDE5A	-10324	-17619.5
PRKG2	-12552	-14002.5
ITPR1	-21072	-7262.5
PDE2A	-7628	-15109.5
KCNMB4	-5262	-13840.5
PDE1B	-12942	-2233.5
KCNMB1	-1721	-14130.5
PDE9A	-2793	-7893.5

Click HERE to show all gene set members

All member genes

	bl	gu
ITPR1	-21072	-7262.5
KCNMA1	-13573	-17709.5
KCNMB1	-1721	-14130.5
KCNMB2	-20581	-17588.5
KCNMB3	-16704	-16685.5
KCNMB4	-5262	-13840.5
PDE10A	-17778	-16980.5
PDE11A	-17065	-17733.5
PDE1A	-19290	-17620.5
PDE1B	-12942	-2233.5
PDE2A	-7628	-15109.5
PDE5A	-10324	-17619.5
PDE9A	-2793	-7893.5
PRKG1	-12589	-16324.5
PRKG2	-12552	-14002.5

---

---

MET activates PTK2 signaling

MET activates PTK2 signaling

metric	value
setSize	18
pMANOVA	9.31e-06
p.adjustMANOVA	7.46e-05
s.dist	0.729
s.bl	-0.594
s.gu	-0.422
p.bl	1.26e-05
p.gu	0.00195

Top 20 genes

Gene	bl	gu
PTK2	-20692	-17173.5
LAMA1	-19760	-16981.5
LAMA4	-20606	-16022.5
MET	-20342	-15646.5
LAMA2	-20701	-14273.5
LAMC1	-19372	-11253.5
LAMB3	-14391	-13861.5
LAMC3	-15744	-12602.5
ITGB1	-14603	-13143.5
LAMB1	-19549	-8462.5
LAMC2	-12343	-7708.5
LAMB2	-15526	-5419.5
LAMA5	-17886	-3580.5
ITGA2	-20013	-2737.5
LAMA3	-1286	-16654.5

Click HERE to show all gene set members

All member genes

	bl	gu
HGF	-19375	2486.5
ITGA2	-20013	-2737.5
ITGA3	2768	-16666.5
ITGB1	-14603	-13143.5
LAMA1	-19760	-16981.5
LAMA2	-20701	-14273.5
LAMA3	-1286	-16654.5
LAMA4	-20606	-16022.5
LAMA5	-17886	-3580.5
LAMB1	-19549	-8462.5
LAMB2	-15526	-5419.5
LAMB3	-14391	-13861.5
LAMC1	-19372	-11253.5
LAMC2	-12343	-7708.5
LAMC3	-15744	-12602.5
MET	-20342	-15646.5
PTK2	-20692	-17173.5
SRC	-18883	2938.5

---

---

Laminin interactions

Laminin interactions

metric	value
setSize	23
pMANOVA	5.23e-07
p.adjustMANOVA	6.58e-06
s.dist	0.722
s.bl	-0.578
s.gu	-0.434
p.bl	1.6e-06
p.gu	0.000317

Top 20 genes

Gene	bl	gu
LAMA1	-19760	-16981.5
LAMA4	-20606	-16022.5
COL18A1	-19564	-16570.5
LAMA2	-20701	-14273.5
HSPG2	-13074	-16986.5
ITGA1	-20562	-10730.5
LAMC1	-19372	-11253.5
LAMB3	-14391	-13861.5
LAMC3	-15744	-12602.5
ITGA7	-13079	-14939.5
ITGB1	-14603	-13143.5
NID1	-17062	-10081.5
LAMB1	-19549	-8462.5
NID2	-17269	-8224.5
ITGB4	-20394	-6698.5
LAMC2	-12343	-7708.5
LAMB2	-15526	-5419.5
LAMA5	-17886	-3580.5
ITGA2	-20013	-2737.5
ITGAV	-13017	-2100.5

Click HERE to show all gene set members

All member genes

	bl	gu
COL18A1	-19564	-16570.5
HSPG2	-13074	-16986.5
ITGA1	-20562	-10730.5
ITGA2	-20013	-2737.5
ITGA3	2768	-16666.5
ITGA6	-20409	3511.5
ITGA7	-13079	-14939.5
ITGAV	-13017	-2100.5
ITGB1	-14603	-13143.5
ITGB4	-20394	-6698.5
LAMA1	-19760	-16981.5
LAMA2	-20701	-14273.5
LAMA3	-1286	-16654.5
LAMA4	-20606	-16022.5
LAMA5	-17886	-3580.5
LAMB1	-19549	-8462.5
LAMB2	-15526	-5419.5
LAMB3	-14391	-13861.5
LAMC1	-19372	-11253.5
LAMC2	-12343	-7708.5
LAMC3	-15744	-12602.5
NID1	-17062	-10081.5
NID2	-17269	-8224.5

---

---

Presynaptic depolarization and calcium channel opening

Presynaptic depolarization and calcium channel opening

metric	value
setSize	12
pMANOVA	0.000668
p.adjustMANOVA	0.00299
s.dist	0.715
s.bl	-0.53
s.gu	-0.481
p.bl	0.00148
p.gu	0.00393

Top 20 genes

Gene	bl	gu
CACNA2D1	-21096	-17647.5
CACNA2D3	-18900	-17783.5
CACNA2D2	-21146	-15490.5
CACNB2	-20012	-16277.5
CACNA1B	-15958	-15341.5
CACNB4	-19827	-11799.5
CACNA1A	-9739	-15594.5
CACNG4	-18867	-5943.5
CACNB3	-16386	-4071.5
CACNA1E	-526	-15998.5
CACNG2	-690	-566.5

Click HERE to show all gene set members

All member genes

	bl	gu
CACNA1A	-9739	-15594.5
CACNA1B	-15958	-15341.5
CACNA1E	-526	-15998.5
CACNA2D1	-21096	-17647.5
CACNA2D2	-21146	-15490.5
CACNA2D3	-18900	-17783.5
CACNB1	-19119	2860.5
CACNB2	-20012	-16277.5
CACNB3	-16386	-4071.5
CACNB4	-19827	-11799.5
CACNG2	-690	-566.5
CACNG4	-18867	-5943.5

---

---

DCC mediated attractive signaling

DCC mediated attractive signaling

metric	value
setSize	14
pMANOVA	0.000206
p.adjustMANOVA	0.00107
s.dist	0.714
s.bl	-0.514
s.gu	-0.496
p.bl	0.000863
p.gu	0.00132

Top 20 genes

Gene	bl	gu
TRIO	-21207	-17791.5
PTK2	-20692	-17173.5
ABLIM1	-18489	-16439.5
ABLIM2	-17887	-16310.5
WASL	-20576	-12533.5
NCK1	-14946	-16200.5
DCC	-15511	-14790.5
DOCK1	-21077	-9064.5
ABLIM3	-5705	-16374.5
FYN	-3404	-17810.5
NTN1	-1878	-13809.5

Click HERE to show all gene set members

All member genes

	bl	gu
ABLIM1	-18489	-16439.5
ABLIM2	-17887	-16310.5
ABLIM3	-5705	-16374.5
CDC42	-9725	1088.5
DCC	-15511	-14790.5
DOCK1	-21077	-9064.5
FYN	-3404	-17810.5
NCK1	-14946	-16200.5
NTN1	-1878	-13809.5
PTK2	-20692	-17173.5
RAC1	-19826	5665.5
SRC	-18883	2938.5
TRIO	-21207	-17791.5
WASL	-20576	-12533.5

---

---

Collagen chain trimerization

Collagen chain trimerization

metric	value
setSize	42
pMANOVA	2.85e-11
p.adjustMANOVA	1e-09
s.dist	0.694
s.bl	-0.429
s.gu	-0.546
p.bl	1.51e-06
p.gu	9e-10

Top 20 genes

Gene	bl	gu
COL11A2	-20420	-17401.5
COL6A3	-20483	-16968.5
COL4A2	-20615	-16756.5
COL1A2	-19811	-16713.5
COL18A1	-19564	-16570.5
COL20A1	-20966	-14194.5
COL5A1	-16794	-17700.5
COL10A1	-17258	-16751.5
COL16A1	-18675	-15124.5
COL12A1	-15624	-16775.5
COL3A1	-20431	-12442.5
COL6A6	-19015	-12593.5
COL9A1	-17978	-12975.5
COL1A1	-14436	-15404.5
COL21A1	-15119	-14690.5
COL22A1	-14218	-15031.5
COL25A1	-18823	-11051.5
COL13A1	-17960	-11296.5
COL19A1	-17103	-11686.5
COL5A2	-17229	-11257.5

Click HERE to show all gene set members

All member genes

	bl	gu
COL10A1	-17258	-16751.5
COL11A1	-9108	-8958.5
COL11A2	-20420	-17401.5
COL12A1	-15624	-16775.5
COL13A1	-17960	-11296.5
COL14A1	-11083	-16343.5
COL15A1	-16247	3927.5
COL16A1	-18675	-15124.5
COL17A1	-8308	-16496.5
COL18A1	-19564	-16570.5
COL19A1	-17103	-11686.5
COL1A1	-14436	-15404.5
COL1A2	-19811	-16713.5
COL20A1	-20966	-14194.5
COL21A1	-15119	-14690.5
COL22A1	-14218	-15031.5
COL23A1	-20065	-2078.5
COL24A1	-11135	-17055.5
COL25A1	-18823	-11051.5
COL26A1	-10754	-13395.5
COL27A1	4102	-16994.5
COL28A1	-12752	-9343.5
COL2A1	-11679	5656.5
COL3A1	-20431	-12442.5
COL4A1	-11953	-11230.5
COL4A2	-20615	-16756.5
COL4A3	-13553	-13882.5
COL4A4	-3311	-14937.5
COL5A1	-16794	-17700.5
COL5A2	-17229	-11257.5
COL5A3	-2525	-10781.5
COL6A1	-3225	-8023.5
COL6A2	-16372	-6645.5
COL6A3	-20483	-16968.5
COL6A5	490	-16873.5
COL6A6	-19015	-12593.5
COL7A1	-3029	-16770.5
COL8A1	-5906	-16529.5
COL8A2	-19803	-5783.5
COL9A1	-17978	-12975.5
COL9A2	-14178	2280.5
COL9A3	-20163	980.5

---

---

Regulation of TP53 Activity through Association with Co-factors

Regulation of TP53 Activity through Association with Co-factors

metric	value
setSize	14
pMANOVA	0.000106
p.adjustMANOVA	0.000606
s.dist	0.69
s.bl	-0.66
s.gu	-0.203
p.bl	1.92e-05
p.gu	0.188

Top 20 genes

Gene	bl	gu
AKT3	-20994	-17521.5
TP63	-20702	-17718.5
BANP	-21198	-11670.5
PHF20	-20282	-12128.5
PPP1R13L	-18524	-10434.5
PPP1R13B	-18084	-9915.5
TP73	-18662	-7397.5
AKT1	-20462	-6604.5
AKT2	-19934	-5837.5
POU4F2	-15590	-6551.5
TP53BP2	-13576	-5649.5
TP53	-6761	-7115.5

Click HERE to show all gene set members

All member genes

	bl	gu
AKT1	-20462	-6604.5
AKT2	-19934	-5837.5
AKT3	-20994	-17521.5
BANP	-21198	-11670.5
PHF20	-20282	-12128.5
POU4F1	-1758	7785.5
POU4F2	-15590	-6551.5
PPP1R13B	-18084	-9915.5
PPP1R13L	-18524	-10434.5
TP53	-6761	-7115.5
TP53BP2	-13576	-5649.5
TP63	-20702	-17718.5
TP73	-18662	-7397.5
ZNF385A	-19438	4794.5

---

---

Carnitine metabolism

Carnitine metabolism

metric	value
setSize	11
pMANOVA	3.98e-05
p.adjustMANOVA	0.000267
s.dist	0.685
s.bl	-0.604
s.gu	0.323
p.bl	0.000522
p.gu	0.0632

Top 20 genes

Gene	bl	gu
CPT1B	-21033	5428.5
SLC22A5	-18577	3452.5
RXRA	-20775	2156.5
THRSP	-10427	3732.5
CPT1A	-20988	1448.5
PRKAB2	-14024	1550.5

Click HERE to show all gene set members

All member genes

	bl	gu
CPT1A	-20988	1448.5
CPT1B	-21033	5428.5
CPT2	-18414	-780.5
PPARD	-13396	-3387.5
PRKAA2	-9755	-633.5
PRKAB2	-14024	1550.5
PRKAG2	-21181	-15519.5
RXRA	-20775	2156.5
SLC22A5	-18577	3452.5
SLC25A20	-8987	-6268.5
THRSP	-10427	3732.5

---

---

Apoptotic cleavage of cell adhesion proteins

Apoptotic cleavage of cell adhesion proteins

metric	value
setSize	11
pMANOVA	0.00229
p.adjustMANOVA	0.00871
s.dist	0.676
s.bl	-0.549
s.gu	-0.394
p.bl	0.00161
p.gu	0.0236

Top 20 genes

Gene	bl	gu
TJP2	-16378	-16839.5
DSG1	-14628	-17494.5
TJP1	-20268	-12512.5
OCLN	-18570	-12670.5
CTNNB1	-17403	-10731.5
CASP3	-15287	-10388.5
CDH1	-15529	-8204.5
DSP	-15449	-7787.5
DSG3	-6617	-15103.5
DSG2	-17512	-1432.5

Click HERE to show all gene set members

All member genes

	bl	gu
CASP3	-15287	-10388.5
CDH1	-15529	-8204.5
CTNNB1	-17403	-10731.5
DSG1	-14628	-17494.5
DSG2	-17512	-1432.5
DSG3	-6617	-15103.5
DSP	-15449	-7787.5
OCLN	-18570	-12670.5
PKP1	-12144	2899.5
TJP1	-20268	-12512.5
TJP2	-16378	-16839.5

---

---

Nitric oxide stimulates guanylate cyclase

Nitric oxide stimulates guanylate cyclase

metric	value
setSize	22
pMANOVA	7.02e-06
p.adjustMANOVA	5.77e-05
s.dist	0.654
s.bl	-0.307
s.gu	-0.578
p.bl	0.0127
p.gu	2.69e-06

Top 20 genes

Gene	bl	gu
KCNMB2	-20581	-17588.5
PDE1A	-19290	-17620.5
PDE11A	-17065	-17733.5
PDE10A	-17778	-16980.5
KCNMB3	-16704	-16685.5
KCNMA1	-13573	-17709.5
PRKG1	-12589	-16324.5
GUCY1B2	-18341	-10804.5
PDE5A	-10324	-17619.5
NOS2	-11919	-15106.5
PRKG2	-12552	-14002.5
ITPR1	-21072	-7262.5
PDE2A	-7628	-15109.5
NOS3	-7798	-12489.5
GUCY1B3	-18450	-4802.5
KCNMB4	-5262	-13840.5
GUCY1A2	-15109	-3725.5
PDE1B	-12942	-2233.5
KCNMB1	-1721	-14130.5
PDE9A	-2793	-7893.5

Click HERE to show all gene set members

All member genes

	bl	gu
GUCY1A2	-15109	-3725.5
GUCY1A3	-6230	1127.5
GUCY1B2	-18341	-10804.5
GUCY1B3	-18450	-4802.5
ITPR1	-21072	-7262.5
KCNMA1	-13573	-17709.5
KCNMB1	-1721	-14130.5
KCNMB2	-20581	-17588.5
KCNMB3	-16704	-16685.5
KCNMB4	-5262	-13840.5
NOS1	-1313	-13872.5
NOS2	-11919	-15106.5
NOS3	-7798	-12489.5
PDE10A	-17778	-16980.5
PDE11A	-17065	-17733.5
PDE1A	-19290	-17620.5
PDE1B	-12942	-2233.5
PDE2A	-7628	-15109.5
PDE5A	-10324	-17619.5
PDE9A	-2793	-7893.5
PRKG1	-12589	-16324.5
PRKG2	-12552	-14002.5

---

---

Bicarbonate transporters

Bicarbonate transporters

metric	value
setSize	10
pMANOVA	0.00616
p.adjustMANOVA	0.0201
s.dist	0.652
s.bl	-0.409
s.gu	-0.508
p.bl	0.0253
p.gu	0.00541

Top 20 genes

Gene	bl	gu
SLC4A7	-20909	-15605.5
SLC4A5	-15434	-17576.5
SLC4A10	-20105	-13426.5
SLC4A4	-19933	-13514.5
SLC4A3	-17790	-14129.5
AHCYL2	-15849	-9368.5
SLC4A8	-8416	-15535.5
SLC4A2	-10298	-6067.5
SLC4A1	-6866	-1998.5
SLC4A9	-700	-7646.5

Click HERE to show all gene set members

All member genes

	bl	gu
AHCYL2	-15849	-9368.5
SLC4A1	-6866	-1998.5
SLC4A10	-20105	-13426.5
SLC4A2	-10298	-6067.5
SLC4A3	-17790	-14129.5
SLC4A4	-19933	-13514.5
SLC4A5	-15434	-17576.5
SLC4A7	-20909	-15605.5
SLC4A8	-8416	-15535.5
SLC4A9	-700	-7646.5

---

---

Eicosanoids

Eicosanoids

metric	value
setSize	12
pMANOVA	9.68e-05
p.adjustMANOVA	0.000565
s.dist	0.649
s.bl	0.626
s.gu	-0.173
p.bl	0.000175
p.gu	0.298

Top 20 genes

Gene	bl	gu
CYP8B1	3938	-14264.5
CYP4B1	3466	-12840.5
CYP4F2	2366	-12085.5
CYP4F8	1319	-12018.5
CYP4F22	1704	-3653.5
CYP4A22	3692	-1519.5

Click HERE to show all gene set members

All member genes

	bl	gu
CYP4A11	2284	1210.5
CYP4A22	3692	-1519.5
CYP4B1	3466	-12840.5
CYP4F11	-1329	-10430.5
CYP4F12	-1514	5871.5
CYP4F2	2366	-12085.5
CYP4F22	1704	-3653.5
CYP4F3	527	3083.5
CYP4F8	1319	-12018.5
CYP8B1	3938	-14264.5
PTGIS	-1119	-16845.5
TBXAS1	-19404	-12756.5

---

---

Induction of Cell-Cell Fusion

Induction of Cell-Cell Fusion

metric	value
setSize	12
pMANOVA	0.00274
p.adjustMANOVA	0.0101
s.dist	0.643
s.bl	-0.463
s.gu	-0.446
p.bl	0.00543
p.gu	0.00744

Top 20 genes

Gene	bl	gu
ANO6	-20840	-16543.5
ANO3	-20222	-13980.5
ANO1	-16078	-12685.5
ANO4	-11283	-17237.5
ANO7	-16850	-10856.5
ANO5	-13083	-12381.5
ANO9	-12440	-12769.5
ANO2	-6201	-17334.5
FURIN	-20646	-5134.5
ANO8	-4241	-13080.5
ANO10	-18817	-1068.5

Click HERE to show all gene set members

All member genes

	bl	gu
ANO1	-16078	-12685.5
ANO10	-18817	-1068.5
ANO2	-6201	-17334.5
ANO3	-20222	-13980.5
ANO4	-11283	-17237.5
ANO5	-13083	-12381.5
ANO6	-20840	-16543.5
ANO7	-16850	-10856.5
ANO8	-4241	-13080.5
ANO9	-12440	-12769.5
FURIN	-20646	-5134.5
TMPRSS2	-11319	4759.5

---

---

VEGFR2 mediated vascular permeability

VEGFR2 mediated vascular permeability

metric	value
setSize	26
pMANOVA	3.62e-07
p.adjustMANOVA	4.7e-06
s.dist	0.635
s.bl	-0.617
s.gu	-0.153
p.bl	5.15e-08
p.gu	0.177

Top 20 genes

Gene	bl	gu
AKT3	-20994	-17521.5
CTNNA1	-19809	-17636.5
MAPKAP1	-21007	-16414.5
PAK1	-18763	-13669.5
CDH5	-19437	-12863.5
MTOR	-20859	-11279.5
CTNND1	-20257	-10744.5
PDPK1	-14458	-13475.5
CTNNB1	-17403	-10731.5
PAK2	-19545	-8414.5
AKT1	-20462	-6604.5
AKT2	-19934	-5837.5
TRIB3	-11413	-9956.5
RICTOR	-19614	-5418.5
NOS3	-7798	-12489.5
CAV1	-7792	-11564.5
CALM1	-7448	-7546.5
PRR5	-20110	-2553.5
VAV1	-7147	-6256.5
VAV3	-20867	-985.5

Click HERE to show all gene set members

All member genes

	bl	gu
AKT1	-20462	-6604.5
AKT2	-19934	-5837.5
AKT3	-20994	-17521.5
CALM1	-7448	-7546.5
CAV1	-7792	-11564.5
CDH5	-19437	-12863.5
CTNNA1	-19809	-17636.5
CTNNB1	-17403	-10731.5
CTNND1	-20257	-10744.5
HSP90AA1	-7227	-2657.5
JUP	-14743	3129.5
MAPKAP1	-21007	-16414.5
MLST8	-13096	6863.5
MTOR	-20859	-11279.5
NOS3	-7798	-12489.5
PAK1	-18763	-13669.5
PAK2	-19545	-8414.5
PDPK1	-14458	-13475.5
PRR5	-20110	-2553.5
RAC1	-19826	5665.5
RICTOR	-19614	-5418.5
THEM4	-13921	5959.5
TRIB3	-11413	-9956.5
VAV1	-7147	-6256.5
VAV2	-19895	2990.5
VAV3	-20867	-985.5

---

---

Adherens junctions interactions

Adherens junctions interactions

metric	value
setSize	26
pMANOVA	5.31e-06
p.adjustMANOVA	4.56e-05
s.dist	0.625
s.bl	-0.391
s.gu	-0.487
p.bl	0.000549
p.gu	1.73e-05

Top 20 genes

Gene	bl	gu
CDH18	-20823	-17770.5
CTNNA1	-19809	-17636.5
CDH4	-18537	-17710.5
CADM1	-18138	-17758.5
CDH8	-19833	-14923.5
CDH3	-19346	-14996.5
CDH6	-15753	-16498.5
CDH5	-19437	-12863.5
CDH2	-14310	-17015.5
CDH7	-16094	-14701.5
CTNND1	-20257	-10744.5
CDH12	-16271	-12581.5
CDH24	-17789	-10650.5
CTNNB1	-17403	-10731.5
CADM2	-20810	-7182.5
CDH1	-15529	-8204.5
CDH17	-7060	-17618.5
PVR	-15019	-7957.5
CDH10	-10250	-6275.5
CDH15	-4520	-8405.5

Click HERE to show all gene set members

All member genes

	bl	gu
ANG	-1792	4528.5
CADM1	-18138	-17758.5
CADM2	-20810	-7182.5
CADM3	-1488	-6120.5
CDH1	-15529	-8204.5
CDH10	-10250	-6275.5
CDH11	-2841	-7854.5
CDH12	-16271	-12581.5
CDH13	3637	-16458.5
CDH15	-4520	-8405.5
CDH17	-7060	-17618.5
CDH18	-20823	-17770.5
CDH2	-14310	-17015.5
CDH24	-17789	-10650.5
CDH3	-19346	-14996.5
CDH4	-18537	-17710.5
CDH5	-19437	-12863.5
CDH6	-15753	-16498.5
CDH7	-16094	-14701.5
CDH8	-19833	-14923.5
CDH9	-4348	-6478.5
CTNNA1	-19809	-17636.5
CTNNB1	-17403	-10731.5
CTNND1	-20257	-10744.5
JUP	-14743	3129.5
PVR	-15019	-7957.5

---

---

SARS-CoV-1 modulates host translation machinery

SARS-CoV-1 modulates host translation machinery

metric	value
setSize	34
pMANOVA	7.87e-08
p.adjustMANOVA	1.2e-06
s.dist	0.621
s.bl	0.541
s.gu	0.304
p.bl	4.72e-08
p.gu	0.00214

Top 20 genes

Gene	bl	gu
HNRNPA1	4439.0	7730.5
RPS27A	4217.0	6097.5
RPS19	3756.0	5741.5
EEF1A1	2492.0	7556.5
RPS27	2035.0	6468.5
RPS12	4469.0	1998.5
RPSA	1139.0	7554.5
RPS18	1998.0	3105.5
RPS17	0.5	0.5

Click HERE to show all gene set members

All member genes

	bl	gu
EEF1A1	2492.0	7556.5
FAU	952.0	-8259.5
HNRNPA1	4439.0	7730.5
RPS10	-4830.0	2832.5
RPS11	2770.0	-14019.5
RPS12	4469.0	1998.5
RPS13	2671.0	-14238.5
RPS14	-9771.0	7745.5
RPS15	-6908.0	-4159.5
RPS15A	-6045.0	5308.5
RPS16	-4604.0	4362.5
RPS17	0.5	0.5
RPS18	1998.0	3105.5
RPS19	3756.0	5741.5
RPS2	-1566.0	-14508.5
RPS20	-2638.0	-5802.5
RPS21	1535.0	-5578.5
RPS23	1473.0	-2117.5
RPS24	-6897.0	6030.5
RPS25	3118.0	-2276.5
RPS26	-8498.0	7869.5
RPS27	2035.0	6468.5
RPS27A	4217.0	6097.5
RPS27L	1739.0	-11820.5
RPS28	-12478.0	2372.5
RPS29	1818.0	-11391.5
RPS3	-1546.0	2099.5
RPS3A	-1072.0	1265.5
RPS5	3833.0	-16355.5
RPS6	-7442.0	-1052.5
RPS7	-5751.0	-5009.5
RPS8	-4628.0	6302.5
RPS9	-8451.0	-11640.5
RPSA	1139.0	7554.5

---

---

Collagen biosynthesis and modifying enzymes

Collagen biosynthesis and modifying enzymes

metric	value
setSize	65
pMANOVA	5.48e-13
p.adjustMANOVA	2.57e-11
s.dist	0.605
s.bl	-0.42
s.gu	-0.436
p.bl	4.75e-09
p.gu	1.22e-09

Top 20 genes

Gene	bl	gu
ADAMTS2	-20648	-17790.5
COL11A2	-20420	-17401.5
COL6A3	-20483	-16968.5
COL4A2	-20615	-16756.5
PLOD2	-19944	-16738.5
COL1A2	-19811	-16713.5
COL18A1	-19564	-16570.5
COL20A1	-20966	-14194.5
COL5A1	-16794	-17700.5
COL10A1	-17258	-16751.5
COL16A1	-18675	-15124.5
P3H2	-19465	-13714.5
COL12A1	-15624	-16775.5
COLGALT2	-18573	-14083.5
COL3A1	-20431	-12442.5
P4HA2	-18891	-13164.5
COL6A6	-19015	-12593.5
COL9A1	-17978	-12975.5
SERPINH1	-14475	-15917.5
COL1A1	-14436	-15404.5

Click HERE to show all gene set members

All member genes

	bl	gu
ADAMTS14	-17847	-8885.5
ADAMTS2	-20648	-17790.5
ADAMTS3	-14478	-13517.5
BMP1	-9248	-13013.5
COL10A1	-17258	-16751.5
COL11A1	-9108	-8958.5
COL11A2	-20420	-17401.5
COL12A1	-15624	-16775.5
COL13A1	-17960	-11296.5
COL14A1	-11083	-16343.5
COL15A1	-16247	3927.5
COL16A1	-18675	-15124.5
COL17A1	-8308	-16496.5
COL18A1	-19564	-16570.5
COL19A1	-17103	-11686.5
COL1A1	-14436	-15404.5
COL1A2	-19811	-16713.5
COL20A1	-20966	-14194.5
COL21A1	-15119	-14690.5
COL22A1	-14218	-15031.5
COL23A1	-20065	-2078.5
COL24A1	-11135	-17055.5
COL25A1	-18823	-11051.5
COL26A1	-10754	-13395.5
COL27A1	4102	-16994.5
COL28A1	-12752	-9343.5
COL2A1	-11679	5656.5
COL3A1	-20431	-12442.5
COL4A1	-11953	-11230.5
COL4A2	-20615	-16756.5
COL4A3	-13553	-13882.5
COL4A4	-3311	-14937.5
COL5A1	-16794	-17700.5
COL5A2	-17229	-11257.5
COL5A3	-2525	-10781.5
COL6A1	-3225	-8023.5
COL6A2	-16372	-6645.5
COL6A3	-20483	-16968.5
COL6A5	490	-16873.5
COL6A6	-19015	-12593.5
COL7A1	-3029	-16770.5
COL8A1	-5906	-16529.5
COL8A2	-19803	-5783.5
COL9A1	-17978	-12975.5
COL9A2	-14178	2280.5
COL9A3	-20163	980.5
COLGALT1	-10706	-9332.5
COLGALT2	-18573	-14083.5
CRTAP	-4171	-8120.5
P3H1	-6204	1898.5
P3H2	-19465	-13714.5
P3H3	-16088	-5856.5
P4HA1	-12743	-3452.5
P4HA2	-18891	-13164.5
P4HA3	-497	-4519.5
P4HB	-19211	7891.5
PCOLCE	-19123	-11623.5
PCOLCE2	-19325	-10775.5
PLOD1	-17536	-3104.5
PLOD2	-19944	-16738.5
PLOD3	-10466	-7142.5
PPIB	-10333	6875.5
SERPINH1	-14475	-15917.5
TLL1	-14031	-9580.5
TLL2	2570	830.5

---

---

Nephrin family interactions

Nephrin family interactions

metric	value
setSize	21
pMANOVA	0.000112
p.adjustMANOVA	0.000629
s.dist	0.603
s.bl	-0.398
s.gu	-0.453
p.bl	0.00158
p.gu	0.000326

Top 20 genes

Gene	bl	gu
MAGI2	-20852	-17801.5
ACTN2	-20390	-15507.5
NCK2	-19953	-15765.5
PIK3CB	-21110	-14048.5
WASL	-20576	-12533.5
CD2AP	-21039	-12150.5
NCK1	-14946	-16200.5
IQGAP1	-19156	-12620.5
ACTN1	-14416	-11502.5
PIK3R1	-11854	-11534.5
NPHS1	-13311	-8765.5
SPTAN1	-9019	-12770.5
ACTN3	-13075	-7544.5
SPTBN1	-21027	-4501.5
FYN	-3404	-17810.5
PIK3CA	-729	-15463.5
KIRREL	-638	-16585.5

Click HERE to show all gene set members

All member genes

	bl	gu
ACTN1	-14416	-11502.5
ACTN2	-20390	-15507.5
ACTN3	-13075	-7544.5
ACTN4	-8183	6416.5
CD2AP	-21039	-12150.5
FYN	-3404	-17810.5
IQGAP1	-19156	-12620.5
KIRREL	-638	-16585.5
KIRREL2	-16991	1941.5
KIRREL3	927	-15817.5
MAGI2	-20852	-17801.5
NCK1	-14946	-16200.5
NCK2	-19953	-15765.5
NPHS1	-13311	-8765.5
PIK3CA	-729	-15463.5
PIK3CB	-21110	-14048.5
PIK3R1	-11854	-11534.5
PIK3R2	-13656	4242.5
SPTAN1	-9019	-12770.5
SPTBN1	-21027	-4501.5
WASL	-20576	-12533.5

---

---

MET promotes cell motility

MET promotes cell motility

metric	value
setSize	29
pMANOVA	2.93e-06
p.adjustMANOVA	2.96e-05
s.dist	0.595
s.bl	-0.513
s.gu	-0.3
p.bl	1.69e-06
p.gu	0.00512

Top 20 genes

Gene	bl	gu
TNS3	-20834	-17563.5
PTK2	-20692	-17173.5
LAMA1	-19760	-16981.5
LAMA4	-20606	-16022.5
MET	-20342	-15646.5
LAMA2	-20701	-14273.5
GAB1	-20667	-12669.5
DOCK7	-20737	-11116.5
LAMC1	-19372	-11253.5
LAMB3	-14391	-13861.5
LAMC3	-15744	-12602.5
ITGB1	-14603	-13143.5
LAMB1	-19549	-8462.5
TNS4	-10992	-14827.5
CRK	-14636	-9160.5
RAPGEF1	-14772	-7968.5
LAMC2	-12343	-7708.5
LAMB2	-15526	-5419.5
LAMA5	-17886	-3580.5
ITGA2	-20013	-2737.5

Click HERE to show all gene set members

All member genes

	bl	gu
CRK	-14636	-9160.5
CRKL	-2282	-1650.5
DOCK7	-20737	-11116.5
GAB1	-20667	-12669.5
GRB2	-12253	2844.5
HGF	-19375	2486.5
ITGA2	-20013	-2737.5
ITGA3	2768	-16666.5
ITGB1	-14603	-13143.5
LAMA1	-19760	-16981.5
LAMA2	-20701	-14273.5
LAMA3	-1286	-16654.5
LAMA4	-20606	-16022.5
LAMA5	-17886	-3580.5
LAMB1	-19549	-8462.5
LAMB2	-15526	-5419.5
LAMB3	-14391	-13861.5
LAMC1	-19372	-11253.5
LAMC2	-12343	-7708.5
LAMC3	-15744	-12602.5
MET	-20342	-15646.5
PTK2	-20692	-17173.5
RAC1	-19826	5665.5
RAP1A	1388	-4020.5
RAP1B	-10302	1579.5
RAPGEF1	-14772	-7968.5
SRC	-18883	2938.5
TNS3	-20834	-17563.5
TNS4	-10992	-14827.5

---

---

Termination of O-glycan biosynthesis

Termination of O-glycan biosynthesis

metric	value
setSize	25
pMANOVA	2.23e-05
p.adjustMANOVA	0.000159
s.dist	0.588
s.bl	-0.505
s.gu	-0.301
p.bl	1.21e-05
p.gu	0.00926

Top 20 genes

Gene	bl	gu
MUC2	-20577	-15880.5
ST6GALNAC3	-20151	-15744.5
MUC5B	-20908	-14915.5
ST3GAL3	-20150	-13868.5
MUC7	-15615	-17282.5
ST3GAL1	-18931	-14095.5
MUC4	-18291	-13186.5
MUC21	-16701	-13519.5
MUC12	-15177	-14501.5
MUC15	-10607	-15746.5
MUC19	-11134	-14276.5
ST6GALNAC4	-11587	-13314.5
ST3GAL4	-20455	-7145.5
MUC13	-9608	-11323.5
MUC6	-15574	-6704.5
MUCL1	-8040	-12413.5
MUC17	-5022	-16487.5
MUC5AC	-17882	-4044.5
ST6GAL1	-14281	-3979.5
MUC20	-12848	-2446.5

Click HERE to show all gene set members

All member genes

	bl	gu
MUC1	-9632	5413.5
MUC12	-15177	-14501.5
MUC13	-9608	-11323.5
MUC15	-10607	-15746.5
MUC16	-8930	1070.5
MUC17	-5022	-16487.5
MUC19	-11134	-14276.5
MUC2	-20577	-15880.5
MUC20	-12848	-2446.5
MUC21	-16701	-13519.5
MUC3A	-11802	4348.5
MUC4	-18291	-13186.5
MUC5AC	-17882	-4044.5
MUC5B	-20908	-14915.5
MUC6	-15574	-6704.5
MUC7	-15615	-17282.5
MUCL1	-8040	-12413.5
ST3GAL1	-18931	-14095.5
ST3GAL2	-20365	4743.5
ST3GAL3	-20150	-13868.5
ST3GAL4	-20455	-7145.5
ST6GAL1	-14281	-3979.5
ST6GALNAC2	-17521	4792.5
ST6GALNAC3	-20151	-15744.5
ST6GALNAC4	-11587	-13314.5

---

---

Neurexins and neuroligins

Neurexins and neuroligins

metric	value
setSize	52
pMANOVA	8.85e-10
p.adjustMANOVA	2.1e-08
s.dist	0.579
s.bl	-0.445
s.gu	-0.371
p.bl	2.73e-08
p.gu	3.71e-06

Top 20 genes

Gene	bl	gu
PDLIM5	-21052	-17652.5
EPB41L2	-20990	-17694.5
SHANK2	-20858	-17789.5
NRXN1	-21137	-17378.5
DLGAP1	-20545	-17540.5
DLGAP2	-19648	-17806.5
DLG2	-19093	-17807.5
SYT1	-18919	-17705.5
GRM1	-19567	-15571.5
NLGN1	-17134	-17726.5
DLGAP4	-20665	-14463.5
EPB41L3	-19601	-14540.5
NRXN3	-16219	-17412.5
LRRTM2	-17871	-15710.5
EPB41L5	-18918	-14324.5
SYT12	-18606	-13870.5
SYT2	-17204	-12054.5
SHANK1	-18908	-10443.5
LRRTM4	-16626	-11819.5
EPB41	-19169	-9987.5

Click HERE to show all gene set members

All member genes

	bl	gu
APBA1	-6527	-14812.5
APBA2	-10801	-9946.5
APBA3	2003	2219.5
BEGAIN	-12746	-13182.5
DBNL	-9439	-1223.5
DLG2	-19093	-17807.5
DLG4	-7564	-9108.5
DLGAP1	-20545	-17540.5
DLGAP2	-19648	-17806.5
DLGAP3	-12436	4767.5
DLGAP4	-20665	-14463.5
EPB41	-19169	-9987.5
EPB41L1	-5621	-11822.5
EPB41L2	-20990	-17694.5
EPB41L3	-19601	-14540.5
EPB41L5	-18918	-14324.5
GRIN1	-11503	-13286.5
GRIN2A	-1551	-8543.5
GRIN2B	-17897	-5765.5
GRIN2C	-13706	-5719.5
GRIN2D	-7457	-7256.5
GRM1	-19567	-15571.5
GRM5	-16497	-9669.5
HOMER1	-12449	-9018.5
HOMER2	-15829	-6631.5
HOMER3	-7557	-9339.5
LIN7A	-12439	-14577.5
LIN7B	-16499	4122.5
LIN7C	-1605	-2612.5
LRRTM1	-18895	1756.5
LRRTM2	-17871	-15710.5
LRRTM3	-5399	-5408.5
LRRTM4	-16626	-11819.5
NLGN1	-17134	-17726.5
NLGN2	-19315	-9612.5
NRXN1	-21137	-17378.5
NRXN2	-16852	-10821.5
NRXN3	-16219	-17412.5
PDLIM5	-21052	-17652.5
SHANK1	-18908	-10443.5
SHANK2	-20858	-17789.5
SHANK3	-14325	-5851.5
SHARPIN	-1509	5143.5
SIPA1L1	-20826	-8213.5
STX1A	-18848	2183.5
STXBP1	4209	2155.5
SYT1	-18919	-17705.5
SYT10	-13653	-3984.5
SYT12	-18606	-13870.5
SYT2	-17204	-12054.5
SYT7	-11398	-13921.5
SYT9	-15176	-7984.5

---

---

RHO GTPases activate IQGAPs

RHO GTPases activate IQGAPs

metric	value
setSize	11
pMANOVA	0.00881
p.adjustMANOVA	0.0269
s.dist	0.576
s.bl	-0.526
s.gu	-0.235
p.bl	0.00251
p.gu	0.177

Top 20 genes

Gene	bl	gu
CTNNA1	-19809	-17636.5
CLIP1	-20974	-12943.5
IQGAP1	-19156	-12620.5
IQGAP2	-19902	-10657.5
CTNNB1	-17403	-10731.5
CDH1	-15529	-8204.5
CALM1	-7448	-7546.5
IQGAP3	-19168	-667.5

Click HERE to show all gene set members

All member genes

	bl	gu
CALM1	-7448	-7546.5
CDC42	-9725	1088.5
CDH1	-15529	-8204.5
CLIP1	-20974	-12943.5
CTNNA1	-19809	-17636.5
CTNNB1	-17403	-10731.5
IQGAP1	-19156	-12620.5
IQGAP2	-19902	-10657.5
IQGAP3	-19168	-667.5
MEN1	2399	-13503.5
RAC1	-19826	5665.5

---

---

Defective C1GALT1C1 causes TNPS

Defective C1GALT1C1 causes TNPS

metric	value
setSize	18
pMANOVA	0.00103
p.adjustMANOVA	0.00438
s.dist	0.567
s.bl	-0.415
s.gu	-0.386
p.bl	0.00228
p.gu	0.00458

Top 20 genes

Gene	bl	gu
MUC2	-20577	-15880.5
MUC5B	-20908	-14915.5
C1GALT1	-18520	-16633.5
MUC7	-15615	-17282.5
MUC4	-18291	-13186.5
MUC21	-16701	-13519.5
MUC12	-15177	-14501.5
MUC15	-10607	-15746.5
MUC19	-11134	-14276.5
MUC13	-9608	-11323.5
MUC6	-15574	-6704.5
MUCL1	-8040	-12413.5
MUC17	-5022	-16487.5
MUC5AC	-17882	-4044.5
MUC20	-12848	-2446.5

Click HERE to show all gene set members

All member genes

	bl	gu
C1GALT1	-18520	-16633.5
MUC1	-9632	5413.5
MUC12	-15177	-14501.5
MUC13	-9608	-11323.5
MUC15	-10607	-15746.5
MUC16	-8930	1070.5
MUC17	-5022	-16487.5
MUC19	-11134	-14276.5
MUC2	-20577	-15880.5
MUC20	-12848	-2446.5
MUC21	-16701	-13519.5
MUC3A	-11802	4348.5
MUC4	-18291	-13186.5
MUC5AC	-17882	-4044.5
MUC5B	-20908	-14915.5
MUC6	-15574	-6704.5
MUC7	-15615	-17282.5
MUCL1	-8040	-12413.5

---

---

Interaction between L1 and Ankyrins

Interaction between L1 and Ankyrins

metric	value
setSize	28
pMANOVA	6.49e-06
p.adjustMANOVA	5.39e-05
s.dist	0.562
s.bl	-0.182
s.gu	-0.532
p.bl	0.0956
p.gu	1.11e-06

Top 20 genes

Gene	bl	gu
ANK3	-21215	-17815.5
ANK2	-19650	-17799.5
NRCAM	-19584	-17547.5
SCN8A	-16903	-15852.5
SCN7A	-14349	-17076.5
SCN9A	-15755	-14513.5
SPTB	-19541	-9118.5
KCNQ2	-12619	-13779.5
SCN5A	-13543	-12758.5
SCN4B	-14674	-11201.5
ANK1	-18153	-9052.5
SCN1B	-16270	-9233.5
SCN1A	-10397	-13272.5
SPTBN5	-7857	-16882.5
SCN2A	-8433	-15141.5
SPTAN1	-9019	-12770.5
SPTBN1	-21027	-4501.5
SCN3A	-7318	-10706.5
SCN4A	-4357	-16682.5
SCN10A	-3487	-17488.5

Click HERE to show all gene set members

All member genes

	bl	gu
ANK1	-18153	-9052.5
ANK2	-19650	-17799.5
ANK3	-21215	-17815.5
KCNQ2	-12619	-13779.5
KCNQ3	4032	671.5
NFASC	-2648	-15944.5
NRCAM	-19584	-17547.5
SCN10A	-3487	-17488.5
SCN11A	1953	-16340.5
SCN1A	-10397	-13272.5
SCN1B	-16270	-9233.5
SCN2A	-8433	-15141.5
SCN2B	-14091	-1112.5
SCN3A	-7318	-10706.5
SCN3B	-2135	6850.5
SCN4A	-4357	-16682.5
SCN4B	-14674	-11201.5
SCN5A	-13543	-12758.5
SCN7A	-14349	-17076.5
SCN8A	-16903	-15852.5
SCN9A	-15755	-14513.5
SPTA1	-13375	-1634.5
SPTAN1	-9019	-12770.5
SPTB	-19541	-9118.5
SPTBN1	-21027	-4501.5
SPTBN2	3536	-16928.5
SPTBN4	-3157	-12422.5
SPTBN5	-7857	-16882.5

---

---

ALK mutants bind TKIs

ALK mutants bind TKIs

metric	value
setSize	12
pMANOVA	0.00505
p.adjustMANOVA	0.017
s.dist	0.56
s.bl	-0.542
s.gu	-0.141
p.bl	0.00114
p.gu	0.399

Top 20 genes

Gene	bl	gu
FN1	-20047	-16793.5
BIRC6	-19965	-15086.5
STRN	-20929	-12481.5
EML4	-19673	-11342.5
EIF2AK3	-14430	-14346.5
PRKAR1A	-20242	-4330.5
ALK	-4596	-16861.5
CLTC	-18368	-1283.5

Click HERE to show all gene set members

All member genes

	bl	gu
ALK	-4596	-16861.5
BCL11A	-17353	1033.5
BIRC6	-19965	-15086.5
CLTC	-18368	-1283.5
EIF2AK3	-14430	-14346.5
EML4	-19673	-11342.5
FN1	-20047	-16793.5
HIP1	-19779	4352.5
NPM1	-12402	7721.5
PPM1B	3632	-1765.5
PRKAR1A	-20242	-4330.5
STRN	-20929	-12481.5

---

---

Non-integrin membrane-ECM interactions

Non-integrin membrane-ECM interactions

metric	value
setSize	40
pMANOVA	2.75e-07
p.adjustMANOVA	3.72e-06
s.dist	0.56
s.bl	-0.451
s.gu	-0.331
p.bl	7.96e-07
p.gu	0.000286

Top 20 genes

Gene	bl	gu
PRKCA	-21112	-17593.5
NRXN1	-21137	-17378.5
LAMA1	-19760	-16981.5
LAMA4	-20606	-16022.5
DDR1	-20586	-14369.5
LAMA2	-20701	-14273.5
AGRN	-18040	-14510.5
NTN4	-15075	-17286.5
THBS1	-16401	-15619.5
DDR2	-12775	-17745.5
HSPG2	-13074	-16986.5
LAMC1	-19372	-11253.5
TNC	-13813	-15263.5
LAMB3	-14391	-13861.5
LAMC3	-15744	-12602.5
ITGB1	-14603	-13143.5
TTR	-10687	-16109.5
ACTN1	-14416	-11502.5
LAMB1	-19549	-8462.5
DAG1	-17838	-7928.5

Click HERE to show all gene set members

All member genes

	bl	gu
ACTN1	-14416	-11502.5
AGRN	-18040	-14510.5
DAG1	-17838	-7928.5
DDR1	-20586	-14369.5
DDR2	-12775	-17745.5
FGF2	-20045	-5363.5
HSPG2	-13074	-16986.5
ITGA2	-20013	-2737.5
ITGA6	-20409	3511.5
ITGAV	-13017	-2100.5
ITGB1	-14603	-13143.5
ITGB3	-1249	-10005.5
ITGB4	-20394	-6698.5
ITGB5	-5855	-16777.5
LAMA1	-19760	-16981.5
LAMA2	-20701	-14273.5
LAMA3	-1286	-16654.5
LAMA4	-20606	-16022.5
LAMA5	-17886	-3580.5
LAMB1	-19549	-8462.5
LAMB2	-15526	-5419.5
LAMB3	-14391	-13861.5
LAMC1	-19372	-11253.5
LAMC2	-12343	-7708.5
LAMC3	-15744	-12602.5
NRXN1	-21137	-17378.5
NTN4	-15075	-17286.5
PDGFA	-4650	7149.5
PDGFB	-6388	823.5
PRKCA	-21112	-17593.5
SDC1	-5501	2645.5
SDC2	-11428	-7878.5
SDC3	-6936	-11310.5
SDC4	-7916	2274.5
TGFB1	-15118	-6888.5
THBS1	-16401	-15619.5
TNC	-13813	-15263.5
TRAPPC4	-9722	1385.5
TTR	-10687	-16109.5
VTN	-11308	5711.5

---

---

Class C/3 (Metabotropic glutamate/pheromone receptors)

Class C/3 (Metabotropic glutamate/pheromone receptors)

metric	value
setSize	39
pMANOVA	3.68e-07
p.adjustMANOVA	4.75e-06
s.dist	0.558
s.bl	-0.307
s.gu	-0.466
p.bl	0.000917
p.gu	4.77e-07

Top 20 genes

Gene	bl	gu
GABBR1	-20978	-17276.5
TAS2R50	-17878	-17422.5
GRM1	-19567	-15571.5
TAS2R8	-18366	-16507.5
TAS2R20	-18302	-16285.5
GRM4	-17156	-16546.5
GPRC6A	-17523	-14750.5
TAS2R1	-15816	-16005.5
TAS2R3	-18754	-13413.5
TAS2R42	-13517	-17594.5
TAS2R9	-17655	-12423.5
GRM7	-13112	-16560.5
GRM6	-14700	-13967.5
TAS2R19	-11579	-17526.5
TAS2R14	-17100	-11836.5
TAS2R7	-16069	-12127.5
TAS2R39	-12640	-15134.5
GRM5	-16497	-9669.5
TAS2R10	-15939	-9578.5
TAS2R30	-11126	-12950.5

Click HERE to show all gene set members

All member genes

	bl	gu
CASR	-8106.0	-1522.5
GABBR1	-20978.0	-17276.5
GABBR2	-10559.0	-11548.5
GPRC6A	-17523.0	-14750.5
GRM1	-19567.0	-15571.5
GRM2	-10436.0	784.5
GRM3	-9144.0	-14492.5
GRM4	-17156.0	-16546.5
GRM5	-16497.0	-9669.5
GRM6	-14700.0	-13967.5
GRM7	-13112.0	-16560.5
GRM8	-7385.0	-17053.5
TAS1R1	-5993.0	-12587.5
TAS1R2	-2995.0	-5443.5
TAS1R3	-10310.0	5036.5
TAS2R1	-15816.0	-16005.5
TAS2R10	-15939.0	-9578.5
TAS2R13	-5843.0	1328.5
TAS2R14	-17100.0	-11836.5
TAS2R16	-7140.0	-16033.5
TAS2R19	-11579.0	-17526.5
TAS2R20	-18302.0	-16285.5
TAS2R3	-18754.0	-13413.5
TAS2R30	-11126.0	-12950.5
TAS2R31	-9281.0	-5948.5
TAS2R38	-4384.0	-10545.5
TAS2R39	-12640.0	-15134.5
TAS2R4	-5245.0	-15937.5
TAS2R40	-11249.0	1154.5
TAS2R41	-11219.0	-11318.5
TAS2R42	-13517.0	-17594.5
TAS2R43	0.5	0.5
TAS2R46	-14243.0	3752.5
TAS2R5	-14231.0	-9430.5
TAS2R50	-17878.0	-17422.5
TAS2R60	-8272.0	-13650.5
TAS2R7	-16069.0	-12127.5
TAS2R8	-18366.0	-16507.5
TAS2R9	-17655.0	-12423.5

---

---

MET activates RAS signaling

MET activates RAS signaling

metric	value
setSize	11
pMANOVA	0.00101
p.adjustMANOVA	0.00433
s.dist	0.557
s.bl	-0.432
s.gu	0.351
p.bl	0.013
p.gu	0.0441

Top 20 genes

Gene	bl	gu
KRAS	-12587	7093.5
SHC1	-10566	7180.5
RANBP9	-15620	4800.5
HGF	-19375	2486.5
GRB2	-12253	2844.5
NRAS	-3860	3686.5

Click HERE to show all gene set members

All member genes

	bl	gu
GRB2	-12253	2844.5
HGF	-19375	2486.5
HRAS	-15765	-8489.5
KRAS	-12587	7093.5
MET	-20342	-15646.5
MUC20	-12848	-2446.5
NRAS	-3860	3686.5
RANBP10	-11385	-1903.5
RANBP9	-15620	4800.5
SHC1	-10566	7180.5
SOS1	-18679	-4590.5

---

---

Reactions specific to the complex N-glycan synthesis pathway

Reactions specific to the complex N-glycan synthesis pathway

metric	value
setSize	10
pMANOVA	0.0236
p.adjustMANOVA	0.0587
s.dist	0.556
s.bl	-0.455
s.gu	-0.32
p.bl	0.0128
p.gu	0.0797

Top 20 genes

Gene	bl	gu
FUT8	-20630	-17454.5
MAN2A1	-20382	-14991.5
FUCA1	-19151	-13997.5
CGA	-20743	-9681.5
MAN2A2	-18464	-9475.5
CHST8	-9032	-14515.5
CHST10	-16636	-2896.5
FUT3	-3462	-11148.5

Click HERE to show all gene set members

All member genes

	bl	gu
CGA	-20743	-9681.5
CHST10	-16636	-2896.5
CHST8	-9032	-14515.5
FUCA1	-19151	-13997.5
FUT3	-3462	-11148.5
FUT8	-20630	-17454.5
LHB	-7521	1244.5
MAN2A1	-20382	-14991.5
MAN2A2	-18464	-9475.5
MGAT2	-6187	2197.5

---

---

Effects of PIP2 hydrolysis

Effects of PIP2 hydrolysis

metric	value
setSize	26
pMANOVA	6.18e-05
p.adjustMANOVA	0.000395
s.dist	0.553
s.bl	-0.459
s.gu	-0.308
p.bl	5.03e-05
p.gu	0.00655

Top 20 genes

Gene	bl	gu
ITPR2	-21180	-17495.5
PRKCE	-20517	-17109.5
DGKH	-20377	-16784.5
ITPR3	-18506	-16423.5
DGKB	-16538	-17640.5
RASGRP1	-16607	-16208.5
DAGLA	-19023	-14110.5
DGKI	-12956	-16264.5
ABHD12	-14779	-10590.5
ITPR1	-21072	-7262.5
DGKQ	-13759	-10749.5
TRPC3	-16112	-8952.5
PRKCQ	-11130	-11532.5
PRKCH	-8201	-15612.5
DGKD	-16449	-6005.5
RASGRP2	-14573	-4879.5
TRPC6	-12494	-4259.5
DGKG	-17495	-2851.5
MGLL	-15468	-2579.5
DGKE	-10823	-3333.5

Click HERE to show all gene set members

All member genes

	bl	gu
ABHD12	-14779	-10590.5
ABHD6	-7010	-4805.5
DAGLA	-19023	-14110.5
DAGLB	-15635	4471.5
DGKA	2970	-14160.5
DGKB	-16538	-17640.5
DGKD	-16449	-6005.5
DGKE	-10823	-3333.5
DGKG	-17495	-2851.5
DGKH	-20377	-16784.5
DGKI	-12956	-16264.5
DGKQ	-13759	-10749.5
DGKZ	-20820	3787.5
ITPR1	-21072	-7262.5
ITPR2	-21180	-17495.5
ITPR3	-18506	-16423.5
MGLL	-15468	-2579.5
PRKCD	-15245	3856.5
PRKCE	-20517	-17109.5
PRKCH	-8201	-15612.5
PRKCQ	-11130	-11532.5
RASGRP1	-16607	-16208.5
RASGRP2	-14573	-4879.5
TRPC3	-16112	-8952.5
TRPC6	-12494	-4259.5
TRPC7	2587	-4295.5

---

---

RHOU GTPase cycle

RHOU GTPase cycle

metric	value
setSize	37
pMANOVA	2.97e-07
p.adjustMANOVA	3.96e-06
s.dist	0.553
s.bl	-0.517
s.gu	-0.196
p.bl	5.26e-08
p.gu	0.0388

Top 20 genes

Gene	bl	gu
DST	-21089	-17786.5
WWP2	-20838	-16788.5
DLG5	-20300	-15516.5
NCK2	-19953	-15765.5
ARHGEF7	-20492	-14793.5
MYO6	-16498	-16147.5
STAM	-16767	-15307.5
PAK1	-18763	-13669.5
GIT2	-19627	-12846.5
NCK1	-14946	-16200.5
IQGAP1	-19156	-12620.5
PEAK1	-17803	-13540.5
PAK4	-15859	-14968.5
GIT1	-16970	-11971.5
PTK2B	-20935	-9402.5
PAK2	-19545	-8414.5
EPHA2	-20912	-7416.5
STAM2	-13845	-10644.5
VANGL1	-14904	-9868.5
PIK3R1	-11854	-11534.5

Click HERE to show all gene set members

All member genes

	bl	gu
ARHGAP30	2744.0	7660.5
ARHGAP31	-16024.0	3528.5
ARHGEF7	-20492.0	-14793.5
CDC42	-9725.0	1088.5
CLTC	-18368.0	-1283.5
DEPDC1B	-3177.0	-6786.5
DLG5	-20300.0	-15516.5
DST	-21089.0	-17786.5
EPHA2	-20912.0	-7416.5
GIT1	-16970.0	-11971.5
GIT2	-19627.0	-12846.5
GRB2	-12253.0	2844.5
HGS	-9787.0	1823.5
IQGAP1	-19156.0	-12620.5
ITSN2	-20579.0	-4126.5
MYO6	-16498.0	-16147.5
NCK1	-14946.0	-16200.5
NCK2	-19953.0	-15765.5
PAK1	-18763.0	-13669.5
PAK2	-19545.0	-8414.5
PAK4	-15859.0	-14968.5
PARD6A	-13787.5	6907.0
PEAK1	-17803.0	-13540.5
PIK3R1	-11854.0	-11534.5
PIK3R2	-13656.0	4242.5
PTK2B	-20935.0	-9402.5
RHOU	-11723.0	-4769.5
SPTAN1	-9019.0	-12770.5
SPTBN1	-21027.0	-4501.5
SRC	-18883.0	2938.5
SRGAP2	-16539.0	-5544.5
STAM	-16767.0	-15307.5
STAM2	-13845.0	-10644.5
TXNL1	-677.0	7068.5
VANGL1	-14904.0	-9868.5
WDR6	-1978.0	-9831.5
WWP2	-20838.0	-16788.5

---

---

Free fatty acids regulate insulin secretion

Free fatty acids regulate insulin secretion

metric	value
setSize	10
pMANOVA	0.0132
p.adjustMANOVA	0.0369
s.dist	0.551
s.bl	-0.537
s.gu	-0.125
p.bl	0.00328
p.gu	0.494

Top 20 genes

Gene	bl	gu
PLCB1	-20738	-17148.5
CD36	-15016	-17769.5
ACSL3	-18859	-12845.5
PLCB2	-15327	-7172.5
PLCB3	-12308	-8691.5
FFAR1	-5899	-6710.5
GNAQ	-20999	-1378.5
GNA14	-6977	-2242.5

Click HERE to show all gene set members

All member genes

	bl	gu
ACSL3	-18859	-12845.5
CD36	-15016	-17769.5
FFAR1	-5899	-6710.5
GNA11	-15648	3875.5
GNA14	-6977	-2242.5
GNA15	-21012	4439.5
GNAQ	-20999	-1378.5
PLCB1	-20738	-17148.5
PLCB2	-15327	-7172.5
PLCB3	-12308	-8691.5

---

---

Repression of WNT target genes

Repression of WNT target genes

metric	value
setSize	13
pMANOVA	0.00946
p.adjustMANOVA	0.0284
s.dist	0.548
s.bl	-0.419
s.gu	-0.353
p.bl	0.00891
p.gu	0.0274

Top 20 genes

Gene	bl	gu
TCF7L2	-20962	-16754.5
CTBP2	-19954	-17371.5
TCF7	-18760	-16158.5
TLE3	-16802	-12619.5
TCF7L1	-11894	-17257.5
TLE1	-14269	-9027.5
AXIN2	-6657	-17161.5
CTBP1	-20314	-3559.5
LEF1	-4253	-11421.5
MYC	-3863	-10261.5

Click HERE to show all gene set members

All member genes

	bl	gu
AXIN2	-6657	-17161.5
CTBP1	-20314	-3559.5
CTBP2	-19954	-17371.5
HDAC1	-17206	4539.5
LEF1	-4253	-11421.5
MYC	-3863	-10261.5
TCF7	-18760	-16158.5
TCF7L1	-11894	-17257.5
TCF7L2	-20962	-16754.5
TLE1	-14269	-9027.5
TLE2	-5974	2590.5
TLE3	-16802	-12619.5
TLE4	-18002	974.5

---

---

PLC beta mediated events

PLC beta mediated events

metric	value
setSize	47
pMANOVA	3.12e-08
p.adjustMANOVA	5.36e-07
s.dist	0.544
s.bl	-0.47
s.gu	-0.274
p.bl	2.44e-08
p.gu	0.00113

Top 20 genes

Gene	bl	gu
PRKCA	-21112	-17593.5
ITPR2	-21180	-17495.5
PLCB1	-20738	-17148.5
ADCY9	-20767	-17089.5
PDE1A	-19290	-17620.5
ADCY2	-18621	-17209.5
ITPR3	-18506	-16423.5
PLA2G4A	-16716	-17207.5
PRKAR1B	-21041	-13226.5
PLCB4	-16503	-16745.5
PDE1C	-20068	-13534.5
CAMK2B	-15714	-17138.5
MAPK1	-14631	-15692.5
CAMK4	-11336	-17404.5
CAMKK1	-14282	-12766.5
PRKACB	-10787	-16616.5
PRKAR2B	-17760	-10072.5
ADCY1	-17240	-10211.5
ITPR1	-21072	-7262.5
ADCY3	-18270	-8209.5

Click HERE to show all gene set members

All member genes

	bl	gu
ADCY1	-17240	-10211.5
ADCY2	-18621	-17209.5
ADCY3	-18270	-8209.5
ADCY4	-16837	-3497.5
ADCY5	-6055	-17513.5
ADCY6	-2940	3158.5
ADCY7	-14137	-6928.5
ADCY8	-11062	-4829.5
ADCY9	-20767	-17089.5
AHCYL1	-10916	-1097.5
CALM1	-7448	-7546.5
CAMK2A	-5006	-15803.5
CAMK2B	-15714	-17138.5
CAMK2D	-3427	-13837.5
CAMK2G	-19662	4509.5
CAMK4	-11336	-17404.5
CAMKK1	-14282	-12766.5
CAMKK2	-19753	-2439.5
CREB1	-19257	-3334.5
GNA11	-15648	3875.5
GNA14	-6977	-2242.5
GNA15	-21012	4439.5
GNAQ	-20999	-1378.5
ITPR1	-21072	-7262.5
ITPR2	-21180	-17495.5
ITPR3	-18506	-16423.5
KPNA2	-5334	-9949.5
MAPK1	-14631	-15692.5
NBEA	-20631	-4861.5
PDE1A	-19290	-17620.5
PDE1B	-12942	-2233.5
PDE1C	-20068	-13534.5
PLA2G4A	-16716	-17207.5
PLCB1	-20738	-17148.5
PLCB2	-15327	-7172.5
PLCB3	-12308	-8691.5
PLCB4	-16503	-16745.5
PRKACA	-13691	6538.5
PRKACB	-10787	-16616.5
PRKACG	-5455	2227.5
PRKAR1A	-20242	-4330.5
PRKAR1B	-21041	-13226.5
PRKAR2A	-1363	-5472.5
PRKAR2B	-17760	-10072.5
PRKCA	-21112	-17593.5
PRKCD	-15245	3856.5
PRKCG	2004	-7402.5

---

---

RHOJ GTPase cycle

RHOJ GTPase cycle

metric	value
setSize	51
pMANOVA	1.59e-09
p.adjustMANOVA	3.61e-08
s.dist	0.543
s.bl	-0.513
s.gu	-0.178
p.bl	2.28e-10
p.gu	0.0275

Top 20 genes

Gene	bl	gu
TRIO	-21207	-17791.5
ARHGAP32	-19901	-17637.5
WWP2	-20838	-16788.5
ARHGAP26	-21203	-16464.5
DIAPH3	-20528	-17000.5
SLC4A7	-20909	-15605.5
MPP7	-21061	-15136.5
ARHGEF7	-20492	-14793.5
WASL	-20576	-12533.5
PAK1	-18763	-13669.5
GIT2	-19627	-12846.5
ARHGAP21	-16646	-14656.5
DOCK8	-18265	-13227.5
PAK4	-15859	-14968.5
FNBP1L	-18536	-12752.5
GIT1	-16970	-11971.5
CDC42BPA	-20353	-8918.5
SCRIB	-19929	-8587.5
PAK2	-19545	-8414.5
VANGL1	-14904	-9868.5

Click HERE to show all gene set members

All member genes

	bl	gu
ARHGAP1	-12869	-7003.5
ARHGAP21	-16646	-14656.5
ARHGAP26	-21203	-16464.5
ARHGAP32	-19901	-17637.5
ARHGAP35	-3908	-17364.5
ARHGAP5	-2903	-11127.5
ARHGEF7	-20492	-14793.5
ARL13B	-18298	-2839.5
CAV1	-7792	-11564.5
CDC42	-9725	1088.5
CDC42BPA	-20353	-8918.5
CDC42BPB	-20855	-4218.5
CDC42EP1	-2627	967.5
CPNE8	-13626	-2532.5
DEPDC1B	-3177	-6786.5
DIAPH3	-20528	-17000.5
DOCK8	-18265	-13227.5
FMNL3	-15885	4361.5
FNBP1	-12021	-631.5
FNBP1L	-18536	-12752.5
GBAS	-16338	3450.5
GIT1	-16970	-11971.5
GIT2	-19627	-12846.5
GJA1	-11968	-7941.5
IQGAP3	-19168	-667.5
JUP	-14743	3129.5
LAMTOR1	-17864	1226.5
MPP7	-21061	-15136.5
PAK1	-18763	-13669.5
PAK2	-19545	-8414.5
PAK4	-15859	-14968.5
PIK3R1	-11854	-11534.5
PIK3R2	-13656	4242.5
PREX1	-20204	1090.5
RAB7A	-10036	-1696.5
RHOJ	-8568	-10513.5
SCRIB	-19929	-8587.5
SLC1A5	-15905	5338.5
SLC4A7	-20909	-15605.5
SNAP23	-10299	4689.5
STEAP3	-12651	-10083.5
STOM	-12809	2577.5
SYDE1	-16905	-8618.5
TFRC	-17028	-2444.5
TMPO	841	-622.5
TRIO	-21207	-17791.5
VAMP3	-13027	-7297.5
VANGL1	-14904	-9868.5
WASL	-20576	-12533.5
WIPF2	-11034	-2703.5
WWP2	-20838	-16788.5

---

---

Defective GALNT12 causes CRCS1

Defective GALNT12 causes CRCS1

metric	value
setSize	18
pMANOVA	0.0018
p.adjustMANOVA	0.007
s.dist	0.543
s.bl	-0.409
s.gu	-0.357
p.bl	0.00267
p.gu	0.00873

Top 20 genes

Gene	bl	gu
MUC2	-20577	-15880.5
MUC5B	-20908	-14915.5
MUC7	-15615	-17282.5
MUC4	-18291	-13186.5
MUC21	-16701	-13519.5
MUC12	-15177	-14501.5
GALNT12	-17030	-9928.5
MUC15	-10607	-15746.5
MUC19	-11134	-14276.5
MUC13	-9608	-11323.5
MUC6	-15574	-6704.5
MUCL1	-8040	-12413.5
MUC17	-5022	-16487.5
MUC5AC	-17882	-4044.5
MUC20	-12848	-2446.5

Click HERE to show all gene set members

All member genes

	bl	gu
GALNT12	-17030	-9928.5
MUC1	-9632	5413.5
MUC12	-15177	-14501.5
MUC13	-9608	-11323.5
MUC15	-10607	-15746.5
MUC16	-8930	1070.5
MUC17	-5022	-16487.5
MUC19	-11134	-14276.5
MUC2	-20577	-15880.5
MUC20	-12848	-2446.5
MUC21	-16701	-13519.5
MUC3A	-11802	4348.5
MUC4	-18291	-13186.5
MUC5AC	-17882	-4044.5
MUC5B	-20908	-14915.5
MUC6	-15574	-6704.5
MUC7	-15615	-17282.5
MUCL1	-8040	-12413.5

---

---

RHOV GTPase cycle

RHOV GTPase cycle

metric	value
setSize	36
pMANOVA	1.71e-06
p.adjustMANOVA	1.89e-05
s.dist	0.54
s.bl	-0.479
s.gu	-0.25
p.bl	6.47e-07
p.gu	0.00947

Top 20 genes

Gene	bl	gu
DST	-21089	-17786.5
MYO9A	-21100	-17723.5
SH3RF1	-20886	-17740.5
DLG5	-20300	-15516.5
NCK2	-19953	-15765.5
ARHGAP12	-18390	-16502.5
ARHGEF7	-20492	-14793.5
WASL	-20576	-12533.5
PAK1	-18763	-13669.5
GIT2	-19627	-12846.5
NCK1	-14946	-16200.5
IQGAP1	-19156	-12620.5
PEAK1	-17803	-13540.5
PAK4	-15859	-14968.5
ZNF512B	-12780	-16300.5
GIT1	-16970	-11971.5
PAK2	-19545	-8414.5
EPHA2	-20912	-7416.5
VANGL1	-14904	-9868.5
PIK3R1	-11854	-11534.5

Click HERE to show all gene set members

All member genes

	bl	gu
ARHGAP12	-18390.0	-16502.5
ARHGEF7	-20492.0	-14793.5
CCP110	-6059.0	-4287.5
CDC42	-9725.0	1088.5
CEP97	3491.0	-2858.5
CLTC	-18368.0	-1283.5
DEPDC1B	-3177.0	-6786.5
DLG5	-20300.0	-15516.5
DST	-21089.0	-17786.5
EPHA2	-20912.0	-7416.5
GIT1	-16970.0	-11971.5
GIT2	-19627.0	-12846.5
IQGAP1	-19156.0	-12620.5
MAP3K11	-11151.0	5980.5
MYO9A	-21100.0	-17723.5
NCK1	-14946.0	-16200.5
NCK2	-19953.0	-15765.5
PAK1	-18763.0	-13669.5
PAK2	-19545.0	-8414.5
PAK4	-15859.0	-14968.5
PAK6	-18306.0	3665.5
PARD6A	-13787.5	6907.0
PARD6B	-12518.0	-4997.5
PEAK1	-17803.0	-13540.5
PIK3R1	-11854.0	-11534.5
RHOV	-4880.0	-2377.5
SH3RF1	-20886.0	-17740.5
SPTAN1	-9019.0	-12770.5
SPTBN1	-21027.0	-4501.5
TPM3	-14472.0	6101.5
TPM4	-15533.0	2599.5
TXNL1	-677.0	7068.5
VANGL1	-14904.0	-9868.5
WASL	-20576.0	-12533.5
WDR6	-1978.0	-9831.5
ZNF512B	-12780.0	-16300.5

---

---

Formation of Senescence-Associated Heterochromatin Foci (SAHF)

Formation of Senescence-Associated Heterochromatin Foci (SAHF)

metric	value
setSize	11
pMANOVA	0.00221
p.adjustMANOVA	0.00847
s.dist	0.54
s.bl	-0.5
s.gu	0.203
p.bl	0.00405
p.gu	0.243

Top 20 genes

Gene	bl	gu
HMGA1	-18787	6766.5
CDKN1A	-7917	6908.5
HIRA	-13726	955.5
EP400	-21081	558.5

Click HERE to show all gene set members

All member genes

	bl	gu
ASF1A	-2388	-8449.5
CABIN1	-19491	-10852.5
CDKN1A	-7917	6908.5
EP400	-21081	558.5
HIRA	-13726	955.5
HMGA1	-18787	6766.5
HMGA2	-20828	-5792.5
LMNB1	-14780	-640.5
RB1	-19029	-6794.5
TP53	-6761	-7115.5
UBN1	-18120	-1350.5

---

---

Defective GALNT3 causes HFTC

Defective GALNT3 causes HFTC

metric	value
setSize	18
pMANOVA	0.00199
p.adjustMANOVA	0.00767
s.dist	0.538
s.bl	-0.407
s.gu	-0.352
p.bl	0.00279
p.gu	0.00963

Top 20 genes

Gene	bl	gu
MUC2	-20577	-15880.5
MUC5B	-20908	-14915.5
MUC7	-15615	-17282.5
MUC4	-18291	-13186.5
MUC21	-16701	-13519.5
MUC12	-15177	-14501.5
MUC15	-10607	-15746.5
MUC19	-11134	-14276.5
GALNT3	-16598	-8870.5
MUC13	-9608	-11323.5
MUC6	-15574	-6704.5
MUCL1	-8040	-12413.5
MUC17	-5022	-16487.5
MUC5AC	-17882	-4044.5
MUC20	-12848	-2446.5

Click HERE to show all gene set members

All member genes

	bl	gu
GALNT3	-16598	-8870.5
MUC1	-9632	5413.5
MUC12	-15177	-14501.5
MUC13	-9608	-11323.5
MUC15	-10607	-15746.5
MUC16	-8930	1070.5
MUC17	-5022	-16487.5
MUC19	-11134	-14276.5
MUC2	-20577	-15880.5
MUC20	-12848	-2446.5
MUC21	-16701	-13519.5
MUC3A	-11802	4348.5
MUC4	-18291	-13186.5
MUC5AC	-17882	-4044.5
MUC5B	-20908	-14915.5
MUC6	-15574	-6704.5
MUC7	-15615	-17282.5
MUCL1	-8040	-12413.5

---

---

Netrin-1 signaling

Netrin-1 signaling

metric	value
setSize	49
pMANOVA	4.11e-08
p.adjustMANOVA	6.84e-07
s.dist	0.535
s.bl	-0.437
s.gu	-0.309
p.bl	1.17e-07
p.gu	0.000183

Top 20 genes

Gene	bl	gu
TRIO	-21207	-17791.5
DSCAM	-20944	-17809.5
PTK2	-20692	-17173.5
DSCAML1	-18608	-17697.5
ROBO1	-20137	-15748.5
TRPC4	-19131	-16067.5
ABLIM1	-18489	-16439.5
SLIT3	-17464	-17307.5
ABLIM2	-17887	-16310.5
SLIT2	-20991	-13718.5
MYO10	-16083	-17706.5
MAPK8	-18009	-15287.5
UNC5A	-19869	-13582.5
NTN4	-15075	-17286.5
WASL	-20576	-12533.5
RGMA	-16653	-15468.5
PAK1	-18763	-13669.5
NCK1	-14946	-16200.5
UNC5D	-14165	-17047.5
DCC	-15511	-14790.5

Click HERE to show all gene set members

All member genes

	bl	gu
ABLIM1	-18489	-16439.5
ABLIM2	-17887	-16310.5
ABLIM3	-5705	-16374.5
AGAP2	-16143	-6247.5
CDC42	-9725	1088.5
DCC	-15511	-14790.5
DOCK1	-21077	-9064.5
DSCAM	-20944	-17809.5
DSCAML1	-18608	-17697.5
EZR	-20317	-943.5
FYN	-3404	-17810.5
HFE2	-19981	-7361.5
MAPK11	-15772	-3770.5
MAPK12	-3493	673.5
MAPK13	-11983	5065.5
MAPK14	-9495	-9662.5
MAPK8	-18009	-15287.5
MYO10	-16083	-17706.5
NCK1	-14946	-16200.5
NEO1	2804	5543.5
NTN1	-1878	-13809.5
NTN4	-15075	-17286.5
PAK1	-18763	-13669.5
PITPNA	-19624	6003.5
PLCG1	-8558	-6821.5
PRKCQ	-11130	-11532.5
PTK2	-20692	-17173.5
PTPN11	-6276	4912.5
RAC1	-19826	5665.5
RGMA	-16653	-15468.5
RGMB	-1417	-1774.5
ROBO1	-20137	-15748.5
SIAH1	-12548	-2961.5
SIAH2	-1055	-2240.5
SLIT1	-18144	-10187.5
SLIT2	-20991	-13718.5
SLIT3	-17464	-17307.5
SRC	-18883	2938.5
TRIO	-21207	-17791.5
TRPC1	-15665	-12008.5
TRPC3	-16112	-8952.5
TRPC4	-19131	-16067.5
TRPC6	-12494	-4259.5
TRPC7	2587	-4295.5
UNC5A	-19869	-13582.5
UNC5B	-13253	-1556.5
UNC5C	-11748	2176.5
UNC5D	-14165	-17047.5
WASL	-20576	-12533.5

---

---

Notch-HLH transcription pathway

Notch-HLH transcription pathway

metric	value
setSize	24
pMANOVA	3.38e-05
p.adjustMANOVA	0.000231
s.dist	0.533
s.bl	-0.529
s.gu	-0.0639
p.bl	7.14e-06
p.gu	0.588

Top 20 genes

Gene	bl	gu
HDAC9	-21182	-17649.5
CREBBP	-21028	-14852.5
MAML3	-17952	-17256.5
HDAC5	-17991	-15541.5
MAML2	-17811	-15627.5
HDAC10	-17413	-14702.5
NOTCH1	-19504	-12013.5
TBL1XR1	-19613	-11945.5
HDAC4	-21235	-8191.5
NOTCH4	-18611	-9212.5
NCOR1	-18697	-6157.5
HDAC3	-14695	-6527.5
RBPJ	-10965	-7180.5
HDAC2	-12435	-6104.5
KAT2A	-16689	-3160.5
NOTCH2	-9182	-4138.5
HDAC11	-10385	-1502.5
KAT2B	-5160	-1731.5

Click HERE to show all gene set members

All member genes

	bl	gu
CREBBP	-21028	-14852.5
HDAC1	-17206	4539.5
HDAC10	-17413	-14702.5
HDAC11	-10385	-1502.5
HDAC2	-12435	-6104.5
HDAC3	-14695	-6527.5
HDAC4	-21235	-8191.5
HDAC5	-17991	-15541.5
HDAC7	-16023	940.5
HDAC9	-21182	-17649.5
KAT2A	-16689	-3160.5
KAT2B	-5160	-1731.5
MAML1	-15275	7812.5
MAML2	-17811	-15627.5
MAML3	-17952	-17256.5
NCOR1	-18697	-6157.5
NCOR2	-21227	7376.5
NOTCH1	-19504	-12013.5
NOTCH2	-9182	-4138.5
NOTCH3	-7095	6815.5
NOTCH4	-18611	-9212.5
RBPJ	-10965	-7180.5
SNW1	3117	7293.5
TBL1XR1	-19613	-11945.5

---

---

Defective EXT1 causes exostoses 1, TRPS2 and CHDS

Defective EXT1 causes exostoses 1, TRPS2 and CHDS

metric	value
setSize	12
pMANOVA	0.0176
p.adjustMANOVA	0.0464
s.dist	0.531
s.bl	-0.402
s.gu	-0.347
p.bl	0.0158
p.gu	0.0374

Top 20 genes

Gene	bl	gu
GPC6	-20804	-17773.5
EXT1	-20977	-17409.5
GPC5	-20028	-17300.5
AGRN	-18040	-14510.5
HSPG2	-13074	-16986.5
SDC2	-11428	-7878.5
EXT2	-13708	-6378.5
SDC3	-6936	-11310.5
GPC1	-18740	-2588.5
GPC2	-5460	-5805.5

Click HERE to show all gene set members

All member genes

	bl	gu
AGRN	-18040	-14510.5
EXT1	-20977	-17409.5
EXT2	-13708	-6378.5
GPC1	-18740	-2588.5
GPC2	-5460	-5805.5
GPC5	-20028	-17300.5
GPC6	-20804	-17773.5
HSPG2	-13074	-16986.5
SDC1	-5501	2645.5
SDC2	-11428	-7878.5
SDC3	-6936	-11310.5
SDC4	-7916	2274.5

---

---

Defective EXT2 causes exostoses 2

Defective EXT2 causes exostoses 2

metric	value
setSize	12
pMANOVA	0.0176
p.adjustMANOVA	0.0464
s.dist	0.531
s.bl	-0.402
s.gu	-0.347
p.bl	0.0158
p.gu	0.0374

Top 20 genes

Gene	bl	gu
GPC6	-20804	-17773.5
EXT1	-20977	-17409.5
GPC5	-20028	-17300.5
AGRN	-18040	-14510.5
HSPG2	-13074	-16986.5
SDC2	-11428	-7878.5
EXT2	-13708	-6378.5
SDC3	-6936	-11310.5
GPC1	-18740	-2588.5
GPC2	-5460	-5805.5

Click HERE to show all gene set members

All member genes

	bl	gu
AGRN	-18040	-14510.5
EXT1	-20977	-17409.5
EXT2	-13708	-6378.5
GPC1	-18740	-2588.5
GPC2	-5460	-5805.5
GPC5	-20028	-17300.5
GPC6	-20804	-17773.5
HSPG2	-13074	-16986.5
SDC1	-5501	2645.5
SDC2	-11428	-7878.5
SDC3	-6936	-11310.5
SDC4	-7916	2274.5

---

---

DAG and IP3 signaling

DAG and IP3 signaling

metric	value
setSize	39
pMANOVA	1.58e-06
p.adjustMANOVA	1.77e-05
s.dist	0.531
s.bl	-0.437
s.gu	-0.302
p.bl	2.32e-06
p.gu	0.0011

Top 20 genes

Gene	bl	gu
PRKCA	-21112	-17593.5
ITPR2	-21180	-17495.5
ADCY9	-20767	-17089.5
PRKCE	-20517	-17109.5
PDE1A	-19290	-17620.5
ADCY2	-18621	-17209.5
ITPR3	-18506	-16423.5
PRKAR1B	-21041	-13226.5
PDE1C	-20068	-13534.5
CAMK2B	-15714	-17138.5
CAMK4	-11336	-17404.5
CAMKK1	-14282	-12766.5
PRKACB	-10787	-16616.5
PRKAR2B	-17760	-10072.5
ADCY1	-17240	-10211.5
ITPR1	-21072	-7262.5
ADCY3	-18270	-8209.5
ADCY5	-6055	-17513.5
NBEA	-20631	-4861.5
ADCY7	-14137	-6928.5

Click HERE to show all gene set members

All member genes

	bl	gu
ADCY1	-17240	-10211.5
ADCY2	-18621	-17209.5
ADCY3	-18270	-8209.5
ADCY4	-16837	-3497.5
ADCY5	-6055	-17513.5
ADCY6	-2940	3158.5
ADCY7	-14137	-6928.5
ADCY8	-11062	-4829.5
ADCY9	-20767	-17089.5
AHCYL1	-10916	-1097.5
CALM1	-7448	-7546.5
CAMK2A	-5006	-15803.5
CAMK2B	-15714	-17138.5
CAMK2D	-3427	-13837.5
CAMK2G	-19662	4509.5
CAMK4	-11336	-17404.5
CAMKK1	-14282	-12766.5
CAMKK2	-19753	-2439.5
CREB1	-19257	-3334.5
ITPR1	-21072	-7262.5
ITPR2	-21180	-17495.5
ITPR3	-18506	-16423.5
KPNA2	-5334	-9949.5
NBEA	-20631	-4861.5
PDE1A	-19290	-17620.5
PDE1B	-12942	-2233.5
PDE1C	-20068	-13534.5
PLCG1	-8558	-6821.5
PRKACA	-13691	6538.5
PRKACB	-10787	-16616.5
PRKACG	-5455	2227.5
PRKAR1A	-20242	-4330.5
PRKAR1B	-21041	-13226.5
PRKAR2A	-1363	-5472.5
PRKAR2B	-17760	-10072.5
PRKCA	-21112	-17593.5
PRKCD	-15245	3856.5
PRKCE	-20517	-17109.5
PRKCG	2004	-7402.5

---

---

POU5F1 (OCT4), SOX2, NANOG repress genes related to differentiation

POU5F1 (OCT4), SOX2, NANOG repress genes related to differentiation

metric	value
setSize	10
pMANOVA	0.00325
p.adjustMANOVA	0.0119
s.dist	0.531
s.bl	-0.387
s.gu	0.364
p.bl	0.0342
p.gu	0.0464

Top 20 genes

Gene	bl	gu
DKK1	-16926	4986.5
HHEX	-12718	5535.5
GSC	-15492	3759.5
SOX2	-9775	2677.5
EOMES	-4748	4826.5

Click HERE to show all gene set members

All member genes

	bl	gu
CDX2	-15789	-7462.5
DKK1	-16926	4986.5
EOMES	-4748	4826.5
GATA6	-13378	-6337.5
GSC	-15492	3759.5
HHEX	-12718	5535.5
NANOG	-15507	-7718.5
POU5F1	-13130	-2506.5
SOX2	-9775	2677.5
TSC22D1	-16035	-600.5

---

---

Defective B3GALTL causes PpS

Defective B3GALTL causes PpS

metric	value
setSize	36
pMANOVA	5.41e-06
p.adjustMANOVA	4.62e-05
s.dist	0.53
s.bl	-0.328
s.gu	-0.417
p.bl	0.000664
p.gu	1.51e-05

Top 20 genes

Gene	bl	gu
ADAMTS2	-20648	-17790.5
SEMA5A	-20184	-17602.5
THSD7A	-20155	-17614.5
THSD4	-18761	-17712.5
ADAMTSL1	-20142	-16252.5
ADAMTS17	-19994	-14053.5
ADAMTS20	-16118	-17123.5
THBS1	-16401	-15619.5
SEMA5B	-13423	-17406.5
THBS2	-17626	-11951.5
ADAMTSL3	-12323	-15886.5
ADAMTS3	-14478	-13517.5
ADAMTSL4	-14967	-12953.5
ADAMTS10	-13842	-12355.5
ADAMTS19	-18605	-8864.5
ADAMTS14	-17847	-8885.5
ADAMTS4	-17301	-8914.5
B3GLCT	-9301	-15696.5
ADAMTS12	-7508	-17781.5
ADAMTS9	-6515	-17567.5

Click HERE to show all gene set members

All member genes

	bl	gu
ADAMTS1	-2414	7813.5
ADAMTS10	-13842	-12355.5
ADAMTS12	-7508	-17781.5
ADAMTS13	-12836	6326.5
ADAMTS14	-17847	-8885.5
ADAMTS15	-11297	-10020.5
ADAMTS16	-4857	-6887.5
ADAMTS17	-19994	-14053.5
ADAMTS18	-4012	-10829.5
ADAMTS19	-18605	-8864.5
ADAMTS2	-20648	-17790.5
ADAMTS20	-16118	-17123.5
ADAMTS3	-14478	-13517.5
ADAMTS4	-17301	-8914.5
ADAMTS5	-20658	5803.5
ADAMTS6	-6341	-12852.5
ADAMTS7	-14149	2221.5
ADAMTS8	-8933	-3649.5
ADAMTS9	-6515	-17567.5
ADAMTSL1	-20142	-16252.5
ADAMTSL2	-3063	-4371.5
ADAMTSL3	-12323	-15886.5
ADAMTSL4	-14967	-12953.5
ADAMTSL5	-9136	-5174.5
B3GLCT	-9301	-15696.5
SBSPON	-7737	-12364.5
SEMA5A	-20184	-17602.5
SEMA5B	-13423	-17406.5
SPON1	-8077	-9969.5
SPON2	-20115	604.5
THBS1	-16401	-15619.5
THBS2	-17626	-11951.5
THSD1	-3864	-4715.5
THSD4	-18761	-17712.5
THSD7A	-20155	-17614.5
THSD7B	501	-17463.5

---

---

O-glycosylation of TSR domain-containing proteins

O-glycosylation of TSR domain-containing proteins

metric	value
setSize	37
pMANOVA	3.79e-06
p.adjustMANOVA	3.55e-05
s.dist	0.529
s.bl	-0.317
s.gu	-0.424
p.bl	0.000831
p.gu	8.17e-06

Top 20 genes

Gene	bl	gu
ADAMTS2	-20648	-17790.5
SEMA5A	-20184	-17602.5
THSD7A	-20155	-17614.5
THSD4	-18761	-17712.5
ADAMTSL1	-20142	-16252.5
ADAMTS17	-19994	-14053.5
ADAMTS20	-16118	-17123.5
THBS1	-16401	-15619.5
SEMA5B	-13423	-17406.5
THBS2	-17626	-11951.5
ADAMTSL3	-12323	-15886.5
ADAMTS3	-14478	-13517.5
ADAMTSL4	-14967	-12953.5
ADAMTS10	-13842	-12355.5
ADAMTS19	-18605	-8864.5
ADAMTS14	-17847	-8885.5
ADAMTS4	-17301	-8914.5
B3GLCT	-9301	-15696.5
ADAMTS12	-7508	-17781.5
ADAMTS9	-6515	-17567.5

Click HERE to show all gene set members

All member genes

	bl	gu
ADAMTS1	-2414	7813.5
ADAMTS10	-13842	-12355.5
ADAMTS12	-7508	-17781.5
ADAMTS13	-12836	6326.5
ADAMTS14	-17847	-8885.5
ADAMTS15	-11297	-10020.5
ADAMTS16	-4857	-6887.5
ADAMTS17	-19994	-14053.5
ADAMTS18	-4012	-10829.5
ADAMTS19	-18605	-8864.5
ADAMTS2	-20648	-17790.5
ADAMTS20	-16118	-17123.5
ADAMTS3	-14478	-13517.5
ADAMTS4	-17301	-8914.5
ADAMTS5	-20658	5803.5
ADAMTS6	-6341	-12852.5
ADAMTS7	-14149	2221.5
ADAMTS8	-8933	-3649.5
ADAMTS9	-6515	-17567.5
ADAMTSL1	-20142	-16252.5
ADAMTSL2	-3063	-4371.5
ADAMTSL3	-12323	-15886.5
ADAMTSL4	-14967	-12953.5
ADAMTSL5	-9136	-5174.5
B3GLCT	-9301	-15696.5
POFUT2	-7671	-13643.5
SBSPON	-7737	-12364.5
SEMA5A	-20184	-17602.5
SEMA5B	-13423	-17406.5
SPON1	-8077	-9969.5
SPON2	-20115	604.5
THBS1	-16401	-15619.5
THBS2	-17626	-11951.5
THSD1	-3864	-4715.5
THSD4	-18761	-17712.5
THSD7A	-20155	-17614.5
THSD7B	501	-17463.5

---

---

CLEC7A (Dectin-1) induces NFAT activation

CLEC7A (Dectin-1) induces NFAT activation

metric	value
setSize	11
pMANOVA	0.0269
p.adjustMANOVA	0.0652
s.dist	0.525
s.bl	-0.35
s.gu	-0.392
p.bl	0.0445
p.gu	0.0244

Top 20 genes

Gene	bl	gu
ITPR2	-21180	-17495.5
PPP3CA	-20865	-17032.5
ITPR3	-18506	-16423.5
NFATC1	-20778	-14606.5
ITPR1	-21072	-7262.5
PPP3R1	-8494	-14651.5
CALM1	-7448	-7546.5
NFATC3	-1914	-7963.5
AHCYL1	-10916	-1097.5
NFATC2	-8926	-976.5
PPP3CB	-1535	-4912.5

Click HERE to show all gene set members

All member genes

	bl	gu
AHCYL1	-10916	-1097.5
CALM1	-7448	-7546.5
ITPR1	-21072	-7262.5
ITPR2	-21180	-17495.5
ITPR3	-18506	-16423.5
NFATC1	-20778	-14606.5
NFATC2	-8926	-976.5
NFATC3	-1914	-7963.5
PPP3CA	-20865	-17032.5
PPP3CB	-1535	-4912.5
PPP3R1	-8494	-14651.5

---

---

Here is the session info with all the versions of packages used.

sessionInfo()

## R version 4.2.1 (2022-06-23)
## Platform: x86_64-pc-linux-gnu (64-bit)
## Running under: Ubuntu 22.04.1 LTS
## 
## Matrix products: default
## BLAS:   /usr/lib/x86_64-linux-gnu/openblas-pthread/libblas.so.3
## LAPACK: /usr/lib/x86_64-linux-gnu/openblas-pthread/libopenblasp-r0.3.20.so
## 
## locale:
##  [1] LC_CTYPE=en_US.UTF-8       LC_NUMERIC=C              
##  [3] LC_TIME=en_US.UTF-8        LC_COLLATE=en_US.UTF-8    
##  [5] LC_MONETARY=en_US.UTF-8    LC_MESSAGES=en_US.UTF-8   
##  [7] LC_PAPER=en_US.UTF-8       LC_NAME=C                 
##  [9] LC_ADDRESS=C               LC_TELEPHONE=C            
## [11] LC_MEASUREMENT=en_US.UTF-8 LC_IDENTIFICATION=C       
## 
## attached base packages:
##  [1] grid      stats4    parallel  stats     graphics  grDevices utils    
##  [8] datasets  methods   base     
## 
## other attached packages:
##  [1] data.table_1.14.2                                  
##  [2] ENmix_1.32.0                                       
##  [3] doParallel_1.0.17                                  
##  [4] qqman_0.1.8                                        
##  [5] RCircos_1.2.2                                      
##  [6] forestplot_3.1.0                                   
##  [7] abind_1.4-5                                        
##  [8] checkmate_2.1.0                                    
##  [9] GEOquery_2.64.2                                    
## [10] RColorBrewer_1.1-3                                 
## [11] IlluminaHumanMethylation450kmanifest_0.4.0         
## [12] topconfects_1.12.0                                 
## [13] DMRcatedata_2.14.0                                 
## [14] ExperimentHub_2.4.0                                
## [15] AnnotationHub_3.4.0                                
## [16] BiocFileCache_2.4.0                                
## [17] dbplyr_2.2.1                                       
## [18] DMRcate_2.10.0                                     
## [19] limma_3.52.4                                       
## [20] missMethyl_1.30.0                                  
## [21] IlluminaHumanMethylation450kanno.ilmn12.hg19_0.6.1 
## [22] R.utils_2.12.0                                     
## [23] R.oo_1.25.0                                        
## [24] R.methodsS3_1.8.2                                  
## [25] plyr_1.8.7                                         
## [26] IlluminaHumanMethylationEPICanno.ilm10b4.hg19_0.6.0
## [27] pkgload_1.3.0                                      
## [28] GGally_2.1.2                                       
## [29] ggplot2_3.3.6                                      
## [30] reshape2_1.4.4                                     
## [31] beeswarm_0.4.0                                     
## [32] gplots_3.1.3                                       
## [33] gtools_3.9.3                                       
## [34] tibble_3.1.8                                       
## [35] echarts4r_0.4.4                                    
## [36] tictoc_1.1                                         
## [37] IlluminaHumanMethylationEPICanno.ilm10b2.hg19_0.6.0
## [38] minfi_1.42.0                                       
## [39] bumphunter_1.38.0                                  
## [40] locfit_1.5-9.6                                     
## [41] iterators_1.0.14                                   
## [42] foreach_1.5.2                                      
## [43] Biostrings_2.64.1                                  
## [44] XVector_0.36.0                                     
## [45] SummarizedExperiment_1.26.1                        
## [46] Biobase_2.56.0                                     
## [47] MatrixGenerics_1.8.1                               
## [48] matrixStats_0.62.0                                 
## [49] GenomicRanges_1.48.0                               
## [50] GenomeInfoDb_1.32.4                                
## [51] IRanges_2.30.1                                     
## [52] S4Vectors_0.34.0                                   
## [53] BiocGenerics_0.42.0                                
## [54] mitch_1.8.0                                        
## [55] eulerr_6.1.1                                       
## [56] kableExtra_1.3.4                                   
## [57] dplyr_1.0.10                                       
## 
## loaded via a namespace (and not attached):
##   [1] rappdirs_0.3.3                rtracklayer_1.56.1           
##   [3] tidyr_1.2.1                   bit64_4.0.5                  
##   [5] knitr_1.40                    DelayedArray_0.22.0          
##   [7] rpart_4.1.16                  KEGGREST_1.36.3              
##   [9] RCurl_1.98-1.9                AnnotationFilter_1.20.0      
##  [11] generics_0.1.3                GenomicFeatures_1.48.4       
##  [13] preprocessCore_1.58.0         RSQLite_2.2.18               
##  [15] bit_4.0.4                     tzdb_0.3.0                   
##  [17] webshot_0.5.4                 xml2_1.3.3                   
##  [19] httpuv_1.6.6                  assertthat_0.2.1             
##  [21] xfun_0.33                     hms_1.1.2                    
##  [23] jquerylib_0.1.4               evaluate_0.17                
##  [25] promises_1.2.0.1              fansi_1.0.3                  
##  [27] restfulr_0.0.15               scrime_1.3.5                 
##  [29] progress_1.2.2                caTools_1.18.2               
##  [31] readxl_1.4.1                  geneplotter_1.74.0           
##  [33] DBI_1.1.3                     htmlwidgets_1.5.4            
##  [35] reshape_0.8.9                 purrr_0.3.5                  
##  [37] ellipsis_0.3.2                backports_1.4.1              
##  [39] calibrate_1.7.7               permute_0.9-7                
##  [41] annotate_1.74.0               biomaRt_2.52.0               
##  [43] deldir_1.0-6                  sparseMatrixStats_1.8.0      
##  [45] vctrs_0.4.2                   ensembldb_2.20.2             
##  [47] cachem_1.0.6                  withr_2.5.0                  
##  [49] Gviz_1.40.1                   BSgenome_1.64.0              
##  [51] GenomicAlignments_1.32.1      prettyunits_1.1.1            
##  [53] mclust_5.4.10                 svglite_2.1.0                
##  [55] cluster_2.1.4                 RPMM_1.25                    
##  [57] lazyeval_0.2.2                crayon_1.5.2                 
##  [59] genefilter_1.78.0             labeling_0.4.2               
##  [61] edgeR_3.38.4                  pkgconfig_2.0.3              
##  [63] nlme_3.1-160                  ProtGenerics_1.28.0          
##  [65] nnet_7.3-18                   rlang_1.0.6                  
##  [67] lifecycle_1.0.3               filelock_1.0.2               
##  [69] dichromat_2.0-0.1             polyclip_1.10-0              
##  [71] cellranger_1.1.0              rngtools_1.5.2               
##  [73] base64_2.0.1                  Matrix_1.5-1                 
##  [75] Rhdf5lib_1.18.2               base64enc_0.1-3              
##  [77] png_0.1-7                     viridisLite_0.4.1            
##  [79] rjson_0.2.21                  bitops_1.0-7                 
##  [81] KernSmooth_2.23-20            rhdf5filters_1.8.0           
##  [83] blob_1.2.3                    DelayedMatrixStats_1.18.1    
##  [85] doRNG_1.8.2                   stringr_1.4.1                
##  [87] nor1mix_1.3-0                 readr_2.1.3                  
##  [89] jpeg_0.1-9                    scales_1.2.1                 
##  [91] memoise_2.0.1                 magrittr_2.0.3               
##  [93] zlibbioc_1.42.0               compiler_4.2.1               
##  [95] BiocIO_1.6.0                  illuminaio_0.38.0            
##  [97] Rsamtools_2.12.0              cli_3.4.1                    
##  [99] DSS_2.44.0                    htmlTable_2.4.1              
## [101] Formula_1.2-4                 MASS_7.3-58.1                
## [103] tidyselect_1.2.0              stringi_1.7.8                
## [105] highr_0.9                     yaml_2.3.5                   
## [107] askpass_1.1                   latticeExtra_0.6-30          
## [109] sass_0.4.2                    VariantAnnotation_1.42.1     
## [111] tools_4.2.1                   rstudioapi_0.14              
## [113] foreign_0.8-83                bsseq_1.32.0                 
## [115] gridExtra_2.3                 farver_2.1.1                 
## [117] digest_0.6.29                 BiocManager_1.30.18          
## [119] shiny_1.7.2                   quadprog_1.5-8               
## [121] Rcpp_1.0.9                    siggenes_1.70.0              
## [123] BiocVersion_3.15.2            later_1.3.0                  
## [125] org.Hs.eg.db_3.15.0           httr_1.4.4                   
## [127] AnnotationDbi_1.58.0          biovizBase_1.44.0            
## [129] colorspace_2.0-3              polylabelr_0.2.0             
## [131] rvest_1.0.3                   XML_3.99-0.11                
## [133] splines_4.2.1                 statmod_1.4.37               
## [135] multtest_2.52.0               systemfonts_1.0.4            
## [137] xtable_1.8-4                  jsonlite_1.8.2               
## [139] dynamicTreeCut_1.63-1         R6_2.5.1                     
## [141] Hmisc_4.7-1                   pillar_1.8.1                 
## [143] htmltools_0.5.3               mime_0.12                    
## [145] glue_1.6.2                    fastmap_1.1.0                
## [147] BiocParallel_1.30.3           interactiveDisplayBase_1.34.0
## [149] beanplot_1.3.1                codetools_0.2-18             
## [151] utf8_1.2.2                    lattice_0.20-45              
## [153] bslib_0.4.0                   curl_4.3.3                   
## [155] openssl_2.0.3                 interp_1.1-3                 
## [157] survival_3.4-0                rmarkdown_2.17               
## [159] munsell_0.5.0                 rhdf5_2.40.0                 
## [161] GenomeInfoDbData_1.2.8        impute_1.70.0                
## [163] HDF5Array_1.24.2              gtable_0.3.1

END of report